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Abstract
Nicotinic acid adenine dinucleotide phosphate (NAADP) 3 has recently emerged as 
the most potent endogenous calcium mobilising, second messenger. NAADP 3 has 
been shown to be essential in many different cell types, ranging from mediating 
fertilisation in sea urchin eggs to the release of insulin from pancreatic p-cells. 
Therefore, a synthetic route was required to enable the formation of NAADP 3 and its 
analogues to explore its intracellular chemistry.
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Our aim was to develop a flexible route to NAADP 3 that allowed modifications at 
key positions, ultimately leading to a range of biological probes. Achieving selective 
introduction of the 2/-phosphate onto suitably protected adenosine was key. The 5'- 
hydroxyl was then phosphorylated to afford the protected adenosine diphosphate 
precursor. Development of a synthetic route towards P-nicotinamide mononucleotide 
(P-NMN) 21 started from the tetra-protected ribose 30. Activating the anomeric 
acetate to allow glycosylation to occur with in-situ protecting group cleavage afforded 
the mononucleoside precursor, which was selectively phosphorylated at the 5'- 
hydroxyl the afford P-NMN 21. With the two phosphate precursors synthesised, 
development of a method towards pyrophosphate formation was undertaken. 
Reported yields for pyrophosphate formation are generally poor due to apparent 
purification difficulties, however activation with carbonyl diimidazole and 
purification on negative ion exchange resin afforded pleasing yields of around 60 %. 
Global deprotection to afford NADP 7 initially failed due to protecting group 
incompatibilities; however with protecting group alteration formation of NADP 7 was 
achieved. Enzymatic base-exchange with Aplysia ADP-ribosyl cyclase [E.C. 3.2.2.5] 
was achieved to afford the synthesis of NAADP 3, which was proven active by 
biological assay. Analogues were formed using this scheme and evaluated.
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The versatile role of calcium
1.1 Overview of calcium signalling
Calcium is a ubiquitous intracellular messenger that controls a diverse range of 
cellular functions. Calcium is versatile, playing a pivotal role in cellular processes 
such as controlling fertilisation, gene transcription, muscle contraction, cell 
proliferation and secretion of bioactive compounds (Figure l) .1'4 These processes 
occur despite the fact that calcium is highly toxic, causing necrosis and programmed 
cell death (apoptosis).1,3,5 How calcium orchestrates these specific processes at the 
cellular level is the subject of intense study, but can be rationalised by the ability of 
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Figure 1: Overview of the effect of insulin release mediated by calcium in response 
to external stimuli.
Resting cells possess a calcium concentration of 100 nM, however stimulation 
elevates this level to around 1000 nM. ’ The intracellular concentration is finely 
controlled by an extensive repertoire of signalling components, which when 
stimulated, activate the ‘on’ mechanisms, to cause a gradient driven influx of calcium
2
into the cytoplasm (1-2 mM extracellular concentration). As a messenger, calcium 
activates a series of dependent processes before finally, the ‘o ff  mechanism re­
establishes the resting state by pumping calcium into stores (Figure 2).3 The ‘on’ 
mechanisms include channels located on the plasma membrane (PM) to regulate the 
supply of calcium from the extracellular space and channels located on the 
endoplasmic or sarcoplasmic reticulum (ER/SR) to control the internal movement 
from selected organelles. Calcium can only travel a short distance within the 
cytoplasm due to rapid binding to various buffers such as parvalbumin, calbindin- 
D28K and calretinin allowing tight control over movement around the cytoplasm.5 
Release can therefore either be confined to a specific spatial region (e.g. the secretory 
pole of an acinar cell) or can be cell wide, propagating a wave that spreads through 
the entire cytoplasm (e.g. egg fertilisation by sperm). The ‘o ff  mechanism functions 
to remove calcium from the cytoplasm through either, plasma membrane calcium 
ATPase (PMCA) pumps and sodium/calcium exchangers to extrude calcium into the 
extracellular domain or, sarco-endoplasmic reticulum calcium ATPase (SERCA) 
pumps to internally store calcium in selected organelles. Mitochondria play an 
important role in this regulation by having a low affinity, yet high capacity, rapid 
calcium uniporter to significantly reduce the cytosol concentration, while allowing 
slow release back into the cytosol during the recovery phase. Due to their low 
sensitivity to calcium, mitochondria function more effectively when closely linked to 
calcium releasing channels that allow reciprocal interaction with the ER/SR. This 
diversity enables the huge variability in role and function in the signals recorded 


















Figure 2: The units of the calcium signalling network to generate the ON signal 
causing down stream events. The response in terminated by the off signal.
There are three main types of channel responsible for the external influx of calcium 
into the cell. All produce a local effect due to brief opening times and the action of
^ o c
calcium chelating proteins, but only two of these are well documented. ’ ’ Most is 
known about vo lta g e-o p era ted  channels  (VOC’s) that respond to transient membrane 
depolarisation and recep to r-o p era ted  channels (ROC’s), that are often coupled to G- 
proteins. Downstream calcium release in ROC’s is normally in response to external 
stimuli such as, vasopressin, acetylcholine and ATP. There is also a third class, of 
uncertain identity, that respond to internal store depletion called s to re -o p era ted  
channels (SOC’s).3
VOC’s are found mainly on excitable cell types including neuronal and muscle cells, 
where activation is a result of depolarisation of the PM. These channels are 
comprised of five main subunits, but an array of isoforms of these subunits allows 
many different possibilities that are conventionally characterised by their different 
gating properties and pharmacology.2 VOC’s increase calcium concentration in the 
muscle cytosol, either as a result of direct influx through the channel, or downstream 
activation of a channel embedded in the SR. Neuronal activation comprises many 
different sub-types of VOC found either at the synapse to trigger exocytosis of 
neurotransmitters, or along the dendrite to induce gene transcription leading to 
memory and learning.3
4
ROC’s comprise a wide range of structurally diverse channels, which all rely on the 
activation by external stimuli. ROC’s include the N-methyl-D-aspartame receptor, 
which in neurons, is responsible for early synaptic modifications that result in 
learning and memory.3 These channels either directly allow gradient driven influx of 
calcium, or are coupled to G-proteins, generating the release of small, water soluble 
second messengers that rapidly diffuse across the cytosol, bind to receptors on the 
ER/SR, and thus initiate the calcium release.
SOC’s respond to depletion of intracellular stores of calcium, however what is unclear 
is the manner in which this occurs. The ability of the SOC to ‘sense’ calcium levels 
has led speculation towards a coupling between calcium entry channels on the PM 
and release channels on the ER/SR. Since depleting cell calcium pools has been 
shown to enhance calcium entry, these SOC’s may be the most ubiquitous of the PM 
calcium channels.2
It is at these PM bound receptors where the variety of drugs altering calcium release 
act. They have been used to treat a variety of conditions such as high blood pressure, 
cardiac dysrhythmias and angina. By working to inhibit calcium influx into cells they 
promote the relaxation of the blood vessels {e.g. nifedipine), or they reduce the 
workload of the heart by making it less excitable {e.g. verapamil). Both of these 
drugs provide very effective treatment, yet for the ubiquity of calcium, this is one very 
small area of medicine.
The calcium signal can also be derived from internal stores mediated by an array of 
distinct, messenger-activated channels located on either the ER, or, the SR in muscle 
cells. Release from these internal stores is initially a result of the messenger, but 
quickly escalates due to calcium induced calcium release (CICR). There are various 
channels controlled by this mechanism of which the inositol-1 ,4,5-trisphosphate 
receptor (InsPaR) and ryanodine receptor (RYR) have been extensively studied.2*4 
This release is initiated by external stimuli binding to cell surface receptors causing 
the synthesis of second messengers, which diffuse across the cell before binding to 
their respective receptor on the ER/SR. Two such second messengers are inositol- 
1,4,5-trisphosphate (Ins(l,4 ,5 )P3) 1 and cyclic ADP-ribose (cADPR) 2 (Figure 3), 
which act on the L1SP3R and RYR respectively. Although InsPsR’s require 
Ins(l,4 ,5 )P3 1 to open, their activity is modulated by the concentration of calcium in 
the neighbouring cytosol and release is enhanced by a modest cytosolic calcium
5
concentration (0.5-1 pM) via CICR, however large calcium concentrations (>1 pM) 
inhibit opening.2 RYR are structurally and functionally similar to InsPaR, however 
they are activated and inhibited by higher concentrations of calcium (1-10 pM: >10 
jliM ) .  RYR are located mainly in excitable cells such as muscle or neurons, unlike
The apparent wave of calcium that sweeps across the entire cell has been attributed to 
CICR, such as that observed during oocytes fertilisation. At low levels of stimulation 
individual Ins(l,4,5)P3R’s or RYR’s open to release calcium characterised as either a
resultant release of either a ‘puff or a ‘spark’, which can then develop into a self- 
propagating wave. Gap junctions allow the calcium waves to bridge the space 
between separate cells to generate intercellular waves, however the exact mechanism 
of this is unclear. What is apparent is that this allows many cells to function as one,
Other messengers have been studied, namely the sphingolipids, cyclic AMP (cAMP), 
cyclic GMP (cGMP) and nicotinic acid adenine dinucleotide diphosphate (NAADP) 
3. The properties of the sphingolipid receptors bear no similarities to those of 
Ins(l,4,5)P3 or RYR and even though they are expressed in many different cell tissues 
the physiological function of this channel is poorly understood. Upon external 
stimulation, AMP and GMP are modified by adenyl and guanyl cyclase respectively 
to form either cAMP or cGMP, which is intimately linked to calcium concentration 
through its action on channels and pumps. With calcium concentrations initiating 
both a positive and negative feedback mechanism, depending on which isoform of 
adenyl cyclase is acted upon, tight regulation of further cAMP/cGMP synthesis can be





‘blip’ or a ‘quark’. Further stimulation causes clusters of channels to open with the
for example, the wave stimulates lung epithelial cells to beat their cilia in tandem to 
expel inhaled contaminants.3
6
achieved. NAADP 3 is emerging as a novel and highly potent mobilising agent of 
calcium that is only just beginning to be understood. It has been shown to act as a 
second messenger, but the identity of its receptor is still a topic of huge debate. 
NAADP 3 will be discussed at far greater depth later in this chapter, however the 
actions of the sphingolipids, cAMP and cGMP will not be further elaborated.
1.2 Intracellular calcium signalling -  lns(1,4,5)P3
External stimuli, such as hormones, interact with PM bound, G-protein coupled 
receptors or tyrosine kinase linked receptors to induce downstream events, mediated 
by calcium. G-protein coupled receptors allow the activation of a trimeric (a, p and 
y) Gq-protein, resulting in the exchange of GDP for GTP in the a  subunit and 
subsequent dissociation of the a  subunit from the py subunit. This a  subunit then 
activates phospholipase C-p (PLCp) to cleave membrane bound 
phosphatidylinositol(4,5)P2 (PtdIns(4,5)P2) 4 generating water soluble Ins(l,4,5)P3 1 





Scheme 1: Hydrolysis of PtdIns(4,5)P2 4 to Ins(l,4,5)P3 1 and DAG 5.
Tyrosine kinase linked receptors dimerize in response to stimuli, to allow ATP 
mediated autophosphorylation of intracellular tyrosine residues. In turn the Src 
homology region 2 domain of phospholipase C-y (PLCy) binds to the receptor, 
initiating activation of PLCy via phosphorylation. Once activated, cleavage of 
PtdIns(4,5)P2 4 to Ins(l,4,5)P3 I and DAG 5 occurs in the same way as shown in 
Scheme 1. The pathways then split into two branches, both playing crucial roles. 
Ins(l,4,5)P3 1 rapidly migrates across the cytoplasm of the cell where it binds to
7
InsPsR’s on the surface o f the ER/SR to initiate calcium release. Ins(l,4,5)P3 1 does 
however have a short lifespan, in the order o f seconds before being either 
phosphorylated or de-phosphorylated by enzymes. Addition o f a phosphate group is 
mediated by the calcium dependant kinase, phosphatidyl-3-OH kinase (PI(3)K), to 
generate inositol-1,3,4,5-tetrakisphosphate (Ins(l,3,4,5)P4), which although its exact 
mechanism is unclear, does bind a specific GTPase-activating protein of the Ras 
family modulating further calcium release.2 Some cellular responses initiated as a 
result of Ins(l,4 ,5 )P3 1 calcium release are collated in Table 1.
Target Tissue Signalling Molecule Major Response
Smooth muscle Acetylcholine Contraction
Blood platelets Thrombin Aggregation
Hippocampus Acetylcholine Memory
Endocrine glands Acetylcholine Secretion
Mast cells Antigen Histamine secretion
Table 1: Overview o f some cellular responses to Ins(l,4 ,5 )P3 1.
The second product o f the hydrolysis o f PtdIns(4,5)P2 4, DAG 5 exerts different 
effects. First, the fatty acid chain can be cleaved, releasing arachidonic acid, which 
can undergo further modifications to achieve the eicosanoids. Second, and more 
importantly, a small rise in intracellular calcium associated with Ins(l,4,5)P3 causes 
C-kinases (serine/threonine protein kinases) to translocate from the cytosol to the 
cytoplasmic face o f the PM. Once achieved, stimulation with DAG 5 and calcium 
enables these kinases to phosphorylate selected serine or threonine residues on target 
proteins within the cell. Due to the rapid metabolism of DAG 5 it cannot sustain the 
required C-kinase activation for long term responses such as cell proliferation, 
therefore a secondary wave of DAG 5 is generated from the hydrolysis of PM bound 
phosphatidylcholine.
1.3 Intracellular calcium signalling -  cADPR
Although Ins(l,4 ,5 )P3 1 appears to operate as a universal calcium mobilising agent,3 it 
was considered that there may well be other messengers that operate within cells. 
Experiments using a robust sea urchin egg model showed the presence o f other
8
calcium release mechanisms, which enhance and differentiate the signal, regulated by 
a family of pyridinium based nucleotide metabolites. By injection of NAD 6 and 
NADP 7, calcium release could be observed in microsomal egg fractions that were 
devoid of Ins(l,4 ,5 )P3 1.6 This calcium efflux was observed from vesicles previously 
loaded by calcium ATPase’s, with the effect of NAD 6 seen as a cellular calcium 
release after a substantial delay, but NADP 7 appeared to initiate an immediate and 
potent calcium emmision.7 Interestingly, calcium release initiated by addition of 
NAD 6 was only observed in a batch of Percoll purified microsomal fractions, 
incubated with supernatant or cytosol fractions from the same Percoll gradients, 
suggesting the requirement for a second soluble factor to enable the calcium release to 
occur.7 Two co-factors were in fact isolated to enable NAD 6 to produce calcium 
release. First was an enzyme responsible for the conversion of NAD 6 into the active 
metabolite, which was later identified as cADPR 2,8 the second, was calmodulin, that 
confers cADPR 2 sensitivity.9 The instantaneous effect due to NADP 7 will be 
discussed in greater detail later in the chapter. These initial experiments lead a 
challenge to rationalise the exact structure and mechanism of action of this metabolite 
of NAD 6. Isolation and mass spectrometry of the product revealed that the structure 
was smaller than ADP-ribose by one water molecule, and in the same way that cAMP 
is 18 units lighter than AMP, it was recognised that this structure had in fact cyclised 
(Scheme 2).10’11
6 - NAD 2 - cADPR
Scheme 2: Cyclisation of NAD 6 into cADPR 2 with NADase.
Clarification of the enzyme responsible for this conversion was then required. An 
endogenous NADase [E.C. 3.2.2.5] was known to hydrolyse NAD 6 into ADP-ribose, 
but generating an inactive metabolite from a crucial redox co-enzyme was considered
9
wasteful and thus not the only role for the enzyme. NADase was shown to catalyse 
the formation of cADPR 2 from NAD 6 with such efficiency to cause complete 
exhaustion of the endogenous cADPR calcium stores.12 As it was clear that this 
enzyme, purified from Aplysia ovotestis, produced cADPR 2 and not ADP-ribose, it 
was named ADP-ribosyl cyclase. In an effort to identify if there was a homologous 
enzyme in the mammalian system, searching of the GenBank database revealed two 
possibilities, CD38 and CD157, both of which are mammalian antigens.13 They were 
shown to possess 30 % sequence homology with the Aplysia ADP-ribosyl cyclase and 
are both capable of producing cADPR 2 from NAD 6 and interestingly, CD38 can 
also hydrolyse cADPR to ADP-ribose. This suggests an inhibitory role of ADP- 
ribose in channel modulation in eggs and smooth muscle cells 2,11 which is similar to 
Ins(l,4 ,5 )P3 1 in that the metabolite, Ins(l,3,4,5)P4 has a cellular function. CD38 was 
first isolated as a surface antigen on lymphocytes, but has since been shown to be 
present in many other tissues including the eye and brain. Not only is it found on the 
cell surface but also within selected organelles. There is however speculation that 
cADPR 2 is formed in the extracellular space by PM CD38. Transportation of NAD 6 
to the extracellular space may be via a conexin 43 hemichannel where it can then 
undergo CD38 (ADP-ribosyl cyclase) catalysed conversion and translocation to the 
intracellular space.2,14 Regardless of where cADPR 2 is synthesised, comparison of 
CD38 knockout mice and wild-type mice has proven that in-vitro cADPR 2 synthesis 
is massively impaired without the enzyme.15
Experiments have shown that cADPR 2, when injected into sea urchin eggs, does 
release calcium by activation of ryanodine receptors (RYR) located on the 
endoplasmic reticulum (ER).2,13 Characterisation of this receptor has shown it to be a 
large homotetrameric calcium release channel that is widely distributed among many 
cell types.7 cADPR 2 induced calcium release is independent to that of Ins(l,4 ,5 )P3 1, 
because treatment with the Ins(l,4,5)P3 1 antagonist heparin does not desensitise the 
response to cADPR 2. Antagonism is achieved by high concentrations of ryanodine 
(-100 pM) with millimolar concentrations of caffeine acting as an agonist.2 cADPR 2 
plays an important role in mediating calcium induced calcium release (CICR) by 
sensitising the RYR to sub-micromolar levels of calcium, thus increasing the 
frequency of the ‘sparks’ leading to formation and propagation of the wave. Many
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agonists o f the cADPR 2 pathway are found to be cell permeant, such as nitric oxide,
glucose and vitamin B 12; however, cell impermeant agonists can act through
interaction with the surface receptor. This is observed during activation o f the T-
cell/CD3 complex by the OKT3 antibody and also in longitudinal intestinal muscles
by cholecystokinin, both causing calcium influx, stimulating ADP-ribosyl cyclase
1 ^
activity to elevate cADPR 2 levels. Alternative evidence however, suggests that 
activation of the cyclase may be a result o f coupling to a G-protein as stimulation with 
a cell surface muscarinic agonist induces a 2-to 3-fold increase in cyclase activity that 
is inhibited with cholera toxin .13 This is in marked contrast to Ins(l,4 ,5 )P3 whereby 
all activation appears to be via cell surface stimulation. This would suggest that the 
cell has employed two separate calcium messengers to distinguish between permeant 
and impermeant signals. There is however a conflicting report that cADPR 2 may not 
actually be an intracellular messenger as appreciable levels of cADPR exist in cells 
that do not express RYR’s. This evidence may suggest that cADPR is a general 
regulator of calcium signalling, or possesses secondary roles discrete from calcium  
release.2
A brief overview o f the main functions o f cADPR 2 is shown in Table 1.
Stimulus Receptor Cell Response
Acetylcholine Muscarinic Tracheal smooth Contraction
muscle
Anti-CD3 mAb TCR/CD3 Jurkat T cell activation
Cholecystokinin CCKa Pancreas: acinar Secretion
(CCK) cell
Glucose Glucose kinase Pancreas: (3 cell Insulin secretion
Table 2: Overview o f cADPR 2 activation pathways.
1.4 Intracellular calcium signalling -  NAADP
Experiments injecting NADP 7 into sea urchin egg homogenate interestingly caused 
significant and rapid calcium release. This suggested that unlike NAD 6 , enzymatic 
modification was not required and once analysed and separated by HPLC it became 
apparent that the release was in fact caused by a minor contaminant and not by NADP
7 .6 Difficulties came when trying to decipher the structure, as lH NMR spectroscopy 
generated a spectrum for NAADP 3 that was hardly distinguishable from that o f  
NADP 7. Mass spectrometry did show that the structure was one mass unit heavier,
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but it was not until eight years later that the structure of NAADP 3 was published 
(Scheme 3) . 16’17 Amazingly, this single functional group inter-conversion from amide 
to acid confers total specificity for the system as NADP 7 is completely inactive. 
Until that time, pyridinium based nucleotides were only thought to be involved in 
redox biochemistry, whereby the pyridinium ring is reduced to afford NADPH, whose 
primary role is to reduce fatty acids during their biosynthesis. Exploration was then 
performed to further understand its biological synthesis and significance.
HO H2N
nh2
- p^ Uo-p=o -—-
 ^ HO OH Nh2
0 -P = 0
- p^ U0 -P = 0  - -
^  HO OH Nh2
0"P =0
HO ORHO OR
6 - R = H NAD 8 - R = H NAAD
7 - R = P 0 3H- NADP 3 - R = P 0 3H‘ NAADP
Scheme 3: Published structure and proposed mechanism of synthesis for NAADP 3.
ADP-ribosyl cyclase [E.C. 3.2.2.5] from A p lysia  California, homologous with CD38
had already been shown to catalyse the cyclisation of NAD 6 , but it was also able to
cyclise NADP 7 to produce cADPR-phosphate 10. 1 Interestingly, this enzyme is also 
able to catalyse the replacement of nicotinamide for nicotinic acid at acidic pH. This 
base-exchange can be used to convert NAD 6  into NAAD 8  and NADP 7 into 
NAADP 3 (Scheme 3). This enzymatic synthesis of NAADP 3 is the only proposed 
mechanism for in -vivo  formation, however in -vitro  studies require high concentrations 
(mM) of nicotinic acid to be present with a pH of 4-5, which in cells is normally only 
observed in the lysosomes. It is also possible to drive the reverse reaction by 
exposing the cell to large quantities of cell permeable nicotinamide (IC50 -1.5 mM), 
thus achieving product inhibition by re-generation of (3-NADP 7. Some feel that these 
reaction conditions are unlikely to exist within the cell and have speculated on the 
involvement of an NAAD kinase,14’16’17 or NADP 6  deaminase, 17 although such 
enzymes are yet to be reported. A recent report using CD38 knockout mice supports 
the theory that CD38 is responsible for NAADP 3 synthesis. Analysis of brain tissue
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homogenate from these animals showed that CD38 -/- tissue was unable to support 
NAADP 3 synthesis from NADP 7, although it is recognised that this does not 
categorically prove that the base-exchange reaction occurs in-vivo, it merely proves 
that CD38 is required for in-vitro NAADP 3 synthesis from NADP 7 using brain 
homogenate.15 Indeed, in this study, little attention is paid to non-base-exchange 
reactions.
NAADP 3 appears to interact with receptors that are discrete from those activated by 
Ins(l,4 ,5 )P3 1 and cADPR 2 in sea urchin egg homogenates. 18 It has also been found 
to be the most potent agonist of calcium channels with ranges of 10-100 nM 
stimulating the largest calcium signal. Interestingly, high concentrations (> 1-100 
pM) fail to cause any detectable calcium release1 and sub-threshold concentrations 
totally desensitise sea urchin egg homogenates, such that subsequent challenge with 
maximal concentrations (10-100 nM) evoke no response.1’18,19 In other cell types 
such as rat brain, rat pancreatic acinar cells and T-cells activation occurs at 
approximately 1 pM, 50 nM and 100 nM (maximum) respectively. Inactivation also 
occurs with pancreatic cells and T-cells at 1-100 pM and 10 pM respectively, yet no 
inactivation at sub-threshold concentrations is observed.20
Experiments using radiolabelled [32P] NAADP showed that binding, and hence 
retention of radioactivity was only observed in preparations where calcium release 
occurred. Once bound it was unaffected by either subsequent exposure to non­
labelled NAADP, change in pH, or the presence of high calcium concentrations (10 
mM) . 19 This corroborates the theory of irreversible binding, which may be linked to 
the self inactivation21 allowing speculation that, at least in sea urchin eggs, there is a 
possible ‘one shot’ calcium release mechanism, employed during fertilisation. 19 [32P] 
NAADP binding was inhibited by NaCl in a completely reversible, and concentration 
dependant manner (0.5-1 M NaCl for a 25-75 % reduction) , 19 and NaCl was able to 
reverse the inhibitory effect caused by sub-threshold NAADP 3 concentrations in sea 
urchin egg homogenates allowing maximal binding when re-exposed to [32P] 
NAADP.22 How this novel pathway interacts in the overall signalling cascade is still 
under intense scrutiny.
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1.5 The synergy of calcium release
It is speculated that there is a close relationship between all three calcium release 
mechanisms and the term ‘channel chatter’ has been used to describe this. In 
pancreatic acinar cells and sea urchin eggs NAADP 3 acts to trigger the calcium 
response, which is subsequendy propagated by Ins(l,4,5)P3 1, and cADPR 2, by 
CICR. However inhibition of either Ins(l,4 ,5 )P3 1 or cADPR 2 blocks the NAADP 3 
response in acinar cells (Figure 4(a)), yet in urchin eggs both receptors require 
inhibition suggesting a redundant pathway in that cell line (Figure 4(b)). 
Interestingly, in sperm cells and T-cell/CD3 complexes it seems to be more 
complicated whereby the NAADP receptors interlink with Ins(l,4,5)P3R in sperm and 
both Ins(l,4,5)P3R and RYR in T-cells.
Clearly the precise mechanism of coupling is still very poorly understood,1 but 
whether NAADP 3 does actually address a discrete calcium pool has still not 
categorically been proven. Experiments revealed that NAADP 3 can still cause 
calcium mobilisation after inhibition of calcium ATPase pumps by thapsigargin, 
which drains the ER calcium stores sensitive to Ins(l,4,5)P3 1 and cADPR 2. This 
shows that NAADP 3 does not mobilise calcium from the ER ’ and later studies 
suggest that calcium is released from lysosome related organelles in sea urchin eggs, 
which will be discussed later.1,24 However a type 2 RYR from dog heart incorporated 
into a lipid bilayer showed a response to NAADP 3, although it should be 
acknowledged that the concentration was 100 times higher than previously reported 
for other systems. These findings may indicate that the NAADP receptor is an 
accessory protein, which binds to a known channel on the ER rather than an actual 
novel intracellular channel.14
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Figure 4: The effect of channel chatter in pancreatic acinar cells and sea urchin egg
oocytes.
There is evidence of spatial separation between stores activated by NAADP 3 and 
those by Ins(l,4 ,5 )P3 1 and cADPR 2 found in starfish oocytes. Uniform photolysis 
of oocytes and pancreatic acinar cells preloaded with caged NAADP 3 showed a 
highly localised release of calcium in the region of the cortex and apical pole 
respectively, which would suggest a fine-tuned signal for a specific function. 
However, localised photolysis of caged NAADP 3 in sea urchin eggs produced a
1 ' Xwave that propagated across the entire cell. ’ There are however differences noted 
in starfish oocytes with a fluorescent halo, restricted to the cytosol, which rapidly 
decays when the NAADP is locally uncaged in Astropecten auranciacus cells. 
However, the wave initiated by activation of Ins(l,4 ,5 )P3R, does eventually spread 
across the cell it just requires a longer time.
1.6 Tissues responsive to NAADP
Not as many cell systems have been identified as being responsive to NAADP 3 
compared to those of cADPR 2. Table 3 lists a large selection of the systems where 
NAADP 3 has been shown to be required.
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Cell or tissue NAADP effect Effective concentration
Cauliflower Inactivation 3nM
Activation 1 pM
Sea urchin egg Inactivation <1 nM (IC50 = 200 pM)
Activation >3 nM (EC50 = 25 nM)
Starfish oocytes Activation < ~ 1  pM





Rat pancreatic acinar Inactivation 1-100 pM
cells Activation 50 nM
Rabbit heart Activation 320 nM
Human T- Inactivation 10 pM
lymphocytes (Jurkat) Activation EC50 = 50 nM
Pancreatic (3 cells Activation ~ 100 nM
Table 3: Overview o f cells responsive to NAADP 3 .20
The mechanism of calcium release mediated by NAADP 3 has been extensively 
studied in a variety o f cell types. NAADP 3 was first shown to mobilise calcium from 
sea urchin eggs16,17 and has since been shown to initiate and co-ordinate calcium 
signalling pathways.1
Sea urchin eggs
Sea urchin eggs have become widely used as a tool for the investigation of calcium  
release as they can be produced in relatively large batches and possess multiple 
signalling mechanisms for calcium release, that are easily manipulated.26 In this way 
using caged compounds in combination with confocal microscopy, identification of 
the organelles targeted by NAADP 3 was obtained.24 It was shown that organelles 
disrupted via osmotic lysis using glycyl-phenylalanine 2-naphthylamide (GPN, 100 
|iM), a substrate o f the lysosomal exopeptidase cathepsin C, produced a significantly 
smaller rise in calcium when subjected to photo-activated NAADP 3 .24 Lysosomes 
were fluorescence labelled with the targeted dye LysoTracker Red, whereupon 
introduction o f GPN caused dissipation o f the fluorescence, confirming their lysis. In 
contrast to this, GPN did not reduce the amount of calcium released by either
16
Ins(l,4 ,5 )P3 1 or cADPR 2, suggesting that GPN-mediated disruption of lysosomes 
selectively reduces the response to NAADP 3 .24 It is known that protons are actively 
pumped into lysosomes through ATPase pumps and it is this gradient which drives 
the influx of calcium via a proton/calcium exchange pumps.24 Bafilomycin A1 is a 
useful tool as it disrupts calcium storage through inhibition of the proton ATPase 
pump, which manifests itself as a reduced calcium release in response to NAADP 3
•nc
activation, for example, dunng fertilisation.
Fertilisation of the egg elicits a cell wide calcium wave, stimulating the initiation of 
cell division and eventual maturation.13 This can be visualised in Figure 5 by the 
localised photorelease of caged NAADP 3.
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Figure 5: Propagation of the calcium wave in a sea urchin egg upon localised 
photorelease of NAADP 3. The calcium released is visualised by its chelation to the 
fluorescent dye, Fluo-3.
Until recently it was believed that immediately after fertilisation, the egg synthesised 
NAADP 3 or released it from a store to initiate the initial calcium release that 
eventually propagated across the entire cell as a wave by CICR .1’21 A recent study 
using the eggs of Lytechinus pictus (a sea urchin) showed binding of the spermatozoa 
to the egg plasma membrane (PM), may present a separate compartment containing 
NAADP 3. As a result, it was postulated that release of the sperm cytosol into the egg 
donated not only nuclear material, but also a locally high concentration of NAADP 3,
9 9which initiated the wave. There is however some contradictory evidence to suggest 
that the spermatozoa interacts with a NAADP receptor at the PM to initiate the 
synthesis of NAADP 3, however no such receptor has been isolated, yet NAADP 3
9 9has been characterised in spermatozoa. Experiments revealed that egg homogenates 
pre-treated with sperm extract, or with an inhibitory concentration of NAADP 3 did
99not bind radiolabelled [ P] NAADP. Furthermore, NAADP 3 and sperm extract were 
unable to displace radiolabelled [32P] NAADP, but high salt concentration could 
displace both.22 These findings are consistent with the theory that spermatozoa
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contain NAADP 3. It was also speculated that the base-exchange reaction was 
responsible in the spermatozoa for the conversion of NADP 7 to NAADP 3 (Scheme 
3) as the absence of nicotinic acid inhibited its formation. The base-exchange 
reaction was time and pH dependent with maximal production after one hour and at 
pH 5, consistent with enzymatic formation.22 This evidence strongly suggests a role 
for NAADP 3 as an initiator of a cell wide calcium wave, once it is released into the 
cytosol of the egg during fertilisation. This in turn initiates downstream events 
leading to maturation of the cell.
T-cells
T-cell proliferation in response to an antigen has been attributed to activation of the T-
cell/CD3 complex. This complex has been shown to elicit a fast increase in calcium
13 oncaused by Ins(l,4 ,5 )P3 1, followed by a sustained response mediated by cADPR 2. ’
It is now emerging that NAADP 3 is closely linked to this activation pathway, but 
unlike sea urchin eggs, NAADP 3 at sub-threshold concentrations (10 nM) does not 
cause inactivation, but instead initiates low-amplitude calcium spikes.27 Stimulation 
with optimal concentrations (50 -  100 nM) triggered CICR from Ins(l,4 ,5 )P3 1 and 
cADPR 2 stores. Interestingly, high concentrations (>10 pM) were self-inactivating, 
abolishing the calcium release arising from subsequent stimulation via the activated 
T-cell/CD3 complex, or Ins(l,4 ,5 )P3 1 and cADPR 2 pathways.27
Pancreatic fi-cells
Calcium release and subsequent downstream insulin secretion has been studied in 
pancreatic P-cells. It has been shown that acetylcholine acts to stimulate Ins(l,4 ,5 )P3 
1 and cADPR 2 pathways through interaction with the ER and that glucose stimulates 
the NAADP 3 pathway mediated by lysosomal related organelles (Figure 6 ) .25 This 
work showed that NAADP 3 mobilised calcium from a store independent from those 
stimulated by Ins(l,4 ,5 )P3 1 and cADPR 2 on the ER. Using whole cells it was 
possible to demonstrate that glucose initiated calcium release lead to subsequent 
insulin secretion via an acidic lysosomal NAADP 3 store that was sensitive to 
bafilomycin A l. It is less clear how NAADP 3 elicits the influx of extracellular 
calcium into p-cells, however a possible mechanism may be linked to voltage 
operated channels similar to those observed in sea urchins. In response to external
18
stimuli, this direct release of calcium from internal stores, independent from those of 
other specific second messengers, confirms NAADP 3 as a second messenger for the 
first time. This rise in calcium has thus been shown to cause a downstream event and 
in this example causes the release of insulin to directly reduce the blood glucose 
concentration.
In te rn a l
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Figure 6 : Effect of glucose causing NAADP 3 mediated calcium release from an 
organelle discrete from that acted on by cADPR 2 and Ins(l,4 ,5 )P3 1.
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1.7 Inactivation of NAADP
NAADP 3 has been shown to be highly active in a range of cell types, so there must 





Scheme 4: Proposed mechanism of inactivation of NAADP 3
It has been shown in brain tissue that NAADP 3 is metabolised predominantly to 
NAAD 8  by dephosphorylation.28 This is in contrast to NADP 7 which mainly 
undergoes metabolism to ADP-ribose.28 Addition of the calcium chelator, EDTA 
showed attenuation of this metabolic pathway to form NAAD 8 , revealing the 
intimate relationship between this feedback mechanism and cytosolic calcium 
concentration. These results also suggest that metabolism does not proceed via base- 
exchange as NAADP 3 is not converted to the NADP 7 metabolite ADP-ribosyl 
phosphate 10.28 Recently emerging data suggest that NAADP 3 might also be 
inactivated by reduction to NAADPH 9, catalysed by glucose-6 -phosphate 
dehydrogenase [E.C. 1.1.1.49] with a small amount of ADP-ribose phosphate 10 also 
produced.29 NAADPH 9 had virtually no calcium release properties with
10 - ADP ribosyl phosphate
8 -NAAD3 - NAADP
HO cp
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concentrations above 400 nM required to observe release. This result seems 
remarkable because one might expect some contamination or degradation of 
NAADPH 9 to NAADP 3 and concentrations as low as 3 nM (of 3) will cause 
calcium release. It was also shown that sub-threshold NAADPH 9 concentrations, 
incubated for 5 minutes, serve to inhibit subsequent NAADP 3 stimulation. However, 
in 5 minutes it would be reasonable to expect that the unstable NAADPH 9 could 
undergo oxidation to NAADP 3, in sufficient concentration to cause the receptor 
inactivation, which would invalidate this result. It was speculated that NAADPH 9 
could either then be used as a precursor molecule to NAADP 3 by undergoing 
oxidation before instigating calcium release, or as a metabolite that can efficiently 
inactivate the calcium signal allowing storage of this molecule in an inert state.29 
Work undertaken within our group found that unlike NADPH, it was very difficult to 
produce NAADPH 9 by either chemical or enzymatic methods, and even harder to 
purify due to decomposition to ADP-ribose phosphate 10, or re-oxidation to NAADP 
3.
1.8 Summary of NAADP
NAADP 3 has been shown to be active in a number of cell types producing an array 
of responses that have been characterised to varying degrees. It has now been firmly 
established as an endogenous molecule responsible primarily for the initiation and co­
ordination of calcium release. Its release from stores independent of Ins(l,4 ,5 )P3 1 
and cADPR 2 suggest that NAADP 3 is a second messenger of immense interest. 
However, the exact mechanism for in-vivo synthesis and metabolism still remain a 
topic of huge debate. Unfortunately, studies are currently restricted due to the limited 
array of chemical probes available to interrogate this system. As the total synthesis of 
NAADP 3 has not been previously published, analogues have been limited to direct 
alteration of NAADP 3 or NADP 7 modifications that still remain substrates for ADP- 
ribosyl cyclase. A disadvantage of this approach is potential contamination with very 
potent NAADP 3 in the product. Total chemical synthesis of NAADP 3 would 
provide a much more feasible route toward structurally relevant analogues. It is 
hoped that these analogues will help isolate the NAADP 3 receptor protein and allow 




2.1 Synthesis of chemical analogues
A small structure-activity relationship (SAR) of NAADP 3 (Figure 7) involving
readily accessible modifications of NADP 7 such as substitution of nicotinic acid for
18analogues using Aplysia ADP-ribosyl cyclase had previously been investigated.
12 - Inactive 11 - Inactive
3 - Active at 15 nM
14-1 0 0 0 0  nM
0 -N +
19 - 75 nM 18 - 300 nM 20 - Inactive °
Figure 7: Activity of NAADP 3 and closely related analogues.
Installation of the alcohol equivalent 11 generated an inactive compound, which 
provided evidence that the carboxylate negative charge was essential for activity. 
This is confirmed by the fact that NADP 7 is totally inactive in the mobilisation of 
calcium. Altering the position of the carboxylic acid from the meta to the para 
position 1 2  also resulted in total loss of activity, suggesting that the active site of the 
receptor is very tightly controlled. There is however a small degree of tolerance of 
the negative charge or aromatic group as both the sulphonic acid 13 and quinoline 3- 
carboxylate 14 remain partially active. Pyridines substituted at the 2-position were 
not substrates for the cyclase enzyme inhibiting their inclusion into the SAR scheme 
(Figure 7) . 18
Other analogues were obtained by conversion of the adenine base. Replacement of
the adenine ring for a hypoxanthine (purinyl amine replaced by a hydroxyl) resulted
18in desamino NAADP 15 after base-exchange. Two fluorescent analogues were
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synthesised by manipulation of commercially available etheno NADP. Replacement 
of the nicotinamide for nicotinic acid resulted in the formation of etheno NAADP 16 
that with further modification led to etheno-aza NAADP 17 (Figure 7) .30 Both were 
partially active but highly fluorescent, potentially enabling in-vivo detection. Both of 
these analogues retained the nitrogen at the 6 -position, suggesting that it may 
contribute to activity.30
NAAD 8  was completely inactive in mobilising calcium, while the 2',3'-cyclic 18 and 
the 3'-regio-isomers 19 were found to be less active, proving that the 2'-phosphate 3 is 
essential for activity. 18 Formation of a phosphate ester at the 2'-position renders the 
molecule inactive, however the nitrophenyl ester 2 0  was synthesised to provide caged 
NAADP which could be activated in-vivo upon flash photolysis (Figure 7) .31
All of the analogues that confer activity are agonists and also retain the self­
inactivation observed for NAADP 3. Despite this intriguing effect there has been no 
reported antagonists, even though agonists may be used as pseudo-antagonists via the 
self-inactivation mechanism. 17,32
This small study provided an invaluable insight into the chemical biology of NAADP 
3; however the range is seriously limited by requiring substrates that can still be 
turned over by enzymes. This is emphasised by the lack of knowledge regarding 
other positions such as the positive charge and substitution at the 2 -position of the 
pyridinium. Total chemical synthesis therefore offers the most practical approach to a 
wider range of analogues without the potential complication of trace NAADP 
contamination skewing observed result. Therefore formation of analogues, devoid of 
any potential trace of NAADP 3 would be of great value.
2.2 Project aims
The aim for this project is the development of a synthetic route that would be 
sufficiently flexible to allow modifications at key positions. Initially, these could 
focus on the pyridinium ring, but later targets include the adenosine-2 '-phosphate and 
the pyrophosphate (Figure 8 ).
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Figure 8 : Target areas for NAADP 3 analogue synthesis.
2.3 Synthetic strategy
Late stage pyrophosphate bond formation would enable the two halves of the 
molecule to be linked through a convergent synthesis, which should enable 
modifications to be installed in the initial stages of the synthesis and reduce potential 
problems that may be associated with late stage alterations. Chemical synthesis of the 
2'-phosphate moiety would be required as biological studies have shown that the 3'- 
phosphate 19 is distinctly less active. 18 To achieve this, an efficient synthetic scheme, 
incorporating minimal protecting groups would ideally be employed, thus avoiding 
potentially problematic late stage cleavage (Scheme 5).
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Scheme 5: Retrosynthetic approach to the synthesis of NAADP.
The formation of nicotinic acid ribonucleotide will provide a number of synthetic 
challenges. Initially, glycosidic bond formation will be required, with a suitably 
protected pyridinium ester moiety that can be cleaved to afford the carboxylate during
the later stages of the synthesis and secondly, selective phosphorylation at the 5 -  
ribose hydroxyl will be required. To facilitate efficient synthesis, work will be carried 
out to achieve this without the use of ribose protecting groups, however, it may 
become necessary to incorporate these to afford the desired ribonucleotide.
Synthesis of the adenosine moiety will require manipulation of protecting groups as 
the 2 '-ribose hydroxyl will need to be either selectively unveiled or activated to allow 
regio-specific phosphorylation to ensure purity of the final compound. Protected 
phosphates will also be required to increase the lipophilicity of the compound to 
enable reactions and purification to be carried out with organic solvents for a large 
proportion of the synthesis.
Once the 5'-hydroxyl has been phosphorylated, pyrophosphate bond formation will be 
required to link the two halves together. This will entail challenging chemistry as 
there is a limited pool of reported methods for this reaction and the yields are often 
poor. A method will need to be developed that offers high yields, as this is the critical 
step in the synthesis.
Once a synthetic route has been developed, the emphasis can shift towards analogue 
formation. Initially, modification to the pyridinium ring will enable further 
understanding of the importance of the positively charged nitrogen along with the 
necessity for the base labile glycosidic linkage. Once formed this analogue will be 
tested for its ability to release calcium in sea urchin egg homogenates to further 
develop the SAR surrounding NAADP 3.
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Chapter Three




Development of a flexible route towards enantiomerically pure pyridinium ribosides 
was sought to enable the total chemical synthesis of NADP 7, NAADP 3 and an array 
of analogues. Phosphorylation at the 5'-position would then provide access to linkage 
with the adenosine moiety via a pyrophosphate bond, providing a late stage, 
convergent synthetic route. A flexible synthesis is required to enable the generation of 
analogues to investigate the biochemistry of NAADP 3.
P-Nicotinamide mononucleotide (P-NMN) 21 is a key portion of co-enzymes NAD 6
<7 <7
and NADP 7, allowing the transfer of hydrogen during redox reactions. In-vivo 
synthesis of NAD 6  proceeds by reaction of the vitamin niacin (nicotinate) 22, which 
is added to phosphoribosylpyrophosphate (PRPP) 23 to form p-nicotinic acid 
mononucleotide (p-NaMN) 24. Linkage to adenosine monophosphate (AMP), from 
adenosine triphosphate (ATP) 25, catalysed by nicotinamide/nicotinate 
mononucleotide adenylyltransferase (NMNAT) [E.C. 2.7.7.1], gives NAAD+ 8 , which 
is finally converted to NAD 6  upon transfer of the amide group by exchanging 
glutamine into glutamate (Scheme 6 ) .34
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Scheme 6 : Biosynthetic pathway for synthesis of NAD 6 .
In-vitro synthesis of A-1-pyridinium ribose compounds requires p-stereoselective 
glycosidic bond formation. Use of protecting groups is limited by requirement for 
subsequent cleavage in the presence of the newly formed labile pyridinium bond. 
Consequently, there have only been four main approaches reported over the past forty 
years.
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p-NMN 21 has been produced by the enzymatic degradation of NAD 6 , using NAD- 
pyrophosphatase.33 Reaction in the presence of enzyme adsorbed on buffered P- 
cellulose at 37°C provided 2.9 g of p-NMN 21 in 82 % yield based on NAD 6 . This 
presents an attractive route to large-scale p-NMN 21 production, however it is 
impractical as a flexible route for the production of structural analogues.
Previous work used adenosine monophosphate (AMP) 26 as the starting material in 
the chemical synthesis of enantiomerically pure p-NMN 21 (Scheme 7) .35 AMP 26 
was degraded to ribose 5-phosphate 27 by refluxing in an aqueous solution of acidic 
Dowex resin. Subsequent treatment with dry ammonia gas afforded the 1-amino 
ribose 5-phosphate 28, which was followed by the in situ Zinke reaction with l-(2,4- 
dinitrophenyl)-3-carbamoyl-pyridinium chloride (NDC) 29. This provided 
diastereotopic NMN 21 in quantitative yield from ribose-5-phosphate 27 in an 
isomeric ratio of 4:6 (a:p). Even though this route provides an efficient synthesis of 
p-NMN 21, it is not generated as the single diastereoisomer. However, as the next 
step required enzymatic coupling with NAD pyrophosphorylase [NADPP, EC 2.7.5.1] 
to ATP 25, resolution was not required due to the specificity of the enzyme for only 
the p-isomer.35
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Scheme 7: Reagents and conditions: i) Dowex H+, water, 100 °C, 6  mins; ii) ethylene 
glycol, ammonia gas, 0°C, 30 mins, then 27, 5 °C, 15 h; iii) NDC, CH3OH, 5 °C, 14 h.
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A recent synthesis of NAD 6  involved bromination of commercially available tetra-O- 
acetyl-p-D-ribose 30 using HBr to afford 31 (Scheme 8 ), prior to glycosylation with 
nicotinamide 32 to afford 33 in a 1:25 a:p ratio after re-crystallization. The reported 
deacetylation using methanolic ammonia caused substantial nucleoside cleavage. 
Low temperature conditions (-5 °C) solved this problem leading to pure p- 
nicotinamide nucleoside 34. Phosphorylation using an excess of POCI3 and 
trimethylphosphate led to the formation of P-NMN 21 after isolation on Dowex resin.
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Scheme 8 : Reagents and conditions: i) HBr, CH2CI2; ii) nicotinamide 32, SO2, -10 
°C; iii) 3 equiv. of NH3, 1 M in CH3OH, -3 to -5  °C, 20 h; iv) POCl3, PO(OMe)3, -5 to 
0 °C, 7 h.
Commercially available tetra-acetyl ribose 30 has also been activated with the Lewis 
acid trimethylsilyltrifluorosulphonate (TMSOTf) and reacted with nicotinamide 32 to
o/r
afford the protected nicotinamide ribose 38. This reaction proceeded via the 
following mechanism. The anomeric acetate was eliminated via the formation of the 
oxonium ion 35, which underwent mframolecular ring closure initiated by the 
neighbouring 2-acetyl 36 to afford the a-oxonium cation 37. Subsequent reaction 
with nicotinamide 32 therefore provided the p-isomer 38 (Scheme 9). In situ 
transesterification was achieved by the addition of CH3OH, which afforded 
nicotinamide nucleoside 39 as the p isomer, in >95 % yield as characterised by *11
30
NMR spectroscopy, whilst avoiding basic protecting group removal, thus making it 





91 % overall yield




















Scheme 9: Reagents and conditions: i) Nicotinamide 32, TMSOTf, CH3CN, 1 h; ii) 
CH3OH, 30 mins.
3.2 Synthesis of nicotinamide riboside and its analogues
This efficient production of p-nicotinamide nucleoside 39 with mild acetate cleavage 
encouraged us to explore the Lewis acid activated route further. The formation of the 
tri-acetyl intermediate 38 was observed by TLC, but never isolated; instead the 
mixture was treated with CH3OH to allow the in-situ transesterification to afford 39. 
Purification of the product on an activated charcoal column, as described in the 
literature, was unsuccessful due to the loss of material on the column. An 
alternative method of purification was thus sought. Partitioning of the reaction 
material between water and «-butanol, followed by silica flash chromatography of the 
concentrated aqueous phase, afforded the nucleoside triflate salt 39 in 91 % yield as 
an oil (Scheme 9). Formation of the glycosidic bond was confirmed by analysis of the 
NMR spectrum, which showed a downfield shift for the pyridinium protons 
suggesting that they were in the electron deficient environment of a positively charged 
nitrogen. By structural examination of the dihedral angle between the anomeric 
proton and the 2' proton it was possible to assign the stereochemistry from the *H 
NMR spectrum. In ribose, the angle exists at approximately 130 to 140° when the 
anomeric proton is a  (hence substitution is p) (Figure 9). By substituting this angle 
into the Karplus equation it equates to a vicinal coupling of 4 to 5 Hz. The
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corresponding value for a  substitution would be approximately 8 Hz. Analysis of the 
anomeric proton indicated that the product had formed the single p-isomer with a 
coupling constant to the 2'-proton of 4.2 Hz. This successful result led us to explore 
how other pyridinium bases react under these conditions.
Dihedral angle
Figure 9: The dihedral angle between the anomeric proton and the 2' proton of P-D- 
ribose. Black = carbon; red = oxygen; blue = hydrogen.
The glycosylation was carried out using different pyridinium bases, initially methyl 
nicotinate and nicotinic acid, to ascertain the flexibility of the route (Scheme 10). 
Under the same conditions the desired methyl nicotinate riboside 40 was synthesised 
in 81 % yield after partition between water and n-butanol followed by flash 
chromatography of the concentrated aqueous phase. Using nicotinic acid, however 





Scheme 10: Reagents and conditions: i) a) Methyl nicotinate, TMSOTf, CH3CN, 1 h; 
b) CH3OH, 30 mins; ii) nicotinic acid, TMSOTf, CH3CN, 2 h; b) CH3OH, 30 mins; 
iii) PSL, 60 °C, 24 h, or 1 M HC1, 18 h.
Analysis of the ‘H NMR spectrum for the methyl ester 40 proved that glycosylation 
had occurred, as shown by a downfield shift of the pyridinium protons, while the p- 
stereochemistry was confirmed by examination of the anomeric coupling constant
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(4.4 Hz). Even though hydrolysis to the carboxylic acid 41 at this stage in the 
synthesis is not required, trial reactions would ascertain whether hydrolysis may be 
possible and if so, highlight any potential problems that could be encountered later in 
the synthesis (Scheme 10). Basic hydrolysis was avoided though, due to possible 
epimerisation to 42 or cleavage of the glycosidic link (43 and 22), as previously 
reported (Scheme l l ) .37
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Scheme 11: Possible results of using aqueous base to perform the ester hydrolysis.
A method utilising an enzyme was investigated using Pseudomonas cepacia lipase 
[E.C. 3.1.1.3] at 60 °C over 24 hours,38 but unfortunately this proved to be 
unsuccessful. Analysis of the NMR spectrum showed that both the anomeric and 
pyridinium protons had shifted upfield, presumably due to glycosidic bond cleavage, 
leaving an impure mixture of ribose 43 and nicotinate 22. Acid catalysed ester 
hydrolysis using 1 M HC1 was also evaluated, but this failed to show that a reaction 
occurred in all but one instance, when the *H NMR spectrum did show the presence of 
a second anomeric peak further upfield at 6.27 ppm. It was not possible to isolate this 
product to obtain any reliable data from this reaction and the focus was therefore 
shifted towards a protecting group, such as a benzyl ester that could undergo late 
stage neutral cleavage using H2, without causing glycosidic bond hydrolysis or other 
side reactions.
Initially nicotinic acid was protected using 0.9 equivalents of benzyl alcohol in the 
presence of DCC and DMAP to afford the ester 44 as a clear colourless oil in 67 % 
yield. The ester 44 was then reacted with teJraacetyl-ribose 30 under the established 
protocol (Scheme 12). As the product was soluble in both water and n-butanol, 
separation was accomplished using H2O and EtOAc, and the concentrated aqueous 
phase later analysed by *H NMR spectroscopy. An anomeric peak at 5.9 ppm (7=3.9 
Hz, characteristic of the (3-isomer), and the pyridinium protons confirmed that
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glycosylation had occurred. However, no signals were observed for the benzylic ester 
protons. Mass spectrometry analysis showed a peak at 256 establishing that the 
nicotinic acid riboside 41 had indeed been formed (Scheme 12) presumably via in situ 
TMS catalysed debenzylation in 87 % yield. For the complete synthesis of NAADP 
the carboxylic acid is required, but it must remain protected until the final stages to 
prevent unwanted side reactions. Avoiding an aqueous workup and subjecting the 
crude material to silica flash chromatography, afforded the benzyl protected material 
45 in 82 % yield, although, it still remained extremely water sensitive, and hence 
unusable in the synthetic scheme.
A c o V r V  —L -ho^ V ^ ')— (. I 82 % )— C -OTf
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Scheme 12: Reagents and conditions: i) a) Benzyl nicotinate 44, TMSOTf, CH3CN, 2 
h; b) CH3OH, 1 h; ii) aqueous work up.
3.3 Phosphorylation of nicotinamide riboside and its 
analogues
Conditions were sought to achieve phosphorylation of the nicotinamide ribose 5'- 
alcohol 39. Methods utilising either trimethyl or triethyl phosphate should allow the 
selective phosphorylation without the need for protecting groups based on precedence 
for phosphorylation of guanosine 46.39 For guanosine, the 5'-hydroxyl group is 
believed to form a hydrogen bond with the P=0 group, which acts as a Lewis base, 
while the N9 interacts with the phosphorus atom (Figure 10). It was speculated that 
nicotinamide riboside 39 would behave in a similar manner to enable the selective 
phosphorylation, but several attempts to treat nicotinamide riboside with 
stoichiometric quantities phosphorus oxychloride (POCI3) in triethylphosphate 
produced no visible results.
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Figure 10: The complex formed between guanosine and triethylphosphate causing the 
activation of the 5' hydroxyl.
The addition of 0.5 equivalents of H2O to POCI3 was explored as this produces a more
OQ
reactive species that may provide better yields (Scheme 13). Monitoring of the 
reaction was difficult due to the high polarity of both the starting material and 
product. Conditions for reverse phase HPLC were found, enabling a change in 
retention time to be detected (Method B: Rt 8  minutes (39) to 3 minutes (21)). 
Purification of the p-NMN 21 from this reaction mixture proved difficult due to the 
polarity of the products. Reverse phase chromatography failed to separate the 
compounds as they eluted on the solvent front when loaded in H2O. Ion exchange 
chromatography was also difficult using positively charged resin, such as AG-MP1 as 
neither the neutral product 21, nor cationic starting material 39, was retained. 
Previous literature purifications of p-NMN 21 utilised two successive negatively 
charged resins, Dowex 1X2 formate and 50 WX8  I f1' respectively.37 Unfortunately, 
attempts at this method only yielded triethylphosphate.
Scheme 13: Reagents and conditions: i) Trimethylphosphate, POCI3, H2 0 , 5 h, 0 °C.
Ultimately, it was found that using trimethylphosphate provided better yields, perhaps 
enabling formation of the complex as shown in Figure 10. Precipitation of the 
product from CH3CN:diethylether (1:3), followed by elution through the same 
negatively charged resins provided p-NMN 21 in 14 % yield. This yield does not 
correlate with the conversion observed by HPLC analysis, leading us to believe that






loss during purification had occurred. Even though this yield is low, it does enable 
the synthesis to continue to attempt the formation of protected acid ribonucleotides. 
Improvements to the yield could be achieved by the development of a negatively 
charged resin purification method that would retain the starting material 39 allowing 
separation from the neutral product 2 1 .
Phosphorylation of the benzyl and methyl nicotinate (45, 40) riboside led to a 
complex mixture of products (as shown by both JH and 13C NMR), which could not 
be purified. Attempts to precipitate the products via a variety of conditions only led 
to product degradation. Phosphorylation of the nicotinic acid riboside 41 gave a 
product that proved just as difficult to purify even though a precipitate was obtained 
(Scheme 14). This method was therefore abandoned as a route to install the 5'- 
phosphate on protected nicotinic acid ribosides.
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Scheme 14: Reagents and conditions: i) Trimethylphosphate, POCI3, H2 0 , 5 h, 0 °C.
An alternative route could involve synthesis of ribose 5-phosphate, followed by 
formation of the glycosidic bond, to afford either p-NMN 21, or protected carboxylate 
analogues. POCI3 could be utilised to install the 5' phosphate, but phosphoramidite 
chemistry may provide a more efficient method of producing a protected phosphate 
that may be easier to purify using silica flash chromatography. Protecting groups on 
the three secondary alcohols would ensure regio-selectivity and may further increase 
lipophilicity, thus aiding organic solubility and purification.
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3.4 Formation of p-D-ribose 5-phosphate
°- ‘OH ii)v *OH oHO \ _ f  — ^
ho'  oh 67 °/e
43 47 48
Scheme 15: Reagents and conditions: i) Triphenylchloromethane, pyridine, 45 °C, 1 
h; ii) AC2O, Et3N, toluene, 18 h.
D-Ribose 43 was selectively protected using trityl chloride and pyridine exploiting the 
higher reactivity of the 5'-alcohol leading to 47 in 67 % yield, after purification 
(Scheme 15).40 Mass spectrometry analysis only showed a peak at 243 due to 
cleavage of the labile trityl group. Acetylation with acetic anhydride and Et3N 
provided rri-acetyl ribose 48 in 69 % yield (Scheme 15).40 The coupling constant of 
the anomeric proton (1.0 Hz) in the *H NMR spectrum indicated the acetate protection 
had adopted the P-conformation, even though the dihedral angle must be strained to 
approximately 110°. This is further supported in the literature 40 which confirms that 
Et3N does afford primarily the p-isomer at 6.22 ppm. When pyridine is used as a 
catalyst both isomers are produced in a 1:1  ratio and the a  isomer is further downfield 
at 6.53 ppm. As no peak is observed in that region, it was concluded that the P- 
isomer had been selectively formed. Trityl deprotection using a 2 % solution of TFA 
in CH2CI2 (Scheme 16) initially led to only partial cleavage of the trityl group due to 
the rapid back reaction with the reactive carbocation species. 2  % H2O was added to 
scavenge this species leading to the improved yield of 76 % of triacetyl-ribose 49 
after purification.
OAc j)
— -— -  ho u T
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48 49
Scheme 16: Reagents and conditions: i) 2 % TFA, 2 % H2O, CH2CI2, 3 h.
The rri-acetyl ribose 49 was then reacted with POCI3 under the standard protocol to 
phosphorylate the primary hydroxyl (Scheme 17).
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Scheme 17: Reagents and conditions: i) Trimethylphosphate, POCI3, H2 0 , 0 °C, 5 h.
As the rriacetyl-ribose 49 no longer possessed a chromophore, TLC visualisation by 
UV light was difficult, but staining with PMA or KMnC>4, revelaed the disappearance 
of starting material 49 and the appearance of a new spot on the baseline. Extraction 
of the product 50 into water afforded a mixture that was difficult to resolve. 
Purification by AG-MP1 chromatography was thought possible as the product was 
negatively charged. However, the poor UV absorbance meant that each fraction 
required staining with PMA, but isolation only afforded trimethyl phosphate. As the 
remaining hydroxyls were protected, phosphoramidite chemistry was employed to 
provide the desired di-benzyl protected 5'-phosphate, which contained a UV active 
chromophore that also aided in detection and purification. Reaction of the primary 
alcohol 49 with the benzyl phosphitylating agent 52 and imidazolium triflate 51 
catalyst afforded, after mCPB A oxidation, the desired protected phosphate 53 in 85 % 
yield following silica flash chromatography (Scheme 18).
Scheme 18: Reagents and conditions: i) a) J5w(benzyloxy)diisopropyl
aminophosphine 52, imidazolium triflate 51, CH2CI2, 3 h; b) mCPBA, -78 °C, 30 
mins.
Attempts to remove both benzyl protecting groups under hydrogenation conditions in 
the presence of 20 % Pd(OH)2/C and cyclohexene proved difficult. Despite both TLC 
analysis and 31P NMR spectroscopy (8  0.69 ppm) showing complete reaction within 
three hours a complicated mixture of products was obtained after purification. A peak 
at 355 by mass spectrometry confirmed that the free phosphate 50 had indeed been 





Scheme 19: Reagents and conditions: i) 20 % Pd(OH)2/C, cyclohexene, CH3OH, 
H20 , 80 °C, 3 h.
Both the benzyl protected 53 and crude free phosphate 50, were subjected to 
glycosylation with nicotinamide 32 using the established protocol. It was speculated 
that if CH3OH, in the presence of TMSOTf cleaved the acetyl protection, it may 
replace the benzyl groups with methyl esters 54 (Scheme 20).
Scheme 20: The hypothesised result of using CH3OH or H2O to perform the 
protecting group cleavage.
With this in mind both CH3OH and water were used in two separate reactions to 
perform the in-situ acetyl cleavage for the benzyl protected material 55. As there was 
no risk of forming the methyl ester in the reaction with the free phosphate 50 only 
CH3OH was used to perform the deacetylation.
In all three cases !H NMR spectroscopy showed the reaction had failed as no 
anomeric and downfield nicotinamide protons were observed. After work up, neither 
ribose moieties could be recovered or adequately characterised to establish the result 









Scheme 21: Reagents and conditions: i) a) Nicotinamide, TMSOTf, CH3CN, 2 h; b) 
CH3OH, 1 h; ii) a) nicotinamide, TMSOTf, CH3CN, 2 h; b) H2O, 1 h; iii) a) 
nicotinamide, TMSOTf, CH3CN, 2 h; b) CH3OH, 1 h.
3.5 Summary
Overall, the Lewis acid catalysed route enabled the synthesis of nicotinamide 
ribosides, but further experimentation is required to develop structural analogues and 
to explore the phosphorylation. An alternative strategy toward late stage installation 
of the nicotinamide led to a synthesis of pyridinium ribose 5'-phosphate, but further 
work will be required to progress the iV-glycosylation. Glycosylation could be carried 
out on tetra-protected ribose 48 (Scheme 22), as the product formation could be easily 
monitored by TLC with purification on silica flash chromatography possible. The 
material could then be selectively deprotected to provide the 5'-alcohol 57, followed 
by phosphitylation and hydrogenation of the resulting dibenzyl phosphate to afford p- 
NMN 21. Purification of these types of compound is still a problem and to further 
this area of work development of an adequate purification protocol, such as using a 
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Scheme 22: Representation of the overall synthetic route to p-NMN 21.
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Chapter Four
Selective adenosine phosphorylation 
and pyrophosphate formation
41
4.1 Selective diphosphate adenosine formation
4.1.1 Introduction
The synthesis of NADP 7 and NAADP 3 could be achieved by pyrophosphate bond 
formation between a suitably protected 2',5'-adenosine bwphosphate and (3-NMN 21 
or (3-NaMN 24. This approach required the development of a method to selectively 
install phosphates onto the 2 '-and 5'-hydroxyls of adenosine without cyclisation, or 
subsequent migration to the 3'-hydroxyl.
Methods to selectively modify the 2'-position of adenosine 58 include routes to either 
selectively activate one hydroxyl (Scheme 23), or achieve protection of the remaining 
hydroxyls (Scheme 24 and Scheme 25).
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Scheme 23: Reagents and conditions: i) Dibutyltin oxide, CH3OH, reflux, 30 mins; ii) 
tosyl chloride, EtsN, 5 mins; iii) benzoyl chloride, EtsN, 15 mins; iv) 
hexabutyldistannoxane, POCI3, 20 mins.
Formation of the stannylene acetal 59 has been investigated as a method to selectively 
functionalise the 2/-hydroxyl.41 Reaction with tosyl chloride led to the single regio- 
isomer 60. The observed regioselectivity was attributed to the formation of the 
dimeric structure 59 ,42 which forces the oxygen atoms to adopt either an apical or 
equatorial position. The apical oxygen is more reactive, since the equatorial position 
is deactivated by coordination to the tin atom. However, benzoylation afforded a 
mixture of regio-isomers, which when crystallised yielded primarily the 3'-product 
61. Whether this was due to ring opening of the acetal at the 3' position or that the 3'
42
regio-isomer was thermodynamically more stable was unclear. Subsequent attempts 
to selectively install a protected phosphate also produced a mixture of 2'-and 3'- 
products 62 (1:9) (Scheme 23).
This method of selective activation was attempted but as a result of failed tosylation 
later abandoned. As a result subsequent phosphorylation was never attempted. 
However, on reflection this approach could have been revisited had time permitted as 
it provides a fast and efficient synthesis of phosphorylated adenosine.
Regioselective deprotection of benzoyl protected adenosine 63 has been explored to 
selectively release the 2/-hydroxyl (Scheme 24). Previous work utilised either 
hydrazine hydrate to afford pure 2'-hydroxyl 64 in 64 % yield,43 or KOlBu to achieve 
a mixture, whereby the prominent species was the exposed 2,-hydroxyl 64 (96 %, 5:1; 
2':3'-hydroxyl) .44 The regioselectivity was attributed to the greater acidity of the 2'- 
hydroxyl group,43 and X-ray crystallography of purine ribosides showed the C(2')~ 
0(2') to be shorter than the other two hydroxyl C -0  bonds, suggesting it may behave 
as the most active towards nucleophiles such as hydrazine hydrate and KOlBu 43
Tri-O-benzoyl adenosine 63 was synthesised to explore the selective cleavage of the 
2'-benzoyl protection (64). Unfortunately, our attempts only led to a mixture of 
products that were inseparable by flash chromatography. This caused us to explore a 
further method that avoided a two-step protocol, and would allow unambiguous 
exposure of the 2 '-hydroxyl.
58 63 64
Scheme 24: Reagents and conditions: i) Benzoic anhydride, DMAP, pyridine, 2 h; ii) 
hydrazine hydrate, glacial acetic acid/pyridine (1:4) 2 days; iii) KOlBu, THF, 1 min.
A protecting group that simultaneously tethers the 3' and 5'-hydroxyls of adenosine 
58 that leaves the 2' hydroxyl free for unambiguous modification has been established 
(65)45 Introduction of the l,3-dichloro-l,l,3,3-tetraisopropyl disiloxane protecting 
group allowed selective formation of 2 '-thioadenosine 6 6 46 and 2 '-deoxynucleotides
43
67,47 which has since become an established route for the synthesis of DNA (Scheme
25).
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Scheme 25: Reagents and conditions: i) l,3-Dichloro-l,l,3,3-tetraisopropyl 
disiloxane, pyridine, 3 h.
4.1.2 Synthesis of 2', 5' phosphorylated adenosine
Adenosine 58 was reacted with one equivalent of l,3-dichloro-l,l,3,3- 
tetraisopropyldisiloxane in pyridine for three hours to afford the 
tetraisopropyldisiloxane (TTPDS) adenosine 65 in an 80 % yield (Scheme 2 5 )45 
Synthesis of a suitably protected phosphitylating reagent was required to install the 
protected phosphate at the 2/-hydroxyl. Diisopropylamine and phosphorus trichloride 
(PCI3) were reacted to afford the chlorophosphine 6 8  in 71 % yield 48 Substitution 
with two equivalents of hydroxypropionitrile afforded the phosphitylating reagent 69, 
in 74 % yield after flash chromatography on silica gel, pre-treated with Et3N (Scheme
2 6 )49 It was important to ensure that the excess Et3N was completely eluted to 
prevent unwanted base-induced cyanoethyl elimination.
Activation of the phosphitylating reagent required displacement of the 
diisopropylamine with a suitable azole catalyst. If tetrazole is used (pK& ~ 5), 
phosphitylation would also occur on the purinyl amine.50’51 However, the analogous 
imidazolium phosphane 70 (imidazole pK& ~ 7) is less reactive enabling 
phosphitylation solely at the free hydroxyl.50 Therefore, the phosphoramidite 69 was 
treated with imidazolium triflate 51 to yield the imidazolium phosphine 70, which 
was reacted with protected adenosine 65, and subsequently oxidised with mCPBA to
44




Scheme 26: Reagents and conditions: i) Hydroxypropionitrile, Et3N, CH2CI2, -78 °C 
to RT, 2 h; ii) imidazolium triflate; iii) a) &w(2-cyanoethoxy) diisopropylamino 
phosphine, CH2CI2, 3 h; b) mCPBA, -78  °C, 30 mins.
Selective protodesilylation of the TIPDS protecting group had previously been 
explored using 0.2 M HC1 in dioxane-fhO, 1 M HC1 in dioxane or HF-pyridine. 
However, under these conditions, total deprotection also occurs and yields are 
moderate.52 With dilute TFA (TFA-H2O-THF (1:1:4; v/v/V)) however, ring opening 
occurs exclusively at the less hindered 5'-sily 1-ether in high yield.52 Reaction of 71 
for three hours at 0 °C under these acidic conditions afforded the adenosine derivative 
with a free primary hydroxyl 72 in quantitative yield (Scheme 27).
TIPDSO O
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Scheme 27: Reagents and conditions: i) TFA-H2O-THF (1:1:4; v/v/v), 0 °C, 3 h; ii) 
a) &w(benzyl)diisopropylaminophosphine, imidazolium triflate, CH2CI2, 18 h; b) 
mCPBA, -78 °C.
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Phosphoramidite chemistry was again used to install the second phosphate. However, 
a second phosphitylating reagent possessing orthogonal protecting groups to the rest 
of the molecule was required to enable later selective cleavage. Bwbenzylphosphine 
52 was synthesised in 79 % yield following the standard protocol.53 Subsequent 
activation with imidazolium triflate 51 and reaction with the deprotected primary 
hydroxyl 72 led to the formation of the phosphite, but this required a greater reaction 
time than the 2 '-phosphitylation, presumably due to increased steric hindrance. 
Overnight reaction followed by mCPBA oxidation, afforded the fcw-phosphate 73 in a 
satisfactory 76 % yield after flash chromatography (Scheme 27).
The final synthetic step, in the preparation of the pyrophosphate bond formation, was 
to selectively remove the 5'-phosphate benzyl groups to afford the free phosphate 74. 
Retention of 3'-and 2'-phosphate protecting groups was desirable in order to reduce 







Scheme 28: Reagents and conditions: i) 20 % Pd(OH)2/C, cyclohexene, CH3OH, 
H20 , 80 °C, 3 h.
Reductive deprotection using 10 % Pd/C and hydrogen at 50 °C proved to be 
successful for the removal of the benzyl protection and was accompanied by a 
downfield shift in the 31P NMR spectrum (-0.42 ppm to 1.5 ppm). However, 
difficulties were encountered in the removal of the catalyst. Initially the compound 
adhered to celite, but this problem was overcome using a membrane filter. However, 
the resulting product was black, suggesting palladium contamination. Subsequent 
treatment with chelex resin sought to remove any remaining metal ions, but analysis 
by *H NMR spectroscopy indicated a complex mixture, betrayed by a second 
anomeric peak 8  0.06 ppm upfield of the major peak. Exploration of the literature
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revealed that adenosine compounds had been cleanly deprotected previously using 2 0  
% Pd(OH)2/C and cyclohexene as a source of hydrogen.54 Reaction in CH3OH and 
water at 80 °C for three hours, followed by membrane filtration, afforded clean, 
deprotected phosphate 74 in 82 % yield without the need for flash chromatography 
(Scheme 28).
With this final step completed, a high yielding (49 % yield, over five steps) and 
robust, synthetic route to a protected 2',5'-adenosine diphosphate 74 in had been 
developed. This could be carried forward to investigate the formation of the 
pyrophosphate bond and subsequent protecting group removal.
4.2 Pyrophosphate bond formation
4.2.1 Introduction
Pyrophosphate bond formation is often difficult to achieve because of slow reaction 
times and the challenging purification of the water-soluble products leading to poor 
yields. Current literature procedures for pyrophosphate bond formation activate one 
of the phosphates to enhance its electrophilic properties, and the common methods are 
described below.
An early synthesis of NAD 6  utilised a vast excess of dicyc/ohexylcarbodi-imide to 
condense racemic NMN 21 and AMP 26. Isolation was achieved by selective enzyme 
reduction of the P-form by alcohol dehydrogenase, followed by alkaline destruction of 
the a-form and subsequent enzymatic oxidation to afford the correct p-isomer of 
NAD 6 .55,56 By using mixed 2/,5/-and 3',5'-adenosine diphosphates, prepared from 
adenosine, they also tried to synthesise NADP. Unfortunately the material was 
contaminated with p-NMN 21 and adenosine diphosphate after purification. It was 
believed that this was due the apparent instability of NADP when the phosphate is 
carried at the 3'-position.55 This would however have provided a method for the 
synthesis of regio-selective NADP 7, if they could separated the two regio-ismoers.
Previous NAD 6  syntheses have activated adenosine monophosphate (AMP) 26 as an 
electrophile using the phospho-imidazolide, triazolide or tetrazolide. Activation of 
p-NMN 21 via the phospho-imidazolide was also explored, but all these routes
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yielded NAD 6  in less than 5 % .37 It was reasoned that the low reactivity of p-NMN 
2 1  was a consequence of inner salt formation, making it less nucleophilic.37 
Accordingly, activation of AMP-imidazolidate and P-NMN 21 using the Lewis acid 
MnCl2-4 H2 0  afforded NAD 6  in an improved, 25 % yield. With further fine-tuning, 
using AMP-morpholidate 75, a respectable 58 % yield was achieved. Interestingly, 
the authors claim that MnC^ was most active when stored in formamide, over 4A 
molecular sieves for three days. Anhydrous MnCl2 was found to be inferior and the 
identity of the active species remains unclear.
Alternative literature examples explore the production of various sugar-base 
pyrophosphate couplings using acid catalysts to accelerate the phosphomorpholidate 
chemistry.57 Kinetic investigations of various different acids such as 1,2,4-triazole, 
acetic acid, A-hydroxysuccinimide and l//-tetrazole, showed that l//-tetrazole was 
the most efficient catalyst providing pyrophosphate synthesis in 76-91 % isolated 
yields, with reactions complete after two days. It was concluded that lH-tetrazole not 
only acted as an acid, protonating the morpholine nitrogen 76, but also as a 
nucleophilic catalyst. This allowed nucleophilic substitution to the more reactive 
phosphotetrazolide 77, which underwent coupling to the second free phosphate 78, 





Scheme 29: Formation of the phosphotetrazolide. Reagents and conditions: i) 1H- 
tetrazole, pyridine, 78 2 days.
48
<*' ■> OHO OH
80
Scheme 30: Activation of a phosphate using CDI. Reagents and conditions: i) CDI, 
Et3N ,D M F ,3h ;ii)50°C .
Phosphate activation via the formation of the imidazolide represents an alternative
CO
strategy that has been incorporated into the syntheses of a uridine dinucleotide 82 
and an oestrogen sulphotransferase inhibitor.59 Addition of carbonyl diimidazole 
(CDI) to uridine monophosphate (UMP) 80 generated the activated imidazolium 
phosphite 81, which when treated with a second phosphate 80 formed the 
pyrophosphate bond 82 (Scheme 30) in acceptable 63 % yield.58 The oestrogen 
sulphotransferase inhibitor was synthesised in 43 % yield59 (not shown).
Further work examined the formation of a pyrophosphate bond between UMP 
morpholidate and imidazolide with galactofuranose to form the anti-microbial UDP- 
a-D-galactofuranose 8 6 . Unfortunately, reaction times were modest (1-2 days) and 
the observed completion, poor (50 %) with corresponding low yields (19-23 % ) .60 
UMP 80 was activated using trifluoroacetic anhydride (TFAA) towards a more 
efficient route leading to the mixed anhydride and simultaneous esterification of the 
remaining hydroxyls 83, providing an intermediate that was soluble in DMF (Scheme 
31). Subsequent addition of 1-methylimidazole afforded the highly reactive 
methylimidazolide-phosphine 84, which could then be coupled to a second free 
phosphate 85 to generate the pyrophosphate 8 6  in an apparently quantitative 
conversion as observed by 31P NMR spectroscopy. Reaction times were very short 
(2h, 0 °C), but purification proved difficult and isolated yields were only 30-40 %.
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Scheme 31: Formation of the methylimidazolide. Reagents and conditions: i) a) 
Dimethylaniline, Et3N, CH3CN, 0 °C; b) added dropwise, TFAA, CH3CN, 0 °C, 5 
mins; ii) 1-methylimidazole, Et3N, CH3CN, 0 °C, 5-10 mins
4.2.2 Pyrophosphate synthesis
We initially explored the well established morpholidate chemistry, which lead us to 
revisit, the reported synthesis of NAD 6 .37 We chose to generate commercially 
available AMP-morpholidate 75 from the free acid of AMP 26.61 Once formed, (Sp 
8.77), the AMP-morpholidate 75 was precipitated by the addition 0.1 M Nal in 
acetone in quantitative yield. This was then reacted with p-NMN 21 using 0.2 M 
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Scheme 32: Reagents and conditions: i) Powdered triphenylphosphine, 2,2'- 
dipyridyldisulphide, morpholine, DMSO, 4 h; ii) 0.2 M MnCh in formamide (stored 
over 4 A molecular sieves for three days), MgS0 4 .'7 H2 0 , 18 h.
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This methodology was transferred directly to the modified adenosine phosphate 74 
and synthesis of the activated morpholidate was attempted. In-situ analysis by 31P 
NMR spectroscopy (8  8.0 ppm) showed the reaction proceeding as expected, but 
purification proved difficult. Eventually, crude material was used to form the 
pyrophosphate bond, but analysis by HPLC and 31P NMR spectroscopy showed that 
no reaction had taken place. This was reasoned to be a result of the poor 
nucleophilicity of p-NMN 21. Previous work circumvented this poor reactivity by
37
employing a Lewis acid, but this did not work for our target. We considered that 
activation of p-NMN 21 as the electrophile component would provide a more 
reactive, organic soluble starting material.
Using the method reported for the synthesis of UDP-a-D-galactofuranose 8 6 , 
generation the p-NMN methylimidazolide, via formation of the trifluoroacetyl mixed 
anhydride was explored.60 Initial phospho-methylimidazolide activation proceeded 
with the observation of a singlet at 8  -1 0  ppm in 31P NMR spectrum. 
Disappointingly, addition of the adenosine analogue 74 did not result in the 
characteristic pyrophosphate signal in the 31P NMR spectrum and no product was 
obtained. This reaction was repeated using a variety of model reactants, including 
coupling between adenosine and cytosine monophosphate, but a pyrophosphate was 
never isolated from these mixtures. This method was therefore abandoned, although 
activation of P-NMN 21 was still regarded as essential.
45 mins 135 mins
8 -1.5 ppm 8 -  -9 ppm 8 -  -9.8 ppm
Scheme 33: Formation of the activated P-NMN via the mixed anhydride to the 
imidazolide with 31P NMR spectra values.
We turned our attention to potentially more simple phosphate activation using 
carbonyl diimidazole (CDI). Activation of P-NMN 21 occurs in two stages; first the
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mixed anhydride is formed 83, followed by subsequent substitution to the imidazolide 
84 (Scheme 33). Initial mixed anhydride 83 formation occurred within forty-five 
minutes and was accompanied by solubilization of p-NMN 21 in DMF and a shift in 
the 31P NMR spectrum from approximately 1 ppm to -9 ppm. The second stage was 
harder to detect by 31P NMR spectroscopy as the chemical shift is only about 0.8 ppm 
upfield, but after three hours phospho-imidazolide 84 formation was complete (Figure 
11). CH3OH was introduced to quench any remaining carbonyl diimidazole, before 
the addition of the protected adenosine 74 (Scheme 34).
Chemical shift of (3- 
NMN 21 .
After 45 mins the 
transition to the 
mixed anhydride 83 
can be observed.
After two hours the 
reactive imidazolide 
84 is partially 
formed.
After three hours the 
imidazolide 84 is 




signal was observed 
after 18 h. (The 
second peak is the 2' 
adenosine phosphate 
at -2 .7  ppm).
Figure 11: NMR spectra to show the chemical shift during the pyrophosphate bond 
formation. Shows reaction drawn in Scheme 34.
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The 31P NMR spectrum showed consumption of both the 5'-adenosine phosphate 74 
and the activated p-NMN 84 through the production of the characteristic 
pyrophosphate multiplet at -10 to -11 ppm (Figure 11). Analysis using ion exchange 
HPLC (AG-MP1) showed the appearance of a new peak at 11 minutes with good 
separation from any impurities. This retention time was longer than expected and 
analysis of the crude mixture by mass spectrometry provided a peak at 1055, which 





Scheme 34: Reagents and conditions: i) a) Carbonyl diimidazole, EtsN, DMF, 3 h; b) 
CH3OH, 10 mins; ii) 74, DMF, 18 h.
4.2.3 Pyrophosphate purification
As ion exchange HPLC analysis showed distinct peaks, initial purification was carried 
out on the same quaternary ammonium AG-MP1 resin (Bio-Rad). However, eluting 
with a gradient of 150 mM aq. TFA apparently caused the gradual cleavage of the 3'- 
TIPDS group and the only material obtained from this column was disappointing 
quantities of the desilylated compound 8 6 . More controlled TIPDS deprotection was 
attempted by reacting the crude pyrophosphate 85 with a 10 % aqueous solution of 
TFA. This was monitored by reverse phase TLC and once complete, neutralised with 
1 M NaOH and purified on a column of AG-MP1 resin, to afford a 10 % yield (from 
adenosine analogue 74) of pyrophosphate 8 6  (Scheme 35). This was a dissatisfying 
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Scheme 35: Reagents and conditions: i) 10% aq. TFA, 2 h.
It was suspected that residual sodium trifluoroacetate from the neutralisation 
increased the conductivity of the solution causing poor adhesion of the compound to 
the resin. Analysis showed that a 1 % solution of 150 mM aq. TFA possessed a 
conductivity greater than 400 jxS; therefore, to ensure correct adhesion of the products 
to the stationary phase a conductivity of less than 400 |iS was required for loading. 
Unfortunately, this did not have a dramatic effect on the yield, therefore it was 
necessary to find a better purification technique.
Size exclusion chromatography was investigated as the product had a molecular 
weight larger than the two starting materials.57 Crude pyrophosphate mixture was 
applied to Biogel P2 beads (1.5 x 70 cm) and eluted using 250 mM N H 4O A C , but this 
failed to provide any separation. Reverse phase column chromatography was also 
explored, but co-elution of product and starting material was repeatedly observed. Ion 
exchange chromatography still offered the best separation due to the negatively 
charged product, so a different quaternary ammonium resin was sought that avoided 
the use of TFA.
Q-Sepharose ion exchange resin offers similar characteristics to AG-MP1, and was 
identified as a purification method incorporating a quaternary ammonium stationary 
phase. Instead of using 150 mM aq. TFA, this resin required 1 M triethylammonium 
bicarbonate (TEAB) (pH 7) as the counter ion. The conductivity of the solution still 
needed to be adjusted to less than 400 jllS, but once loaded and eluted, this method 
produced pure pyrophosphate 85 as the triethylammonium salt, in 63% yield from 
starting adenosine 74, with the silyl ether still in place (Scheme 34). Excess Et3N
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needed to be removed, but this was accomplished with repeated co-evaporation with 
CH3OH. Isolation and characterisation of this material confirmed that the removal of 
one cyanoethyl group had indeed occurred, with four cyanoethyl protons being 
observed in the NMR spectrum, instead of eight (Figure 12).
3.09.0 6.0
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Figure 12: !H NMR spectrum showing the signals for the residual cyanoethyl 
protecting group on 85.
4.2.4 Protecting group removal
The base labile cyanoethyl and fluoride labile TIPDS protection were selected 
because of their potential to undergo global deprotection with the addition of 
tetrabutyl-ammonium fluoride (TBAF).62
Initial cleavage conditions were evaluated using the protected diphosphate adenosine 
precursor 74. After three hours treatment with 1 M TBAF in THF buffered with 
AcOH, an increase in the HPLC retention time was observed from 13 to 15 minutes. 
Purification on Q-Sepharose resin and *H and 31P NMR spectroscopy of the isolated 
material revealed that both the cyanoethyl group and silyl protecting group had indeed 
been cleaved, but the 2' phosphate had undergone cyclisation to afford 2',3'-cyclic 
phosphate 87 (Scheme 36) characterised by 31P NMR spectroscopy (8 20 ppm). This 
was confirmed in the ]H NMR spectrum by a downfield shift for the 3'-proton to 5.04 
ppm together with an increased complexity due to phosphorus coupling.
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Scheme 36: Reagents and conditions: i) 1 M TBAF, AcOH, THF, 0 °C.
It was suspected that cyclisation was the result of Et3N catalysed attack on the free 2'- 
phosphate by the deprotected 3'-hydroxyl, during TEAB evaporation. While, 
deprotection appeared possible under these conditions, purification would need to be 
carried out using acidic AG-MP1. Repeating these reaction conditions with the 
protected pyrophosphate 85 afforded T1FDS cleavage, but removal the second 
cyanoethyl group did not occur leading to monoprotected NADP 8 6  in 75 % yield 
(Scheme 37). It may be that the deprotection observed in the model was due to 
nucleophilic substitution by the 3'-hydroxyl to afford the cyclic phosphate 87. To 
enhance the reaction the pH of the solution was increased by the removal of the acetic 
acid. As there was no longer a buffer present, any hydroxide ions formed by water 
contamination reacting with fluoride ions, would accelerate the /^-elimination. Upon 
reaction with 85, phosphate deprotection was still elusive, with only the desilylated 
material 8 6  produced. However, this revealed the glycosidic linkage had a greater 
stability than previously expected.
Scheme 37: Reagents and conditions: i) 1 M TBAF, AcOH, THF, 0 °C.
Even though the global deprotection failed, it was satisfying to achieve the NADP 8 6  




protecting group. It was speculated that the negative oxygen on the mono-deprotected 
2' phosphate repelled the TBAF, thus hampering P elimination (Scheme 38).
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Scheme 38: The repulsion of the negative oxygen and fluoride ion.
Different methods were sought to try to remove the cyanoethyl group using stronger 
basic conditions.63,64 A number of literature methods including methanolic ammonia, 
lBuNH2, Me2NH and diisopropylethylamine were attempted but were all 
unsuccessful. All of these conditions only returned starting material, which although 
unsuccessful, indicated the pyridinium bond to be more stable than initially expected.
Methods were then sought to chemically neutralise the negatively charged oxygen 
atom to enable base cleavage of the remaining 2 /-phosphate protecting group. 
Previous work during the synthesis of Calyculin A required the removal of 
fcfscyanoethyl protecting groups to unveil a free phosphate late in the synthesis. The 
first protecting group was removed under basic conditions by the addition of DBU, 
but difficulties in removing the second protecting group were observed. This problem 
was solved by quenching the newly generated negative charge by silylation of the 
oxygen 89 using TMSC1. Complete deprotection of the second protecting group was 
achieved in-situ with DBU (90), allowing the formation of the free phosphate 91 
under mild conditions in excellent yield. However, no reference was made to the 
deprotection of the TMS groups.65 A further development used TMSC1 with 
tetramethylguanidine (TMG) as base, to perform the /^-elimination of the cyanoethyl 
groups 90.66 Methanolic ammonia was then added before the TMS groups were 
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Scheme 39: i) TMS protection; ii) protecting group cleavage; iii) TMS cleavage.
TMSC1 and TMG were explored in a trial reaction using fully protected 2',5'- 
adenosine fcwphosphate 74. The methanolic ammonia step was removed, due to the 
potential hydrolysis of the pyridinium. The acid hydrolysis was also replaced by 
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Scheme 40: Reagents and conditions: i) a) TMSC1, TMG, CH3CN, 16 h; b) 1 M 
TBAF, THF, 3 h, 0 °C.
Unfortunately, there were difficulties in observing even monocyanoethyl cleavage by 
HPLC analysis and isolation of any materials proved impossible. Due to poor 
reactivity an alternative TMS donor was used instead TMSC1. Again, a trial reaction 
was undertaken using 2'-protected fo'sphosphate adenosine 74 to initially cleave the 
first cyanoethyl group, followed by in-situ TMS protection using N ,0-
fnfos(trimethylsilyl) acetamide (BSA). Subsequent cleavage of the second cyanoethyl
with DBU and simultaneous silyl deprotection with TBAF generated a new peak by
HPLC analysis at 14 minutes. Purification on AG-MP1 afforded 2',5'-ADP 87 in an
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Scheme 41: Reagents and conditions: i) a) BSA / DBU, 90 mins; b) TBAF, THF, 3 h, 
0°C.
This method was transferred directly to the 2/,3/-protected pyrophosphate 85, and the 
reaction monitored by HPLC. It was expected that the retention time of the product 
would be similar at 11 minutes, as the overall charge on the molecule should remain 
the same. This is because the pATa of the second phosphate hydroxyl is around 8-9 so 
only one 2' phosphate hydroxyl would be ionised during analysis. Upon addition of 
the BSA / DBU there was no visible change, but after treatment with TBAF the 
retention time surprisingly increased to 14 minutes. Purification on ion exchange 
chromatography afforded only the hydrolysed 2',5'-ADP 87 (Scheme 42).
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Scheme 42: Reagents and conditions: i) BSA / DBU, 90 mins; ii) TBAF, THF, 3 h, 
0°C.
It was suspected that silylation not only occurred at the 2'-phosphate, but also on the 
pyrophosphate backbone (Scheme 42) and once silylated, the pyrophosphate 
underwent hydrolysis. Milder conditions were therefore sought to cleave the TMS 
groups in the hope of avoiding pyrophosphate hydrolysis. TBAF was therefore 
replaced with an aqueous solution of TFA or AcOH, but both of these afforded 2/,5'- 
ADP 87. Material, pre-treated with TBAF to cleave the monoprotected NADP 8 6 , 
was subjected to BSA / DBU treatment, followed by, overnight stirring in H2O to
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hydrolyse the TMS groups. This did provide a poor yield, of a product that closely 
resembled NADP 7, but careful examination using mass spectrometry revealed a 
discrete peak at 765, possibly corresponding to the single sodium salt of NADP 7. 
Unfortunately, the !H and 13C NMR spectra provided conflicting results, as no signal 
was detected for 2nH and 6 aC. When this reaction was repeated, the de-purinated 
product was isolated, as characterised by the absence of the two purine protons in the 
*H NMR spectrum. Further work will be required to understand what has taken place, 
especially as the changes observed relate to different parts of the molecule.
As treatment with BSA / DBU resulted in the total deprotection of the 2/-phosphate, a 
further method was sought to cleave the TMS groups, whilst avoiding pyrophosphate 
hydrolysis. Literature TMS deprotection has been performed using HF as the source 
of fluoride.67 It was hoped that the S'-TIPDS along with all the TMS groups could 
finally be simultaneously removed with anhydrous acidic HF / pyridine to afford 
NADP 7. Purification of the result of this reaction on AG-MP1 resin unfortunately 
only provided nicotinamide adenine dinucleotide (2'-cyanoethoxy) phosphate 8 6 . It 
remains unclear why the second cyanoethyl group remained intact as the initial 
reaction conditions should have removed the protecting groups and reactions reported 
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Scheme 43: Overview of the synthetic route adopted in this synthesis
This synthesis provided a high yielding route to the selectively phosphorylated 
adenosine (Scheme 43) and retains the flexibility to enable rapid analogue synthesis. 
Pyrophosphate bond formation was successfully optimised and two purification 
methods were developed, which ultimately provided high yields of pure 
pyrophosphate. Removal of the final protecting group to afford NADP 7 has proven 
elusive, but the chemistry developed for the removal of TIPDS group and knowledge 
gained from the TMS installation will prove invaluable in the development of a 
secondary route involving different protecting groups at the 2 /-phosphate.
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Chapter Five
Synthesis of NADP and NAADP
5.1 Introduction
In chapter four it was shown that protection of the 3'-and 5'-hydroxyls allowed 
installation of a phosphate group at the 2 '-hydroxyl without spurious phosphorylation 
on the purinyl amine. Deprotection and subsequent phosphorylation of the 5'- 
hydroxyl led to the adenosine diphosphate intermediate 74. Pyrophosphate chemistry 
was extensively explored and the resultant CDI coupling proved very reliable 
affording high yields. Purification was aided by the serendipitous discovery of the 
cleavage of one phosphate protecting group, enabling isolation and characterisation. 
Subsequent deprotection however remained elusive and to this end restarting the 
synthesis with alternative 2 '-phosphate protecting groups that could be cleaved under 
neutral conditions would be required for a route to synthetic NADP 7 and NAADP 3.
5.2 Selective 2', 5' phosphorylation of adenosine
It was anticipated that benzyl phosphoramidite 52, previously installed at the 5'- 
alcohol, could be added to the 2 '-hydroxyl, ultimately enabling facile cleavage by 
hydrogenation in the latter stages of the synthesis. It was also expected to be stable to 
mild basic and acidic conditions and therefore, remain intact throughout the synthesis.
65 93
Scheme 44: Reagents and conditions: i) a) J5w(benzyl)diisopropylaminophosphine 
52, imidazolium triflate 51, CH2CI2, 18 h; b) mCPBA, -78 °C, 30 mins.
The 3'-and 5'-positions were protected as previously described (see chapter four) .46,47 
Activation of the phosphitylating reagent required in-situ reaction between 
Z?wbenzylphosphoramidate 52 with imidazolium triflate 51 to afford the phosphite at 
the 2'-hydroxyl.50 Subsequent oxidation with mCPBA afforded the desired phosphate 
93 in 78 % yield after silica flash chromatography (Scheme 44). Regio-selective ring 
opening of the less hindered 5'-silyl-ether was accomplished using mild acidic 
conditions (TFA-H2O-THF (1:1:4; v/v/v)) leading to the alcohol 94 in 76 % yield 
(Scheme 45) .52
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Scheme 45: Reagents and conditions: i) TFA-H2O-THF (1:1:4, v/v/v), 0 °C, 4 h.
A range of phosphate protecting groups were explored to generate the 5'-phosphate 
without degradation of the rest of the molecule.
Treatment of 5'-alcohol 94 with fo’s(2-cyanoethyl)phosphoramidite 69 afforded 
diphosphate 95. It was hoped that strong basic conditions could be utilised to afford 
the free phosphate 96, however ten equivalents of LiOH destroyed the molecule after 
one hour with no recognisable peaks remaining in the JH NMR spectrum (Scheme 
46). Removal of the protecting groups was abandoned due to the problems associated 
with the release of the free phosphate. Only after this work was complete were 
conditions developed to remove both protecting groups effectively. A second 
problem was the possibility of base-catalysed cleavage of a benzyl group, which may 
have been reactive during pyrophosphate bond formation.
Scheme 46: Reagents and conditions: i) a) £/s(2-cyanoethoxy)diisopropyl- 
aminophosphine 69, imidazolium triflate 51, CH2CI2, 5 h; b) mCPBA, -78 °C, 40 
mins; ii) 10 equivalents LiOH, 1 h.
Exploring further possible protecting groups suggested that the allyl phosphate could 
be cleaved using mild, neutral conditions such as, Pd(PPh3)4, or Rh(PPh3)3Cl, that 
should be compatible with the rest of the adenosine functionality. Phosphoramidate 
chemistry with ftwallyldiisopropyl-aminophosphine suggested that the reaction had 
proceeded as expected as observed by the new peak at 0.0 ppm in the 31P NMR 
spectrum. However, analysis by ]H NMR spectroscopy revealed that the integration 
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suggesting that a second protected phosphate had been installed (Scheme 47). This 
was further confirmed by mass spectrometry data, which showed a peak at 1108 
consistent with either the formation of compound 97 or 98. Based on literature 
precedent51 we expected that phosphitylation would only proceed at the purinyl NH2 
if the more reactive phosphotetrazolide was used instead of the imidazolide.50 To date 
we have not been able to confirm whether the extra phosphate was bound to the 
purinyl NH2 97 or the silanol hydroxyl 98. However, an experiment carried out by 
Christelle Moreau using the protected purinyl amine still observed secondary 
phosphitylation, suggesting formation of the silanol phosphate related to structure 98. 
How an allyl-protected phosphoramidate is sufficiently reactive to attack either the 
deactivated amine or silanol hydroxyl remains unclear, especially when other 
phosphitylating reagents, such as &w(2-cyanoethyl)-phosphoramidate 69, only reacted 
with the riboside hydroxyls.
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Scheme 47: Reagents and conditions: i) a) &w(allyl_-diisopropylaminophosphine, 
imidazolium triflate, CH2CI2, 4 h; b) mCPBA, -78 °C, 40 mins.
A diverse range of phosphitylating reagents were screened within the group including 
the paramethoxybenzyl, tertiarybutyl and 2 -(methylsulphonyl)ethyl protected 
phosphoramidites. Unfortunately these were unsuccessful due to difficulties in 
installing the phosphate using either the paramethoxybenzyl or tertiarybutyl 
phosphoramidites (1 0 2  and 1 0 1 ); however installation of the sulphonyl
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phosphoramidite was possible, affording 99, but deprotection with 0.1 M NaOH 
destroyed the molecule (Scheme 48). It was suspected that the failure of the first two 
routes was due to steric hindrance around the primary hydroxyl. Interestingly though, 
no secondary phosphitylation was observed on either the purinyl amine or silanol 
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Scheme 48: Overview of work exploring 5' phosphitylation.
The phosphoramidite chemistry was therefore abandoned and further methods of 
phosphate installation explored. Formation of H-phosphonates is a highly efficient 
reaction at primary, secondary and aromatic hydroxyls.69 The resulting H- 
phosphonate is poorly reactive and required activation prior to modification. Work by 
Christelle Moreau formed the triimidazoylphosphine by the in-situ reaction between 
PCI3 and imidazole. This species is a mild, yet highly reactive intermediate that upon 
treatment with hydroxyl efficiently formed the desired 5'-H-phosphonate.69 After 
quenching with 1 M aq. TEAB and silica flash chromatography the H-phosphonate 
103 was isolated in 70 % yield (Scheme 49). The identity of this product 103 was 
confirmed by characteristic signals of the H-phosphonate69 in the 31P and ]H NMR 
spectra (8 p 6 .8  ppm; 8 h 6.72, lJp,u 630 Hz). The highly reactive P111 
triimidazoylphosphine is also relatively small and may be able to overcome the steric 
hindrance difficulties encountered with the phosphoramidite chemistry. Quenching of
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the reaction with triethylammonium carbonate led to the formation of an organic 
soluble salt that could be readily purified using silica flash chromatography.
H0^ !r v V \
-  -  i )  ;  -  N w N  j j )  -  -  n ^ . n
TIPDSO q Q ^  ----------- -— -  TIPDSO q o  ^  ------------ 1— -  TIPDSO q Q  ^
Y- 70 % ,p? 50 % Y'
BnO OBn BnO OBn BnQ OBn
94 103 104
Scheme 49: Reagents and conditions: i) a) Imidazole, PCI3, Et3N, THF, 0 °C, 15 
mins; b) 94, THF, 15 mins; c) 1 M aq. TEAB, 15 mins, ii) a) BSA, CDCI3, 1 h; b) 
CSO, 15 mins; c) CH30H:CHC13:D20 , 2 h.
Oxidation of the 77-phosphonate is often difficult, but we chose to explore a recently 
described protocol. Treatment of the if-phosphonate with the silylating reagent 
6 is,(trimethylsilyl)acetamide (BSA) led to a highly reactive trivalent silyl phosphite 
105, which can be oxidised to the silyl phosphate.70 It was reported that initial 
treatment with mCPBA failed to afford oxidised product, due to excess TMS 
silylating the peroxide. Oxidising agents were thus sought that did not possess acidic
7 0hydrogens. (1 £)-(+)-( 10-camphorsulphonyl) oxaziridine (CSO) 106 performs the
oxidation in good yield with no observed side reactions. Consequently, reaction of H- 
phosphonate 103 with fcw(trimethylsilyl)acetamide proceeded to completion in one 
hour (105). Subsequent oxidation using CSO afforded the bis{TMS) phosphate ester 
107 in 15 minutes. The two TMS groups were then hydrolysed (with 
CH3 0 H:CHCl3:D2 0  over two hours) to afford the free phosphate 104 in 50 % yield 
after flash chromatography (Scheme 49 and Scheme 50). This process can be 
conveniently monitored by 31P NMR spectroscopy (Figure 13) that demonstrates 
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Scheme 50: //-phosphonate oxidation to the phosphate with approximate NMR 
values and the structure of CSO Reagents and conditions: i) BSA, CDCI3, 1 h; ii) 
CSO, 15 mins; iii) CH3OH:CHCl3:D20 , 2 h.
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'//-phosphonate 103 
peak at 8 5.5 ppm.
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phosphonate 105.
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Figure 13: A 31P NMR comparison showing the chemical shift associated with the 
oxidation from //-phosphonate 103 to phosphate 104 of the 5'-alcohol. The stationary 
peak at 8 -0.9 ppm is that of the 2'-benzyl phosphate.
It is interesting to note that the //-phosphonate is strongly UV active, however upon 
oxidation to the phosphate the chromophore is apparently quenched. This may be due 
to a change in conformation causing the aromatic rings on the protected phosphate to 
interact with the purine ring. This does however make visualisation of the subsequent 
reactions difficult as HPLC analysis requires a chromophore for detection.
5.3 Pyrophosphate bond formation
With the free phosphate generated, work could be carried out to synthesise the 
pyrophosphate with subsequent exploration of the deprotection strategy. 
Pyrophosphate synthesis was performed using the protocol established during 
previous studies. 58,59 A solution of p-NMN 21 in DMF was activated with carbonyl 
diimidazole (CDI) and monitored by 31P NMR spectroscopy for generation of the
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phosphoimidazolide. CH3OH was added to quench any remaining CDI, before the 
addition of the protected adenosine 104. The coupling was monitored by 31P NMR 
spectroscopy, which showed the disappearance of starting adenosine 104 after 24 
hours and the appearance of the characteristic pyrophosphate multiplet at 8  - 1 0  ppm 
(Scheme 51).
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Scheme 51: Reagents and conditions: i) a) Carbonyl diimidazole, Et3N, DMF, 3 h 
then CH3OH; b) 104, DMF, 24 h.
At this stage, HPLC analysis and purification of 108 proved difficult, as the product 
was still only slightly UV active. Both benzyl groups remained intact throughout the 
pyrophosphate formation resulting in an amphiphilic product that was difficult to 
purify by all chromatographic methods. Methods were therefore sought to cleave at 
least one benzyl group, generating a negative charge that could aid purification by ion 
exchange chromatography and hopefully enhance the UV activity of the molecule to 
enable detection.
5.4 Selective protecting group removal
A variety of hydrogenation conditions were explored using the crude pyrophosphate 
108 to only release the 2/-phosphate with the aim of aiding purification. 10 % Pd/C 
with hydrogen and 10 % Pd/C with cyclohexadiene, failed to release the benzyl 
protected phosphate with only starting material recovered. Catalyst poisoning by the 
excess imidazole present from the coupling reaction may hinder this debenzylation. 
Attempts using 20 % Pd(OH)2/C with cyclohexene at 80 °C resulted in the destruction 
of the material, presumably a result of the high temperature. Methods were therefore
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sought to enable the cleavage of at least one benzyl group to allow purification on ion 
exchange.
A review of the literature showed that it was possible to achieve monobenzyl 
deprotection using either TBAF52 or aqueous TFA,71 which would be expected to 
proceed with concomitant desilylation (Scheme 52). The crude pyrophosphate 
product was treated with a 1:1 (v/v) mixture of TFA and H2O for one hour resulting in 
simultaneous monobenzyl deprotection and TIPDS cleavage. Monitoring by ion 
exchange HPLC showed a new peak at 11 minutes, with a retention time similar to 
peaks observed for the monocyanoethyl pyrophosphate 8 6 . Notably the monobenzyl 
NADP 109 was strongly UV absorbing. Observation of the complete shift of the 2'- 
phosphate peak in the 31P NMR spectrum allowed monitoring of when the reaction 
was complete (8 p -1.0 ppm to -0.1 ppm). Complete TIPDS cleavage occurred, thus 
allowing isolation of the desired mono-protected benzyl NADP 109 using AG-MP1 
ion exchange resin, albeit, in a disappointing yield (<5% from starting adenosine 
104).
Further crude pyrophosphate mixture 108 was treated with 1 N TBAF in THF at 0 °C 
for two hours. AcOH was used to buffer the reaction to protect the labile pyridinium 
from base hydrolysis (Scheme 52). Again both the TIPDS and a single benzyl group 
were removed and the mono-benzyl protected NADP 109 was produced in 14 % yield 
from adenosine 5' phosphate 104 (Figure 14). Later experiments by Christelle 
Moreau marginally improved the overall yield to 23 %. Since the fully protected 
product 108 could not be isolated, we could not conclude whether the pyrophosphate 
bond formation was high yielding, although we speculate that the main problem is the 
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Scheme 52: Reagents and conditions: i) TFA:H20 (1:1; v/v) 1 h, or 1 N TBAF, 
AcOH, THF, 0 °C, 2 h.
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Figure 14: ‘H NMR spectrum showing the presence of the benzyl protection.
To check the debenzylation step, fully protected adenosine diphosphate 104 was 
treated with buffered TBAF, until TLC analysis (with staining) showed that all 
starting material had been consumed after two hours (Scheme 53). Analysis by ion 
exchange HPLC showed the desired peak at 14 minutes as well as many impurities. 
The desired b/sphosphate 110 was obtained in only a 4 % yield. This is consistent 
with the destruction observed when the protected NADP 108 analogue was subject to 
the same conditions and justifies the idea that the poor yield can be attributed to this 
deprotection step. Further work would be required to explore any other methods for 
singular benzyl deprotection after pyrophosphate formation that may ultimately aid 




Scheme 53: Reagents and conditions: i) 1 M TBAF, AcOH, THF, 0 °C, 2 h.
It appears that to date, at least the best route to monobenzyl protected NADP 109 is 
using TBAF even though this has been shown to be destructive to the molecule with 
yields of around 20 %, however this could relate to two 50 % reactions if the 
pyrophosphate synthesis is not as efficient. It is important to note that the cyanoethyl 
protected compound afforded a 47 % yield (approximately two times 70 %) over the 
same two steps with visualisation and isolation available throughout the reactions.
5.5 Synthesis of NADP and NAADP
Isolation of pure monobenzyl NADP 109 did enable hydrogenation conditions to be 
explored to cleave the final benzyl group. 10 % Pd/C with hydrogen was dismissed as 
it was found to cleave the pyridinium base. An identical result was obtained when the 
same conditions were applied to commercial NADP. Transfer hydrogenation using 
10 % Pd/C with cyclohexadiene in degassed solvents showed a downfield movement 
of the 2'-phosphate to 8  0.38 in the 31P NMR spectrum after two hours, indicating the 
formation of NADP 7. The mixture was passed through a membrane filter to remove 
the catalyst and the product eluted on a column of AG-MP1 resin to yield NADP 7 in 
an unoptimised 31 % (Scheme 54 and Figure 15).
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Figure 15: 'H NMR spectrum of NADP showing the total absence of benzyl protons.
Synthetic NADP 7 and nicotinic acid 22 were dissolved in 100 mM AcOH-NaOH 
buffered to pH 4 to which was added Aplysia ADP ribosyl cyclase [EC 3.2.2.5], used 
to catalyse the base-exchange reaction. The enzyme was used directly from crude 
extracts from the ovotestis of Aplysia califomica72 as it was observed within the 
group that the quality of the commercially available enzyme varies greatly from batch 
to batch. The reaction was monitored by ion exchange HPLC for the characteristic 
increase in retention time, from 10 to 16 minutes (7 to 3; Figure 17), caused by the 
introduction of the acid functionality (Scheme 55). It can also be observed on the 
HPLC trace the formation of the side product of the reaction with is the hydrolysis of 
the pyridinium ring to form ADP-ribose (Rt 19 mins). Purification of the reaction by 
AG-MP1 ion exchange chromatography and isolation of the desired peak at 16 
minutes afforded NAADP 3 in 60 % yield (Figure 16 and Figure 17).
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Scheme 55: Reagents and conditions: i) Aplysia ADP ribosyl cyclase, nicotinic acid, 
100 mM AcOH-NaOH (pH 4).
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Figure 17: HPLC trace (method A -  see experimental general methods) of the 
enzymatic base-exchange reaction from NADP 7 to NAADP 3. Part A -  Reaction 
after 1 h. B -  Reaction after 3 h. C -  reaction after 6 h Also shows the appearance of 
ADP-ribose as a side product. D -  Purified NAADP.
5.6 Biological testing
NAADP 3 was quantified using the Brigg’s test65 (see experimental general method) 
before being evaluated for inducing calcium release in sea urchin eggs. As the 
NAADP 3 had been produced from synthetic NADP 7 it was important to establish 
that its activity was identical to authentic NAADP (produced from the base-exchange 
reaction carried out on commercial NADP).
Biological results are obtained from homogenised sea urchin egg cells, diluted to 5% 
and incubated at 17°C. A fluorescent dye, Fluo-3 is added to the suspension before 
the addition of NAADP. As calcium is released from the homogenate it binds to 
Fluo-3, causing it to fluoresce, which is detected and recorded. The organelles in the 
homogenates then pump down the free calcium in an ATP dependant manner, causing 
a gradual decrease in fluorescence. The cells can then be subjected to repeat injection 
by NAADP, but this time no calcium is observed as a result of its self-inactivation 
properties.
Synthetic NAADP 3 produces an identical calcium release profile to authentic 
NAADP and also produces the same self-inactivation profile when a subsequent batch 
is re-injected (Figure 18). It is also possible to competitively bind non-labelled, 
synthetic NAADP 3 in preference to [32P] NAADP in exactly the same concentration 
as non-labelled authentic NAADP during binding experiments (Figure 19). This 
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Figure 18: Representation of the calcium release profile observed when synthetic 
NAADP is compared to authentic NAADP.










Figure 19: Representation of the competitive binding of 0.2 nM [32P] NAADP with 
either synthetic or authentic NAADP.
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5.6 Summary
Installing a phosphate on the 2/-hydroxyl with protecting groups that are labile to 
hydrogenation allowed the first total chemical synthesis of NADP 7 to be 
accomplished. Care was required to isolate the important monobenzyl intermediate 
109 ensuring the least amount of material was degraded. Conversion to NAADP 3 
afforded the first chemical synthesis to date of this novel calcium releasing second 
messenger. The biological analysis obtained has proven the identity of the material.
5.7 Future work
Further work will need to be undertaken to synthesise the nicotinic acid 
ribonucleotide to enable the total chemical synthesis of NAADP 3, but the overall 
route is a significant and essential step towards the development of analogues, such as 
C-glycosides that are inaccessible by any other means. This will allow the 
interrogation of this important biological pathway to further understand the 
importance of NAADP at a molecular level.
With a synthetic route in place, work can be undertaken to prepare analogues based 
on the core structure of NAADP. Initially, this will centre on the replacement of the 
pyridinium ring with a non-hydrolysable C-C bond to the ribose backbone to further 




Synthesis of an NAADP analogue
6.1 Synthesis of a non-hydrolysable p-NaMN analogue
6.1.1 Introduction
no
With a synthetic route to NA(A)DP 7(3) developed , exploration of analogues was 
pursued.
Previous reports have shown that replacement of the pyridinium ring with a 4-amide 
substituted thiazole, have inhibited some NAD dependent enzymes through its 
increased stability to hydrolysis.34 Tiazofurin74 111 (2-(p-D-ribofuranosyl) thiazole-4- 
caroxamide) is a non-hydrolysable C-nucleoside analogue, which has known 
biological activity against both human lymphoid and lung tumour cells by being 
phosphorylated and linked to AMP via NMNAT [E.C. 2.7.7.1] to afford thiazole-4- 
carboxamide adenine dinucleotide (TAD) 112 in-vivo.34,75 As TAD 112, it mimics the 
structure of NAD 6  (Figure 20) and inhibits inosine monophosphate dehydrogenase 
(IMPDH) [EC 1.1.1.205] causing the suppression of de-novo biosynthesis of 
guanidine nucleotides.34,75 Subsequent decrease in guanidine monophosphate (GMP) 
and 2'-deoxyGMP not only hinders RNA and DNA synthesis, but also compromises 
the ability of G-proteins to function as transducers of intracellular signals. Tiazofurin 
111 has been shown to be active in reducing the numbers of leukaemic cells in acute 
myelogenous leukaemia, however, it has been found to be too toxic for clinical 
application. Recent discovery of two different isoforms of IMPDH,76 which the type 
two is up-regulated in human leukaemia has promoted further interest in tiazofurin 
111.
We were interested in producing a carboxylic acid analogue of tiazofurin 113, which 
when joined with an appropriately functionalised adenosine would lead to TAADP, 
114 that would retain the non-hydrolysable C-C bond to the ribose backbone and also 
its aromaticity. It is anticipated that the negative charge would be held in a spatially 
similar position when linked to 2/,5'-ADP 87. This could produce a novel NAADP 
analogue that may possess activity and enable further investigation of the mechanism 
of action of NAADP 3 at a molecular level (Figure 20).
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Figure 20: Schematic to show how tiazofurin (red) and its acid counterpart (blue) 
reflect the structure of the intended pyridinium.
Early syntheses towards tiazofurin 111 used H2S to generate a thioamide en route to 
the thiazole ring,77 but H2S is too toxic and difficult to work with on a large scale. A 
later synthesis described the formation of the thiazoline ring 115 from the (3-cyano 
ribose 116 using cysteine ethyl ester. Despite testing a wide range of reactions the 
authors could not oxidise the thiazoline ring instead observing formation of the 1,4- 
substituted furan 117 (Scheme 56).75 To alleviate this problem, extra protecting group 
manipulations were introduced into the synthesis. The 2'-and 3'-benzoate esters were 
replaced with an isopropylidene group 118, thus eliminating the unnecessary ribose 
oxidation. This then allowed successful production of the thiazole 119 via the 
thiazoline 120, followed by subsequent two-stage deprotection to afford tiazofurin 
111 (Scheme 56).
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Scheme 56: Reagents and conditions: i) Cysteine ethyl ester, Et3N, CH3OH, 3 h; ii) 
MnC>2, benzene or A-bromosuccinimide, DBU; iii) cysteine methyl ester, EtsN, 
CH2CI2, 24 h; iv) Mn0 2 , benzene, reflux, 2  h; v) 90% TFA, 1 h; vi) methanolic 
ammonia, 12  h.
6.1.2 Synthesis of Tiazofurin and analogues
We believed that it was possible to perform the oxidation to the thiazole 121 without 
concomitant elimination of the two benzoate esters. Commercially available tetra- 
ester protected ribose 122 was treated with trimethylsilyl cyanide (TMSCN) and 1 M 
SnCU in CH2CI2, leading to the nitrile 116, in high yield as an orange foam (Scheme 
57) .78 The /^-stereochemistry was introduced at this stage via neighbouring group 
participation and was confirmed by analysis of the anomeric proton coupling constant 
of 4.4 Hz in the !H NMR spectrum. Near quantitative conversion to the nitrile 116 
allowed the product to be used without chromatography of the crude material. 
Subsequent reaction with cysteine methyl ester led to the ring closure and the 
thiazoline 123, again with high conversion.75 Formation of the thiazoline ring was 
confirmed by the downfield shift in !H NMR spectrum of the methylene and methine 
protons originally from the starting amino acid. Splitting of the signals was observed 
due to the epimerisation of the C-4 on the thiazoline ring. Resolution was not 










Scheme 57: Reagents and conditions: i) TMSCN, 1 M SnCfi, CH2CI2, 2 mins; ii) 
cysteine methyl ester, Et3N, CH2CI2, 3 h; iii) BrCC^, DBU, CH2CI2, 12 h, 0 °C.
The thiazoline 123 was reacted with either I2-DBU or DDQ-toluene to perform the 
oxidation to thiazole 1 2 1 , but these were found unsuccessful due side reactions 
complicating isolation.75 Milder BrCCl3-DBU 79 treatment with the thiazoline 123, 
led to smooth dehydrogenation affording the thiazole 1 2 1  with no observed 2 ',3'- 
benzoate elimination (Scheme 57). *H NMR spectroscopy confirmed the oxidation by 
the presence of a single aromatic proton (8  8.15), and the absence of thiazoline 
methylene and methine protons. The oxidation also removed the chiral centre and 
simplification of the spectrum was observed. Over the three steps (122 to 121) the 
isolated yield was 61 % (85 % per reaction), which was only subject to flash 
chromatography at this final stage, providing a high yielding, synthetic route.
Catalytic C^CrNa* in CH3OH was utilised to afford the benzoate deprotection with 
retention of ester functionality to afford the methyl ester 124 as a white gum in 80 % 
yield. The tribenzoate precursor 121 was also treated with either methanolic 
ammonia, or 1 M NaOH to afford either tiazofurin 111 in 8 6  % yield, or the 
carboxylic acid analogue 113 in 8 6  % yield (Scheme 58).
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Scheme 58: Reagents and conditions: i) CH3 0 'Na+, CH3OH, 12 h; ii) 1 M NaOH, 
dioxane, 12 h; iii) methanolic ammonia, 36 h.
This route provided an improved synthesis of tiazofurin 111 and its analogues (124, 
113) without the need for toxic H2S and unnecessary protecting group manipulation. 
This route confirmed that the selective oxidation of a thiazoline in the presence of 
sensitive functionality, such as esters is possible with BrCCfj and DBU. To reach the 
end products required two chromatographic purifications for the methyl ester 124 or 
in the case of the carboxylic acid 113 and amide 111 only one due to their hydrophilic
OA
nature, making this a very fast and efficient route. Both amide 111 and the ester 124 
could be used once phosphorylated, in the formation of a pyrophosphate bond to a 
suitably modified adenosine analogue that once deprotected would afford either a 
NADP 7 or NAADP 3 analogue respectively.
6.1.3 Phosphorylation of the primary hydroxyl
Phosphorylation was performed on the methyl ester 124 as it was suspected that the 
free carboxylic acid 113 might undergo side reactions during pyrophosphate 
formation. It was reasoned that the carboxylic acid could be unveiled by late stage 
treatment with alkali, such as 1 M NaOH, but that adequate protection on the 3'- 
adenosine hydroxyl may be necessary to avoid base catalysed 2 '-phosphate 
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Scheme 59: Reagents and conditions: i) 1 M NaOH.
Treatment of the ester 124 with triethylphosphate and POCI3 resulted in the formation 
of a new peak by ion exchange HPLC analysis (Rt 14 minutes). As the product was 
negatively charged, purification by quaternary ammonium AG-MP1 ion exchange 
resin was possible. Isolation from the excess triethylphosphate afforded the 
phosphate 127 as a hygroscopic yellow gum in 72 % yield after lyophilisation 
(Scheme 60). This material could then undergo pyrophosphate bond formation. 
Before that occurred, conditions were sought to provide ester hydrolysis that could be 
utilised later in the synthesis. Treatment with aqueous alkali (pH 10) produced an 
increase in retention time as observed by ion exchange HPLC, from 14 to 17 minutes 
indicating the formation of a second negative charge. Upon isolation using AG-MP1 
resin, it was found that the ester 127 had indeed undergone hydrolysis to the acid 128. 
This was confirmed by the disappearance of the methyl peak in both the ]H and 13C 
NMR spectra. This test reaction confirmed that late stage deprotection may be 
possible, thus allowing the phosphorylated methyl ester to be carried forward into the 
pyrophosphate synthesis.
H O  O H  H O  O H  H O  O H
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Scheme 60: Reagents and conditions: i) Triethylphosphate, POCI3, 0 °C, 90 mins; ii) 
H20  (pH 10 with 1 M NaOH), 18 h.
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6.2 Synthesis of the NAADP analogue
6.2.1 Pyrophosphate bond formation
The phosphorylated methyl ester 127 was subjected to pyrophosphate coupling using 
carbonyl diimidazole (CDI) through the formation of the activated phospho- 
imidazolide via the mixed anhydride. 31P NMR spectroscopy was used to monitor the 
reaction for the formation of the imidazolide peak at 8  -9.5 ppm, which occurred, as 
expected after three hours; however, the formation of a second peak at 8  - 2 0  ppm was 
also observed, which remains difficult to explain. After excess CDI was deactivated 
with CH3OH 2'-benzyl-phosphate adenosine 104 was introduced, and the reaction 
monitored for the appearance of the characteristic pyrophosphate multiplet at 8  - 1 0  
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Scheme 61: Reagents and conditions: i) a) CDI, Et3N, DMF, 3 h; b) CH3OH, 10 
mins; c) 104, DMF, 24 h.
After 24 hours the reaction appeared to be complete, as observed by 31P NMR 
spectroscopy and initial purification was carried out on silica flash chromatography to 
try and isolate the pyrophosphate 129. The product was poorly UV absorbing, 
presumably due to the quenching of the adenosine chromophore such that TLC only 
showed the appearance of a new product after staining with PMA (Rf 0.5). Isolation 
of the material was difficult as the product 129 and starting material 104 have similar 
Rf’s. This did, however, remove excess imidazole from the reaction, allowing 
hydrogenation to be explored as for the synthetic pathway to NADP 7. Crude
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material 129, was subject to 10 % Pd/C-catalysed hydrogen transfer conditions to 
unveil the 2'-phosphate 130 (Scheme 62) that would enable purification by ion 
exchange chromatography. Analysis by HPLC provided no detectable evidence that 
debenzylation had occurred, however 31P NMR spectroscopy showed complete 
conversion to the phosphate (31P 8  1.5 ppm). The material was applied to a Q- 
Sepharose column, but attempts to elute the product with 1 M aq. TEAB failed to 
provide product. Without the positive charge normally associated with NA(A)DP 
7(3) the affinity to the quaternary ammonium resin could be greater, and increasing 
the concentration of buffer to 2 M, did result in compound elution. This material was 
still impure, however and more importantly, the yield was very low.
129 130
Scheme 62: Reagents and conditions: i) 10 % Pd/C, cyclohexadiene, CH3OH/H2O 
(3:1; v/v), overnight.
In light of the purification difficulties it was decided that the cyanoethyl protected 
adenosine 74 would be utilised as it had already provided higher yields along with 
being easier to handle as a result of the labile 2' phosphate ester. It was speculated 
that due to the increased stability of the C-glycoside linkage, strongly basic conditions 
could be used to perform the removal of the second phosphate-protecting group. 
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Scheme 63: Reagents and conditions: i) a) Carbonyl diimidazole, EtsN, DMF, 3 h; b) 
CH3OH, 10 mins; c) 74, DMF, 24 h.
The methyl ester 127 was activated following the established protocol and after three 
hours the cyanoethyl protected adenosine phosphate 74 was added and the reaction 
stirred overnight. Monitoring of the reaction by 31P NMR spectroscopy showed a 
complex signal around 8 - 1 0  ppm, in conjunction with the consumption of the 5'- 
adenosine phosphate peak 74. Analysis by ion exchange HPLC showed the formation 
of a new peak at 18 minutes enabling the reaction to be purified on Q-Sepharose ion 
exchange resin and product eluted using 2 M aq. TEAB. HPLC analysis showed the 
product remained impure however, with a second peak at 14 minutes, that 
corresponded to starting material 74. Even though the ion exchange HPLC retention 
times are different for starting adenosine phosphate 74 and newly formed 
pyrophosphate 131, Q-Sepharose resin seemed unable to resolve them. At this stage 
it was not possible to use AG-MP1 ion exchange resin, as TFA would cause the 
cleavage of the 3'-TIPDS protection, which is required until basic ester hydrolysis has 
occurred to ensure that 2'-phosphate migration does not occur (Scheme 59). It was 
therefore decided to use the product crude in the subsequent phosphate deprotection
6.2.2 Protecting group cleavage
It was speculated that the base labile cyanoethyl group would undergo /^-elimination 
using a strong base, such as aqueous NaOH. As no other base sensitive groups are 
contained in the molecule and the 2'-phosphate can not migrate, NaOH would afford 
the concomitant phosphate deprotection and thiazole-methyl ester cleavage to afford
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the 3'-protected TAADP 132. After treatment of crude 131 with aqueous NaOH (pH 
10) overnight the 31P NMR spectrum showed the downfield movement of the 
phosphate peak from 8 -2.0 ppm to 8 4.2 ppm suggesting that cyanoethyl deprotection 
had proceeded as expected (Scheme 64). HPLC analysis showed a new peak at 20 
minutes, a result of the carboxylic acid negative charge, but again purification on Q- 
Sepharose resin afforded a mixture of products, so the product was used crude in the 
subsequent TIPDS cleavage.
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Scheme 64: Reagents and conditions: i) H2O (adjusted to pH 10 with 1 M NaOH), 
overnight; ii), HF / pyridine (7/3), pyridine, 20 mins.
Finally, with the basic reactions accomplished the 3'-TIPDS67 protection could be
removed using acidic HF in pyridine for 20 minutes. Purification on AG-MP1 
allowed successful separation of the two materials and isolation of TAADP 114 as a 
white hygroscopic powder. Unfortunately, when analysed this material was found to 
be contaminated with approximately 10 % of an unknown compound. It is speculated 
that this maybe a result of degradation producing 2',5'-ADP 87, but further analysis
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Figure 21: 'H NMR spectrum of TAADP 114.
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6.3 Biological results
To enable accurate phosphate quantification a Brigg’s test65 (see experimental general 
methods) was carried out on TAADP 114 before being evaluated for calcium release 
properties within sea urchin egg homogenates. Preliminary data suggest that crude 
TAADP 114 does cause calcium release from a pool receptive to either Ins(l,4 ,5 )P3 1, 
cADPR 2 or NAADP 3 as the data shows a depleted release in response to subsequent 
activation by TAADP 114 (Figure 23). It has been rationalised that the calcium store 
depleted by TAADP 114, is that stimulated by Ins(l,4 ,5 )P3 1 as successive exposure 
leads to a minimal response (Figure 24). Both cADPR 2 and NAADP 3 are 
unaffected by this store depletion and function as normal. Initial indication therefore 
is that TAADP 114 is an Ins(l,4 ,5 )P3R partial agonist. This is a very interesting 
discovery for two reasons. Firstly it does in fact cause calcium release and secondly it 
appears to be from a store other than that of NAADP 3. This was a surprising result, 
as the SAR data lead us to believe that TAADP 114 could be a potential NAADP 
receptor agonist, along with a longer duration of action if pyridinium hydrolysis was 
the mechanism of inactivation. TAADP 114 does share some similarity to the potent 
Ins(l,4 ,5 )P3 agonist adenophostin 134 insomuch as the adenosine is phosphorylated at 
the 2 '-position, but this does not account for the thiazole component, but may explain 
some of the observed activity (Figure 22).
134
Figure 22: Adenophostin
It has also been shown that stores inhibited by thapsigargin are not responsive to 
calcium release by TAADP 114 and that the release from NAADP stores is 
independent of TAADP 114 concentration, confirming its action on the Ins(l,4 ,5 )P3R. 
At this stage though the material that is being tested does contain a small percentage 
of impurity as observed in Figure 21 and this does need to be characterised to enable 
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Figure 23: Data representing depletion of all three discrete calcium stores followed 
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Figure 24: Data representing the depletion of Ins(l,4,5)P3 1 sensitive calcium stores 
after exposure to TAADP 114. Calcium stores responsive to cADPR 2 and NAADP 
3 are unaffected.
6.4 Summary
This synthetic route provided an analogue, which has undergone biological testing. It 
brings together two very high yielding and efficient synthetic schemes through the 
formation of a pyrophosphate bond between phosphorylated thiazole riboside 127 and 
cyanoethyl protected adenosine bfsphosphate 74. Unfortunately, even though the 
pyrophosphate formation appeared high yielding, problems with purification meant 
that the intermediates could not be accurately characterised. It has been possible 
though to synthesise an analogue that retains the 2'-phosphate, without formation of 
the 3'-regio-isomer, whilst retaining the negative charge on the aromatic ring.
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Disappointingly, it proved problematic to remove the small percentage of impurity 
from this sample and to obtain indisputable biological results, requires this to be 
accomplished.
6.5 Future work
Isolation of the impurity observed in the sample of TAADP 114 is important and as it 
is currently suspected to be 2',5VADP 87, this could be synthesised by the hydrolysis 
of NADP 7. Work will need to be carried out to try and develop the purification 
techniques to allow the isolation of the intermediates from the pyrophosphate 
formation. This will not only allow accurate quantification and characterisation of the 
compounds, but will also help overall yield optimisation by highlighting the poor 
reactions. For the purposes of biological evaluation further analogues would need to 
be produced to provide standards and also SAR information. These would need to 
include the amide derivative of the carboxylic acid, TADP 135 and also the 
dephosphorylated product TAAD 136 (Scheme 65).
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Scheme 65: Proposed analogues required for biological testing. The FGI to the 







All compounds were used as received unless otherwise stated. !H and 13C NMR 
spectra were recorded on either a Jeol JMX GX-270 MHz, Varian EX-400 MHz or 
600 MHz Inova spectrometer using deuterated chloroform, acetone, methanol, 
dimethyl sulfoxide or D2O. 31P NMR reaction monitoring was accomplished in either 
a deuterated solvent or via an internal capillary filled with either C D 3 C O C D 3  or 
C D 3 O D . 31P NMR chemical shifts were measured in ppm and relative to external 
reference 85 % H 3 P O 4 . The following abbreviations are used to describe the signals 
in the :H NMR spectra, s, singlet; br, broad singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet. For dinucleotides, the top half (e.g. nicotinamide ribose) is no prime and 
the bottom half (e.g. adenosine) is prime. To differentiate the base (e.g. adenine) is by 
subscript letters (e.g. ad)- The ribose moiety is without letters.
Thin layer chromatography (TLC) was performed on precoated plates (Merck silica 
gel 60 F254 aluminium sheets) with visualization using UV light and staining with 
KMn0 4 , anisaldehyde in EtOH and phosphomolybdic acid in MeOH. Column 
chromatography was carried out using silica gel (Matrix 60 particle size 35 -  70 
microns).
Mass spectrometry data were obtained using a Micromass Autospec machine. IR 
spectra were obtained using a Perkin Elner spectrum RX 1FT-IR using either a KBr 
disk or thin film and are expressed as cm'1.
Optical rotations were obtained at ambient temperature using an Optical Activity Ltd 
AA-10 polarimeter in a cell volume of 1 ml or 5 mL and specific rotation are 
expressed as 0 ml g' 1 dm'1.
Melting points were determined using a Reichert-Jung Therm Galen Kofler block and 
are uncorrected.
C H 3 C N  was distilled from CaH2 and stored over 4 A  molecular sieves. E t3 N  was 
distilled from Et3N and stored over KOH. Pyridine was distilled from KOH and 
stored over KOH. Trifluoroacetic anhydride was freshly distilled from P2O5 and used 
immediately.
Ion exchange analysis was carried out on a Hewlet Packard 1050 HPLC using an AG 
MP-1 column (3 x 150 mm) with UV detection set at 254 nm. Small particles were 
removed from the AG MP-1 by suspending in a large volume of Milli-Q (MQ) water
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(100 mL / lOg) then discarding any material left in suspension. The AG MP-1 was 
washed with 1 M NaOH (20 mL / g) then with MQ water until pH < 9. This was then 
washed with 150 mM aq. trifluoroacetic acid (TFA) (20 mL / g). To pack the column, 
two columns were joined together with a sleeve, securing them vertically, fitting an 
end cap with a frit to the bottom, then adding the slurry and allowing it to settle by 
gravity. An end cap with a frit was fitted to the column and it was then attached to the 
HPLC machine and 150 mM aq. TFA was pumped through at 5 mL / min for 15 
minutes to pack the column. The sleeve was then removed and the bottom column 
fitted with an end cap with a frit. The compounds were then eluted from the column 
using a gradient of water -  150 mM aq. TFA to elute the compounds.
Method A: 1 minute -  1% aq. TFA, 2 minutes - 2% aq. TFA, 5 minutes - 4% aq. TFA, 
9 minutes -  8 % aq. TFA, 13 minutes -  16% aq. TFA, 17 minutes - 32% aq. TFA, 18 
minutes -  100% aq. TFA, 21.10 minutes - 0% aq. TFA, 25 minutes -  0% aq. TFA. 
Reverse phase ion exchange chromatography was carried out on a Phenomenex Aqua 
column, 5 microns, C l8 ; 125A 150 x 4.60 mm.
Method B: 100 % H2O for 10 mins, linear gradient to H2 0 :CH3CN 1:1 over 20 mins, 
linear gradient to 100 % H2O over 1 min, 100 % H2O for 5 mins.
Product isolation using ion exchange was carried out on a Pharmacia LKB-gradifac. 
The conductivity of solutions loaded onto the resins was adjusted to less than 400 pS. 
AG-MP1 resin was eluted using a linear gradient of water -  150 mM aq. TFA eluting 
at 2 mL / min and Q-Sepharose fast flow resin eluted using a linear gradient of either 
1 or 2 M aq. TEAB at 5 mL / min. Both methods collected 10 mL fractions per test 
tube. Peak determination was carried out using UV absorption at 260 nm.
Synthetic phosphates were assayed by adaptations of the Brigg’s test65 as follows. 
For a quantitative test a standard curve was generated to calculate the quantity of the 
synthetic compound. Care was taken to use clean test tubes free from detergent. 
Using a series of tubes (in triplicate) increasing quantities of 10 mM KH2PO4 (10 
nmol phosphate in 10 pL) were added.
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Tube 1 0 pL phosphate 200 pL MQ water.
Tube 2 10 pL phosphate 190 pL MQ water.
Tube 3 20 pL phosphate 180 pLMQ water.
Tube 4 30 pL phosphate 170 pL MQ water.
Tube 5 40 pL phosphate 160 pL MQ water.
Tube 6 50 pL phosphate 150 pL MQ water.
Tube 7 60 pL phosphate 140 pL MQ water.
Tube 8 30 pL of compound 170 pL MQ water.
Tube 9 40 pL of compound 160 pL MQ water.
Tube 10 50 pL of compound 150 pL MQ water.
Tubes were placed in the oven at 180 °C for 15-30 minutes to evaporate to dryness. 
Once dry 4 drops of conc. H2SO4 was added to each tube and replaced in the oven for 
90 minutes at 180 °C.
The following solutions were then freshly prepared.
Solution 1 -  ammonium molybdate (5 g) in MQ water (40 mL) and conc. H 2 S O 4  (16 
mL) while cooling.
Solution 2 -  hydroquinone (200 mg) in MQ water (40 mL) and conc. H 2 S O 4  (2 
drops).
Solution 3 -  sodium sulphite (8  g) in MQ water (40 mL).
Tubes were the removed and cooled to room temperature.
To each tube was added: 250 pL of MQ water
500 pL of solution 1 
250 pL of solution 2 
250 pL of solution 3 
The resulting mixtures were heated until boiled for 10 seconds.
Each solution was diluted with MQ water to 10 mL in a volumetric flask.
Each sample was analysed using a UV spectrophotometer at 340 nm.
Quantification of the compound is then calculated using the standard curve.
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Extraction of ADP-ribosyl cyclase enzyme from ovotestis.
Buffer: 250 mM sucrose, 20 mM HEPES pH 8 , 1 mM EDTA, 1 mM phenylmethyl- 
sulfonylfluoride (PMSF) and 1 |Hg/mL leupeptin.
2.8 g of ovotestis were homogenisedin buffer (5:1 buffer volume to wet weight of 
tissue) followed by a two-step centrifugation procedure. The first step was a low 
speed centrifugation (13000 rpm at 4 °C for 20 minutes). The pellets were then 
discarded and the supernatant was subjected to a high-speed centrifugation (37000 
rpm at 4°C for 2 hours). The supernatant was collected and the enzyme activity was 
assayed by completing the sunthesis of NAADP.
Enyme assay
5 mM NADP (4 mg) and 100 mM nicorinic acid (12 mg) in a 100 mM solution of 
AcOH / NaOH (pH 4, 1 mL) were incubated with 5 pL of crude enzyme at room 
temperature. After 5 hours, HPLC analysis (method A) showed complete 
comsumption of NADP and formation of NAADP (R t  = 16 minutes).
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Nicotinamide (8 6  mg, 0.70 mmol) and trimethylsilyl trifluoromethanesulphonate 
(TMSOTf) (1.0 mL, 5.2 mmol) were added to a solution of tetra-1,2,3,5-0-acetyl-p- 
D-ribose (200 mg, 0.63 mmol) in CH3CN (5 mL) and stirred at room temperature 
under a nitrogen atmosphere for one hour after which time TLC (CH3 0 H:CH2Cl2 1:9; 
Rf 0.1) showed complete conversion to a new peak. The reaction was then treated 
with CH3OH (2.5 mL) and stirred for a further thirty minutes. The reaction was then 
evaporated to dryness, suspended in H2O (20 mL) and extracted three times with 
butan-l-ol (3 x 20 mL). The organic layer was extracted with H2O (3 x 10 mL) and 
the combined aqueous layers washed five times with CH2CI2 (5 x 10 mL). The 
aqueous layer was collected and evaporated to dryness. The residue was subjected to 
flash chromatography (CH2CI2 to CH2Cl2:CH3 0 H; 8 :2 ) to afford the desired product 
39 as a pale orange syrup (232 mg, 91 %).
Rf 0.35 (butan-l-ol:AcOH:H20 , 5:2:3); *H NMR 5H (270 MHz; D20 )  9.60 (1H, s, H- 
2™), 9.27 (1H, d, J  6.2, H-6niC), 8.98 (1H, d, J  7.9, H A c ), 8.27 (1H, m, H-5nic), 6.24 
(1H, d, 74 .2 , H -l'),4.52-4.47 (2 H, m, H-2', H-3'), 4.35 (1H, m, H-4'), 4.05 (1H, dd, J
13.1, 2.7, H-5'a) and 3.89 (1H, dd, J  13.1, 3.3, H-5'b); 13C NMR 6 C (100 MHz; D20 )
164.5 (C=0), 144.8, 141.6, 139.4 (CH), 133.1 (C), 127.8, 99.3, 87.1, 76.8, 69.3 (CH) 






Methyl nicotinate (96 mg, 0.70 mmol) and TMSOTf (1.0 mL, 5.2 mmol) were added 
to a solution of tetra-1,2,3,5-O-acetate-p-D-ribose (200 mg, 0.63 mmol) in CH3CN (5 
mL) and stirred at room temperature under a nitrogen atmosphere for one hour after 
which time TLC (CH3 0 H:CH2Cl2 1:9) showed complete conversion to a new peak 
(Rf 0.15). The reaction was then treated with CH3OH (2.5 mL) and allowed to stir for 
a further thirty minutes. The reaction was evaporated to dryness, suspended in H2O 
(20 mL) and extracted with butan-l-ol (3 x 20 mL). The organic layer was back 
extracted three times with H2O (3 x 10 mL) and the combined aqueous layers were 
washed five times with CH2CI2 (5 x 10 mL). The aqueous layer was collected and 
evaporated to dryness. The residue was subjected to flash chromatography (CH2CI2 
to CH2Cl2:CH3 0 H; 8:2) to produce the desired product 40 as an orange syrup (215 
mg, 81 %).
Rf 0 .3 8  (butan-l-ol:AcOH:H20 , 5 :2 :3 );  *H NMR 8H (2 7 0  MHz; CD3OD) 9 .8 1  (1 H , s, 
H -2 nic) , 9 .4 0  (1 H , d, J 6 .3 ,  H - 6 niC), 9 .8 5  (1 H , d, J  7 .9 ,  H -4niC), 8 .2 7  (1 H , dd, J  7 .9 ,  6 .3 ,  
H -5niC), 6 .1 8  (1 H , d, J 4 .4 ,  H-l'), 4 .4 4 - 4 .3 8  (2 H , m , H -2 ', H -3 ') ,  4 .3 0  (1 H , m , H -4 ') ,
4 .0 3  (3 H , s, OCH3), 3 .9 8  ( 1 H , m , H -5 'a) and 3 .8 4  (1 H , dd, J 1 2 .4 , 2 .5 ,  H -5 'b); 13C  
NMR 5 C ( 1 0 0  MHz; CD3OD) 1 6 2 .1  (C=0), 1 4 6 .9 , 1 4 3 .5 , 1 4 2 .0  (C H ), 1 3 1 .1  (C ),  
1 2 8 .3 , 1 0 1 .2 , 8 9 .0 ,  7 8 .4 ,  7 0 .7  (C H ), 6 0 .7  (C H 2) and 5 3 .2  (C H 3); m/z [FAB+] 2 7 0 .2  




Benzyl alcohol ( 0 .7 6  mL, 7 .3 9  mmol), DCC (1 .7  g, 8 .1 3  mmol) and DMAP ( 9 0  mg, 
0 .8 1  mmol) were added to a solution of nicotinic acid (1 .0  g, 8 .1 3  mmol) in CH2CI2 
(3 6  mL) under a nitrogen atmosphere. The solution was stirred at room temperature 
overnight after which the resulting precipitate was removed by filtration and washed 
with CH2CI2. The organic phase was extracted with aq. saturated NaHCC>3 (3  x 5 0  
mL) and brine (3  x 5 0  mL), dried (Na2SC>4), filtered and evaporated to dryness under 
vacuum. The resulting oil was subject to flash chromatography on silica gel using a 
gradient of CH2CI2 to CI^CkiCHsOH ( 1 0 0  to 9 8 :2 )  as eluent. The required fractions 
were collected and evaporated to dryness to afford the ester 44 as a clear colourless 
oil ( 1 .0  g, 6 7 % ) .
*H NMR 5 h  ( 4 0 0  MHz; C D C 13) 9 .2 1  (1 H , s, H -2n k ), 8 .6 9  (1 H , d, J 4 .7 ,  H - 6 nic) , 8 .2 4  
(1 H , d, J 7 .8 ,  H -4n iC), 7 .4 2 - 7 .3 9  (2 H , m, H-Ar), 7 .3 7 - 7 .2 8  (4 H , m, H -5niC, H-Ar) and 
5 .3 5  (2 H , s, C H 2); 13C  NMR 8 C ( 1 0 0  MHz; C D C 13) 1 6 5 .1  ( C = 0 ) ,  1 5 3 .6 , 1 5 1 .1 , 1 5 1 .0 ,
1 3 7 .3  (C H ), 1 3 5 .7  (C ) , 1 2 8 .9 , 1 2 8 .7 , 1 2 8 .5  (C H ), 1 2 6 .2  (C )  and 6 7 .4  (C H 2). 2  carbon 
signals equivalent; m/z [F A B +] 2 1 4 .2  (M+, 1 0 0  %) [found 2 1 4 .0 8 6 5  Ci3Hi2N0 2 + 
requires 2 1 4 .0 8 6 8 ] .
1 -Benzylnicotinate-p-D-ribose
45
Benzyl nicotinate 44 ( 1 4 7  mg, 0.69 mmol) and TMSOTf (1 mL, 5.2 mmol) were 
added to a solution of tetra-l,2,3,5-0-acetate-p-D-ribose (200 mg, 0.63 mmol) in 
C H 3 C N  (5 mL). This was stirred at room temperature under a nitrogen atmosphere
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for two hours after which time TLC (CH2Cl2:CH3 0 H 9:1) showed complete 
conversion to a new peak (Rf 0.5). The reaction mixture was then treated with 
CH3OH (2.5 mL) and allowed to stir for a further hour. The reaction was evaporated 
to dryness and the resulting oil subject to flash chromatography on silica gel using a 
gradient of CH2CI2 to CH2C12:CH3 0 H (10 to 8:2). The required fractions were 
collected and evaporated to dryness to afford the benzyl nicotinate ribose 45 as a pale 
brown oil (254 mg, 82 %).
vmax (NaCl disk)/cm 3 4 0 1  (O H ), 1 6 5 1  (COOBn); *H NMR 8 H ( 4 0 0  MHz; CD3 OD) 
9 .7 0  (1 H , s, H -2nic), 9 .3 2  (1 H , d, /  6 .3 ,  H - 6 niC), 9 .0 0  (1 H , d, J 8 .1 , H -4n iC), 8 .1 9  (1 H ,  
dd, J  8 .1 , 6 .3 ,  H -5nic), 7 .4 5 - 7 .4 3  (2 H , m, H-Ar), 7 .3 4 - 7 .2 5  (3 H , m, H-Ar), 6 .1 7  (1 H , d, 
J 4 .7 ,  H-l'), 5 .4 2  (2 H , s, CH2Ar), 4 .4 4  (1 H , t, J  4 .7 ,  H -2 ') ,  4 .3 8  (1 H , dd, J  5 .8 ,  2 .5 ,  H -  
4 ') ,  4 .3 1  (1 H , m, H -3 ') ,  3 .9 5  (1 H , dd, J  1 2 .5 , 2 .5 ,  H -5 'a) and 3 .8 3  (1 H , dd, J 1 2 .5 , 2 .5 ,  
H -5 'b); 13C NMR 8 C (6 7 .5  MHz; CD3 OD) 1 6 2 .2  (C=0), 1 4 7 .6 3 ,  1 4 7 .6 1 , 1 4 4 .1 , 1 4 2 .7  
(C H ), 1 3 5 .7 , 1 3 1 .5  (C ) , 1 2 9 .2 , 1 2 9 .1 , 1 2 9 .0 , 1 0 1 .7 , 8 9 .6 ,  7 8 .8 ,  7 1 .2  (C H ), 6 9 .0 ,  6 1 .2  
(CH2). 2  carbon signals equivalent; m/z [FAB*] 3 4 6 .1  (M+i 10 0 % ).
1-Nicotinic acid-p-D-ribose
41
Repeat of method for 1 -Benzylnicotinate-(3-D-ribose but after silica flash 
chromatography the product was then fractionated between EtOAc (20 mL) and water 
(20 mL). The organic layer was extracted with water ( 3 x 5  mL) and the aqueous 
layer extracted with EtOAc (3 x 20 mL). The combined aqueous layers were 
evaporated to dryness to generate the acid 41 as a pale yellow oil (220 mg, 87 %).
Vmax (NaCl disk)/cm 3422 (OH), 1919 (COOH); lH NMR 8 H (400 MHz; D20 )  9.38 
(1H, s, H-2mC), 8.90 (1H, d, J 6.3, H-6 mC), 8.74 (1H, d, J  9.2, H-4mC), 7.92 (1H, m, H- 
5nic), 5.89 (1H, d, J  3.9, H-l'), 4.15 (1H, m, H-2'), 4.13 (1H, m, H-4'), 4.01 (1H, t, J 
4.9, H-3'), 3.73 (1H, m, H-5'a) and 3.55 (1H, dd, J  12.9, 3.5, H-5'b); 13C NMR 8 C 
(67.5 MHz; D20 )  162.3 (C=0), 147.3, 143.6, 142.3, 128.6 (CH), 122.8 (C), 101.3,
100
89.6, 78.6, 71.2 (CH) and 61.0 (CH2); m/z [FAB+] 256.1 (M+, 100%) [found 256.0819 
ChHi4N 0 6+ requires 256.0821].
P-Nicotinamide mononucleotide (p-NMN)37
H 2N v s - 0
& o
ho' '  o h  
21
Nicotinamide ribose triflate 39 (350mg, 0.87 mmol) was treated with activated 
charcoal and freeze dried from H20 . This was suspended in a solution of 
trimethylphosphate (4.5 mL) and water (12 pL, 0.67 mmol) at 0°C. POCI3 (528 pL,
5.6 mmol) was added and the reaction stirred at 0°C for four hours after which time a 
second portion of POCI3 (200 pL, 2.1 mmol) was added. After a further hour a 
solution of CH3CN:ether (1:3) as added causing the formation of a white precipitate. 
The supernatant was removed, the precipitate dissolved in water (5 mL) and applied 
to a Dowex 1 X 2  formamide (1 cm x 5 cm), which was eluted with water (50 mL). 
The volume was reduced under vacuum to 5 mL and the solution applied to a second 
column of Dowex 50 WX8-100 H* (1 cm x 5 cm) washed with water (50 mL). The 
solution was evaporated to dryness and lyophilised from D20  to afford p-NMN 21 as 
a white solid (42 mg, 14 %).
lH NMR 8 h (400 MHz; D20 )  9.23 (1H, s, H -2niC), 9.04 (1H, d, J  6.3, H-6  niC), 8.75 
(1H, d, /  7.8, H-4 niC), 8.07 (1H, dd, J  7.8, 6.3, H-5 nic), 6.00 (1H, d, J 5.4, H-l'), 4.43 
(1H, m, H-20, 4.33 (1H, m, H-3'), 4.22 (1H, m, H-4'), 4.14 (1H, ddd, J  12.1, 4.3, 2.3, 
H-5'a), 3.97 (1H, ddd, J  12.1, 5.0, 2.3, H-5b); 13C NMR 8 C (100 MHz, D20 )  165.7 
(C=0), 145.8, 142.3, 139.8 (CH), 133.8 (C), 128.4, 99.8, 87.2, 77.6, 70.8 (CH) and
64.3 (CH2); 31P NMR 8 P (109 MHz; D2Q) 0.96; m/z [FAB+] 334.2 (M+, 80%)
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5-O-T riphenylmethyl-p-D-ribose40
^  \  H O  O H
47
Triphenylchloromethane (5.4 g, 19.5 mmol) was added to a solution of P-D-ribose 43 
(3.0 g, 20.0 mmol) in pyridine (10 mL) and stirred at 45°C for sixty minutes. The 
solution was evaporated to dryness under vacuum, re-suspended in CH2CI2 (20 mL) 
and extracted with H2O (3 x 10 mL). The organic layer was dried (MgSC>4), filtered 
and evaporated to dryness. The residue was dissolved in CH2CI2 (6  mL), added 
drop wise to a solution of hexane (20 mL) and CH2CI2 (2 mL) and stirred at room 
temperature for one hour. The resulting precipitate was filtered, washed with hexane 
and H2O and dried at 50°C under vacuum to afford the 5'-protected ribose 47 as a 
white solid (5.1 g, 67 %).
mp 124-128°C (from hexane) (lit.40 125°C); *H NMR 8 h (400 MHz; CDC13) 7.49-7.44 
(6 H, m, H-Ar), 7.32-7.22 (9H, m, H-Ar), 5.42 (1H, d, 74.0, H-l), 4.81 (1H, br s, OH- 
1), 4.27 (1H, dd, 7 7.0, 3.8, H-4), 4.23 (1H, m, H-3), 4.07 (1H, m, H-2), 3.98 (1H, br 
s, OH-3), 3.58 (1H, br s, OH-2), 3.32 (1H, dd, 7 10.1, 3.8, H-5a) and 3.13 (1H, dd, 7
10.1, 3.8, H-5b); 13C NMR 8 C (100 MHz; CDC13) 143.7 (C), 128.7, 127.9, 127.2, 96.8 
(CH), 86.9 (C), 83.2, 72.0, 71.9 (CH) and 64.1 (CH2). 2 C and 14 CH equivalent.
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1,2,3-T ri-Oacetyl-5-triphenylmethyl-p-D-ribose40
/ = { ° y - C
^  Ac O OAc 
48
Acetic anhydride (4.1 mL, 43.4 mmol) and Et3N (6.9 mL, 50 mmol) were added to a 
solution of 5-trityl-p-D-ribose 47 (4.9 g, 12.5 mmol) in toluene (12.5 mL) and stirred 
at room temperature overnight. Iced water (15 mL) was added and the reaction stirred 
for a further ten minutes, separated and the aqueous layer extracted with toluene (3 x 
10 mL). The combined organic layers were collected, washed with water (2 x 10 
mL), dried (MgS0 4 ), filtered and evaporated to dryness. The oil was subject to flash 
chromatography on silica gel using a gradient of hexane to hexane-EtOAc (7:3) as the 
eluent to afford the triacetate protected ribose 48 as a white foam (4.43 g, 69 %).
*H NMR 8 h (270 MHz; CDC13) 7.46-7.43 (6 H, m, H-Ar), 7.31-7.22 (9H, m, H-Ar), 
6.20 (1H, d, J  1.0, H-l), 5.49 (1H, dd, J  7.0, 4.8, H-3), 5.43 (1H, dd, J 4.8, 1.0, H-2),
4.07 (1H, ddd, J  7.0, 4.1, 3.5, H-4), 3.35 (1H, dd, J  10.4, 3.5, H-5a), 3.14 (1H, dd, J 
10.4,4.1, H-5b), 2.03 (3H, s, CH3), 2.00 (3H, s, CH3) and 1.98 (3H, s, CH3); 13C NMR 
8 C (100 MHz; CDC13) 169.7, 169.5, 169.4 (C=0), 143.7 (C), 128.7, 127.9, 127.1, 98.4 
(CH), 8 6 .8  (C), 80.9, 74.4, 70.9 (CH), 63.2 (CH2), 21.1, 20.6 and 20.5 (CH3). 2 C and 
14 CH equivalent.
1,2,3-Tri-Oacetyl-p-D-ribose40
/•s^O s^O A c
H O y X
AcO' OAc 
49
A solution of l,2,3-tri-0-acetyl-5-trityl-P-D-ribose 48 (1.9 g, 3.67 mmol) in CH2CI2 
(48 mL), H20  (1 mL) and TFA (1 mL) was stirred at room temperature for three 
hours. The reaction was extracted with H20  ( 3 x 1 5  mL), dried (MgS0 4 ) filtered and 
evaporated to dryness. The residue was subject to flash chromatography on silica gel 
eluting with a gradient of hexane to hexane-EtOAc (7:3) then EtOAc-CH3OH (9:1) to 
afford the alcohol 49 as a white foam (768 mg, 76 %).
103
*H NMR 8 h  (270 MHz; CDCI3) 6.00 (1H, d, J 0.9, H-l), 5.26 (1H, dd, /  6.9, 4.9, H-
3), 5.21 (1H, dd, J  4.9, 0.9, H-2), 4.12 (1H, ddd, J  6.9, 4.0, 3.4, H-4), 3.69 (1H, dd, J
12.4, 3.4, H -5 a ), 3.51 (1H, dd, J  12.4, 4.0, H - 5 b), 2.00 (3H, s, CH3), 1.97 (3H, s, C H 3) 
and 1.94 (3H, s, CH3); 13C NMR 8 C (100 MHz; CDC13) 169.0, 168.5, 168.2 (C=0),
97.2, 81.3, 73.5, 6 8 .8  (CH), 60.8 (C H 2), 20.1 (CH3) and 19.5 (2 x CH3).
A/,A/-diisopropylaminodichlorophosphine48
68
N^V-diisopropylamine (141.0 mL, 1.0 mol) in dry ether (150 mL) was added drop wise 
to a stirred solution of phosphorus trichloride (44.0 mL, 0.5 mol) in dry ether (100 
mL) at -78°C. The solution was diluted with dry ether (100 mL), vigorously stirred 
overnight at room temperature and the precipitated amine salt filtered, washed with 
ether (500 mL) and discarded. The organic phase was evaporated to dryness to afford 
a crude oil that was distilled (50-52°C; 0.5 mmHg, lit.48 62-63 °C; 7 mmHg) to afford 
the phosphine 6 8  as a clear colourless oil (72.0 g, 71 %).
*H NMR 8 h (400 MHz; CDC13) 3.93 (2H, m, 2 x CH) and 1.20 (12H, d, J 7.0, 4 x 
CH3); 31P NMR 8 P (162 MHz; CDC13) 169.5.
B/s(benzyloxy)diisopropylaminophosphine53
Benzyl alcohol (3.1 mL, 29.4 mmol) in dry CH2CI2 (25 mL) was added dropwise to a 
stirred solution of 7V,iV-diisopropylaminodichlorophosphine 6 8  (3.0 g, 14.7 mmol) in 
dry CH2CI2 (25 mL) and dry triethylamine (4.4 mL, 31.6 mmol) at -78°C. This was 
stirred for two hours at room temperature, then poured into aq. saturated NaHC03 
(100 mL) and extracted with three portions of CH2CI2 (3 x 50 mL). The combined 
organic layers were dried (Na2S0 4 ), filtered, evaporated to dryness. The crude 
mixture was subject to flash chromatography on silica gel conditioned using
pen
N—P 
" Y  OBn
52
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ether:hexane:Et3N (74:25:1) (400 mL). The column was eluted using 
ether:hexane:Et3N 74:25:1 to obtain the phosphine 52 as a clear oil (3.9 g, 79 %).
R f 0.45 (ether:hexane 3:1); *H NMR 8 H (400 MHz; CDC13) 7.42-7.30 (10H, m, H- 
Ar), 4.86-4.74 (4H, m, 2 x CH2Ar), 3.82-3.71 (2H, m, 2 x CH), 1.29-1.25 (12H, dd, J
6.7, 2 .2 ,4  x CH3); 31P NMR 8 P (162 MHz; CDC13) 148.5.
Imidazolium triflate50
H
<rN>  CF3SO3- 
NH+
51
To a stirred solution of imidazole (0.77g, 11.3 mmol) in CH2CI2 (15 mL) at 0°C was 
added triflic acid (1.0 mL, 11.3 mmol). The reaction was warmed to room 
temperature and stirred for twenty minutes after which time ether (20 mL) was added. 
The white precipitate 51 was filtered dried under vacuum (2.2 g, 90%) and stored 
under nitrogen and used within twenty-four hours, 
mp 197-198°C (from ether) (lit.50 197-198°C)
5-(Dibenzylphosphoryl)-1,2,3-tri-0-acetyl-p-D-ribose
o
BnO''Pr 0 ^ V ' V ‘OAcOBn \  I
AcO' OAc 
53
Rw(benzyloxy)diisopropylaminophosphine 52 (339 mg, 1.00 mmol) and imidazolium 
triflate 51 (436 mg, 2.00 mmol) were added to a solution of 1,2,3-tri-O-acetyl-p-D- 
ribose 49 (130 mg, 0.47 mmol) in CH2CI2 (10 mL) and stirred for three hours. TLC 
analysis showed quantitative conversion to the phosphite intermediate (hexane:EtOAc 
7:3 Rf 0.3). The reaction was cooled to -78°C, mCPBA (517 mg, 3.00 mmol) was 
added and the oxidation was monitored by 31P NMR (139 ppm to -0.69 ppm) and 
TLC (hexane:EtOAc 1:1 Rp 0.2). The reaction was quenched with 10% Na2S20 3  (50 
mL) and warmed to room temperature. The mixture was washed three times with aq. 
saturated NaHCC>3 (3 x 20 mL), brine (3 x 20 mL), dried (MgS0 4 ), filtered and 
evaporated to dryness. The product was then subject to flash chromatography on
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silica gel using a gradient of hexane to hexane:EtOAc (1:1) as eluent to produce the 
protected phosphate 53 as a glassy solid (164 mg, 85 %).
!H NMR 8 h (400 MHz; CDC13) 7.36-7.34 (10H, m, H-Ar), 6.15 (1H, s, H-l), 5.39 
(1H, dd, J  7.2, 4.9, H-3), 5.34 (1H, d, J  4.9, H-2), 5.06 (2H, t, 7PH 2.5, CH2Ar), 5.04 
(2H, t, Jm  2.5, CH2Ar), 4.33 (1H, m, H-4), 4.18 (1H, ddd, 7hh 11.3, 6.2, Jm  2.5, H- 
5.), 4.09 (1H, ddd, 7hh 11.3, 6.3, Jm  2.5, H-5b), 2.12 (3H, s, CH3), 2.04 (3H, s, CH3) 
and 1.99 (3H, s, CH3); 13C NMR 8 C (100 MHz; CDC13) 169.6, 169.4, 169.2 (C=0),
135.7, 135.6 (C), 128.6, 128.0 (10 x CH), 98.0, 79.8, 74.1, 70.1 (CH), 69.5, 69.4, 66.3 
(CH2), 20.6, 20.5 and 20.4 (CH3); 31P NMR 8 P (109 MHz; CDC13) -0.52.
1,2,3-T ri-Oacetyl-p-D-ribose-5-phosphate
HO' P' o '  ^ ° ^ OAc
AcO' OAc 
50
To a stirred solution of 5-&w(benzylphosphate)-l,2,3-tri-0-acetylribose 53 (75 mg, 
0.15 mmol) in CH3OH (5 mL) and H20  (0.25 mL) was added 20% Pd(OH)2/C (50 
mg) and cyclohexene (2 mL, 20 mmol). This was heated to 80°C for three hours after 
which time the catalyst was removed using a membrane filter and the product 
evaporated to dryness under vacuum to afford the free phosphate 50 as a white foam 
(27 mg, 50 %).
31P NMR 8 P (109 MHz; CD3OH) 0.69; m/z [FAB ] 355.0 (M+, 100%). lU and 13C 
NMR proved inconclusive.
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Hydroxypropionitrile (4.4 mL, 64.5 mmol) in dry CH2CI2 (50 mL) was added 
dropwise to a stirred solution of TV, Af-diisopropylaminodichlorophosphine 6 8  (6.5 g,
32.3 mmol) in dry CH2CI2 (50 mL) and dry triethylamine (9.6 mL, 69.4 mmol) at -  
78°C. This was stirred for two hours at room temperature, poured into aq. saturated 
NaHCC>3 (200 mL) and extracted with three times with CH2CI2 (3 x 100 mL). The 
combined organic extracts were dried (Na2SC>4), filtered, evaporated to dryness. The 
resulting oil was subject to flash chromatography on silica gel conditioned using 
ether:hexane:Et3N (74:25:1) (400 mL) then ether:hexane 3:1 (400 mL) before loading. 
The column was eluted using ether:hexane 3:1 to obtain the phosphine 69 as a clear 
oil (6.5 g, 74%).
Rf 0.61 (ether:hexane 3:1); ]H NMR 5h (400 MHz; CDC13) 3.92-3.77 (4H, m, 2 x 
CH2CN), 3.68-3.44 (2H, m, 2 x CH), 2.65 (4H, t, J 6.2, 2 x CH20), 1.18 (12H, d, J
7.0 ,4  x CH3); 31P NMR 8 P (162 MHz; CDC13) 149.6.
3 ',5 '-0 -(1 ,1,3,3-Tetraisopropyldisiloxane-1,3-diyl)adenosine45,46
l,3-Dichloro-l,l,3,3-tetraisopropyldisiloxane (1.20 mL, 3.75 mmol) was added to a 
solution of adenosine 58 (1.0 g, 3.75 mmol) in pyridine (40 mL) and stirred for three 
hours at room temperature. The solvent was removed under vacuum and the product 
dissolved in CH2CI2 (20 mL) washed with aq. saturated NaHCC>3 (3 x 20 mL), dried 
(Na2SC>4), filtered and evaporated to dryness. The compound was then subject to
65
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flash chromatography on silica gel using CH2CI2-CH3OH as eluent to afford the cyclic 
protected adenosine 65 as a white solid (1.5 g, 80 %).
R f 0.34 (CH2C12:CH3OH 95:5); mp 95-96 °C (from CH2C12) (lit.46 97-99 °C); [a ]25D -  
33 (c 1 in CHCI3); *H NMR 6 H (400 MHz; CDC13) 8.29 (1H, s, H-2ad), 8.03 (1H, s, H- 
8 ad), 6.01 (1H, d, J  0.8, H-l'), 4.99 (1H, dd, J 8.2, 5.4, H-3'), 4.56 (1H, dd, J  5.4, 0.8, 
H-2'), 4.19-4.13 (2H, m, H-4, H-5'a), 4.04 (1H, m, H-5'b) and 1.12-1.04 (28H, m, 4 x 
CH(CH3)2); 13C NMR 6 C (100 MHz; CDC13) 155.6 (C), 152.8 (CH), 149.1 (C), 139.5 
(CH), 120.4 (C), 90.1, 82.3, 75.4, 70.7 (CH), 61.8 (CH2), 17.9, 17.82, 17.80, 17.76, 
17.54, 17.46, 17.43, 17.36 (CH3), 13.8, 13.5, 13.2 and 13.0 (CH); m/z [FAB+] 510.2, 






Z?w(2-cyanoethoxy)diisopropylaminophosphine 69 (455 mg, 1.6 8  mmol) and 
imidazolium triflate 51 (976 mg, 4.48 mmol) were added to a solution of 3', 5' 
protected adenosine 65 (522 mg, 1.03 mmol) in CH2CI2 (30 mL) and stirred under a 
nitrogen atmosphere. After three hours TLC analysis showed quantitative conversion 
to the phosphite intermediate (CHCl3:acetone 2:8; Rf 0.45 P(m)). The reaction was 
cooled to -78°C, mCPBA (293 mg, 1.7 mmol) added and the oxidation was monitored 
by 31P NMR (139.6 ppm to -1.3 ppm), then quenched with 10% Na2S2C>3 (50 mL) and 
warmed to room temperature. The mixture was washed with aq. saturated NaHCC>3 
(3 x 20 mL) and brine (3 x 20 mL), dried (Na2SC>4), filtered and evaporated to 
dryness. The product was then subject to flash chromatography on silica gel using 
chloroform-acetone as eluent to afford the protected phosphate adenosine 71 as a 
white solid (699 mg, 98 %).
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R f 0.34 P0 0  (CHC13:acetone 2:8); mp 168-170 °C (from CHC13); [a ]25D -24  (c 1 in 
CHC13); *H NMR 8H (400 MHz; CDC13) 8.24 (1H, s, H-2ad), 8.12 (1H, s, H-8 ad), 6.18 
(1H, s, H -l'), 5.30 (1H, m, H-2'), 4.92 (1H, m, H-30, 4.50-4.35 (4H, m, 2 x 
CH2C/J2O) 4.26 ( 1H, dd, J  13.4, 2.4, H-5'a), 4.15 ( 1H, m, H-4'), 4.03 (1H, dd, J 13.4,
2.4, H-5'b), 2.90 (2H, t, J 6.2, CH2CN), 2.81 (2H, t, J  6.2, CH2CN) and 1.20-1.02 
(28H, m, 4 x CH(CH3)2); 13C NMR 5C (100 MHz; CDC13) 155.3 (C), 152.8 (CH), 
148.9 (C), 138.8 (CH), 120.2, 116.3, 116.0 (C), 88.2, 81.2, 80.7, 68.0 (CH), 62.7,
62.6, 59.4, 19.7, 19.6 (CH2), 17.4, 17.2 (3 x CH3), 16.97, 16.88, 16.85, 16.81 
(CH3),13.4, 12.9, 12.8, 12.5 (CH); 31P NMR 8 P (162 MHz; CDC13) -1.30; m/z [FAB+] 








A solution of 2' phosphate adenosine 71 (689 mg, 0.99 mmol) in TFA-H2O-THF 
(1:1:4; v/v/v) (60 mL) was stirred at 0°C for three hours. The reaction was neutralised 
with aq. saturated NaHC03 (60 mL) and the organic phase washed with H2O (3 x 20 
mL) and brine (3 x 20 mL), dried (Na2SC>4), filtered and evaporated to dryness to 
yield the selectively deprotected hydroxyl 72 as a white solid (705 mg, 100 %).
R f 0.19 (CHC13:acetone 2:8); mp 142-144 °C (from THF); [a ]25D -52  (c 1 in CHC13); 
lU NMR 5h (400 MHz; CDC13) 8.43 (1H, s, H-2ad), 8.22 (1H, s, H-8 ad), 6.31 (1H, d, J
6.2, H-l'), 5.59 (1H, m, H-2'), 4.89 (1H, m, H-3'), 4.34 (1H, d, J 2.0, H-4'), 4.26-4.06 
(4H, m, 2 x CH20), 3.92 (1H, dd, J  12.5, 2.0, H-5'a), 3.40 (1H, dd, J  12.5, 2.0, H-5'b), 
2.78 (2H, dd, J 10.1, 5.4, CH2CN), 2.73 (2H, dd, J  10.1, 5.4, CH2CN) and 1.15-1.01 
(28H, m, 4 x CH(CH3)2)\ 13C NMR 5C (100 MHz; CDC13) 160.2 (C), 156.5 (CH),
152.8 (C), 144.7 (CH), 123.7 (C), 121.0 (2 x C), 91.5, 91.3, 82.7, 75.6 (CH), 67.6 ,
67.6, 65.4, 23.1, 23.0 (CH2), 21.0 (3 x CH3), 20.93 (2 x CH3), 20.91, 20.84, 20.80
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(CH3), 17.8 (2 x CH), 17.52, 17.50 (CH); 31P NMR 5P (162 MHz; CDC13) -1.80; m/z 







Bw(benzyl)diisopropylaminophosphine 52 (1.07 g, 3.15 mmol) and imidazolium 
triflate 51 (1.83 g, 8.40 mmol) were added to a solution of 5' alcohol 72 (1.50 g, 2.10 
mmol) in CH2CI2 (50 mL) and stirred overnight after which time TLC showed 
complete conversion to phosphite intermediate (CHCI3:acetone 2:8; Rf 0.3 P(III)). The 
reaction was cooled to -78°C, mCPBA (1.35 g, 6.0 mmol) added and the oxidation 
monitored by 31P NMR (140.4 ppm to -2 .0  ppm), then quenched with 10% Na2S20 3  
(100 mL) and warmed to room temperature. The mixture was washed with aq. 
saturated NaHC03 (3 x 20 mL) and brine (3 x 20 mL), dried (Na2S0 4 ), filtered and 
evaporated to dryness. The product was then subject to flash chromatography on 
silica gel using chloroform-acetone as eluent to afford the diphosphate 73 as a white 
solid (1.55 g, 76 %).
Rf 0.23 Pw  (CHC13:acetone 2:8); mp 157-159 °C (from CHC13); lH NMR 5H (400 
MHz; CDCI3) 8.16 (1H, s, H-2), 8.08 (1H, s, H-8 ), 7.28-7.14 (10H, m, H-Ar), 6.19 
(1H, d, J  3.7, H-l'), 5.41(1H, m, H-20, 4.96-4.88 (5H, m, 2 x (OCH2Ph), H-3'), 4.38-
3.97 (7H, m, 2 x (CH2C/720), H-4', 5'a, H-5'b), 2.64-2.55 (4H, m, 2 x CH2CN) and 
1.01-0.72 (28H, m, 4 x CH(CH3)2)\ 13C NMR 8C (100 MHz; CDC13) 155.9 (C), 153.1 
(CH), 149.4 (C), 139.4 (CH), 135.6 (C), 135.5 (C), 128.88, 128.87, 128.81, 128.79, 
128.20, 128.17 (CH), 120.0, 116.7, 116.4 (C), 87.0, 82.9, 79.1 (CH), 70.1, 70.0 (CH2),
70.0 (CH), 68.2, 66.4, 66.3, 20.0, 19.9 (CH2), 17.81, 17.75, 17.70, 17.68,17.61 (CH3), 
14.0, 13.9, 13.8 and 13.7 (CH), 4 aromatic CH and 3 silanol CH3 occluded; 31P NMR
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8 P (162 MHz; CDC13) -2.00 and -0.42; m/z [FAB+] 974.9 (M+,H+, 56%) [found 





To a stirred mixture of 2', 5' phosphorylated adenosine 73 (300 mg, 0.304 mmol) in 
CH3OH (10 mL) and water (0.5 mL) was added 20% Pd(OH)2/C (100 mg) and 
cyclohexene (3.5 mL). The reaction was heated to 80°C for three hours and monitored 
by 31P N M R  (-0.42 ppm to 1.03 ppm) for completion. After cooling the reaction 
mixture was passed through a membrane filter and the catalyst washed copiously with 
a methanol /  water mixture (1:1). Concentration of the filtrate afforded the 
deprotected phosphate 74 as a white solid (200 mg, 82 %).
mp 1 3 9 - 1 4 1  °C  (from methanol); [a]25o - 1 4 °  (c  0 .3 6  in Methanol); *H N M R  8 h  (2 7 0  
M H z ; C D 3 O D ) 8 .6 5  (1 H , s, H - 2 ad) , 8 .2 5  (1 H , s, H - 8 ad) , 6 .3 2  (1 H , d, 7  5 .9 ,  H-l'), 5 .3 3  
(1 H , m, H -2 ') , 4 .8 2  (1 H , m, H -3 ') ,  4 .4 1  (1 H , m, H -4 ') ,  4 .1 6 - 4 .0 7  ( 6 H , m, 2  x C H 2 0 ,  
H -5 'a, H -5 'b ), 2 .7 6 - 2 .6 7  (4 H , m, 2  x C H 2 C N ) ) and 1 .0 5 -0 .7 5  (2 8 H , m, 4  x CH(CH3)2)\ 
13C  N M R  8 C (1 0 0  M H z ; C D C 13) 1 5 0 .8 , 1 4 7 .7  (C ), 1 4 6 .4  (C H ), 1 4 1 .2  (C H ), 1 1 8 .8
1 1 7 .4 , 1 1 7 .1  (C ) , 8 8 .1 ,  8 1 .9 ,  8 0 .5 ,  7 1 .5  (C H ), 6 7 .3 ,  6 3 .9 ,  6 2 .1 ,  1 9 .1 , 1 9 .0  (C H 2), 1 6 .9 ,  
1 6 .8 4 , 1 6 .7 5  (C H 3) , 1 6 .6 2  ( 2  x C H 3), 1 6 .5 5 , 1 6 .5 1 , 1 6 .3  (C H 3), 1 3 .9 , 1 3 .7 , 1 3 .4 , 1 3 .2  
(C H ); 31P N M R  8 P ( 1 0 9  M H z ; C D C 13) - 2 . 4 0  and 1 .0 3 ;  m/z [FAB+] 7 9 4 .3  (M + H )+, 
10 0 %  [found 7 9 4 .2 5 4 8  C28H5oN7Oi2P2Si2 requires 7 9 4 .2 5 3 1 ] .
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7.4 Synthesis of the pyrophosphate bond
Adenosine-5'-monophosphate morpholidate61
-nh-
-  -  n ^ / N
H O  O H
75
Powdered triphenylphosphine (131 mg, 0.5 mmol), 2,2/-dipyridyldisulphide (110 mg, 
0.5 mmol) and morpholine (87 |iL, 1.0 mmol) were added to a stirred solution of 
adenosine 5'-monophosphate 58 (free acid) (69 mg, 0.2 mmol) in DMSO (1.0 mL). 
The reaction was stirred at room temperature and monitored using ion exchange 
HPLC. After three hours another portion triphenylphosphine (6 8  mg, 0.25 mmol) and 
2,2'-dipyridyldisulphide (55 mg, 0.25 mmol) were added and stirred for a further 
hour. The reaction was quenched using 0.1 M Nal in acetone (10 mL) and the white 
precipitate filtered, washed with acetone until any yellow discolouration had been 
removed. The product was dried under vacuum over phosphorous pentoxide to afford 
the morpholidate 75 as a white solid (83 mg, 100 %).
*H NMR 8 h (400 MHz; D20 )  8.21 (1H, s, H-2ad), 8.00 (1H, s, H-8 ad), 5.88 (1H, d, J
5.1, H-l'), 4.58 (1H, m, H-2'), 4.30 (1H, t, J  4.6, H-3'), 4.13 (1H, br s, H-4'), 3.89- 
3.82 (2H, m, H-5'a, H-5'b), 3.32 (4H, t, J 4.7, 2 x CH2N) and 2.69 (4H, t, J  4.7, 2 x 




H O  O H  
6
p-NMN 21 (25 mg, 0.075 mmol) and MgS0 4 '7 H2 0  (34 mg, 0.136 mmol) were added 
to a solution of AMP morpholidate 75 (28 mg, 0.068 mmol) in 0.2 M MnCh* in 
formamide (563 pL, 0.1125 mmol) under a nitrogen atmosphere. The solution was 
stirred at room temperature for eighteen hours after which time RP ion pair HPLC 
analysis showed completion of the reaction. The mixture was applied to a column of 
Q-Sepharose and eluted with a gradient of water-1 M TEAB (eluting at 5-8%). The 
required fractions were analysed by reverse phase HPLC, collected, treated with 
chelex resin, filtered, concentrated under vacuum and lyophilised from D2O to afford 
NAD 6  as a white hygroscopic powder (12 mg, 27 %).
* MnCh dissolved in formamide and left over 4  A molecular sieves for three days.37 
R t  7 .5  minutes (R P -H P L C  9 4  % aq. 0 .1  M  K H 2P O 4 , 6  mM tetrabutylammonium 
bromide and 6 % C H 3 O H ; Isocratic for 3 0  mins); *H N M R  8 h  ( 2 7 0  MHz; D 2 O ) 9 .2 9  
(1 H , s, H -2niC), 9 .1 1  (1 H , d, J  6 .1 ,  H - 6 nic) , 8 .7 8  (1 H , d, J  8 .2 ,  H -4niC), 8 .3 7 , (1 H , s, H -  
2 'ad), 8 .1 5  (1 H , m, H -5n iC), 8 .0 5  (1 H , s, H - 8 'ad), 6 .0 4  (1 H , d, J 5 .2 ,  H-l'), 5 .9 8  (1 H , d, J 
5 .8 ,  H-l), 4 .7 2  (1 H , t, J  5 .8 , H -2 )  and 4 .5 1 -4 .2 1  (9 H , m, H -3 , H -4 , H -5 , H -2 ', H -3 ' ,  H -  
4 ' ,  H -5 ') ;  13C  N M R  8 C (100MHz; D 2 0 )  1 6 5 .1 , 1 5 5 .1  (C ) , 1 5 2 .5  (C H ), 1 4 8 .7  (C ),
145.7, 142.3, 139.8, 139.6 (CH), 133.5 (C), 128.5 (CH), 118.2 (C), 99.9, 86.9, 86.5,
83.7, 77.5, 73.9, 70.6, 70.3 (CH), 65.3 and 64.8 (CH2); 31P NMR 8P(162 MHz; D20 )  
-11.5; m/z [FAB-] 663.3 (M \  35%). Identical to commercial sample.
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Nicotinamide adenine dinucleotide 2'(2-cyanoethoxy) phosphate
Carbonyl diimidazole (48 mg, 0.3 mmol) and Et3N (14 pL, 0.1 mmol) were added to a 
solution of p-NMN 21 (33 mg, 0.1 mmol) in DMF (300 |iL). This was stirred at 
room temperature under a nitrogen atmosphere for three hours and monitored by 31P 
NMR (-9.5 ppm). Once complete a few drops of methanol were added and the 
solution stirred for a further five minutes. The solution was evaporated to dryness, 
co-evaporated with DMF (3 x 100 pL) to afford a yellow oil, to which was added a 
solution of 5' phosphate adenosine 74 (63 mg, 0.08 mmol) in DMF (300 pL) and the 
resulting mixture stirred at room temperature overnight. The reaction was then 
quenched with 25 mM NH4OAC (6  mL) and extracted with CH2CI2 ( 3 x 5  mL). The 
aqueous phase was evaporated to dryness and re-suspended in a solution of 1 0  % aq. 
TFA (10 mL) and EtOAc (0.5 mL). This was stirred for three hours and monitored by 
reverse phase TLC for the disappearance of starting material. The reaction was 
evaporated to dryness, re-suspended in H2O, loaded onto an ion exchange gradifac 
column (AG-MP1) and eluted using a linear gradient of 150 mM aq. TFA. Fractions 
analysed by ion exchange HPLC (method A) and the appropriate fractions were 
concentrated and lyophilised from D2O to afford the pyrophosphate 8 6  as a white 
hygroscopic powder (6  mg, 10  %).
Rt  11 minutes (AG-MP1 water:150 mM aq. TFA); NMR SH (600 MHz; D20 )  9.27 
(1H, s, H-2niC), 9.11 (1H, d, J  6.3, H-6 niC), 8.79 (1H, d, J  8.0, H-4niC), 8.44, (1H, s, H- 
2'ad), 8.29 (1H, s, H - 8 'ad), 8.14 (1H, m, H -5niC), 6.15 ( 1H, s, H-l'), 6.01 (1H, s, H-l),
5.00 (1H, m, H-2'), 4.53 (1H, m, H-3'), 4.44-4.41 (2H, m, H-2, H-3), 4.34 (1H, m, H-
4), 4.27-4.10 (5H, m, H-4', 5', 5), 3.81 (2H, m, CH2Ctf20), 2.58 (2H, m, CH2CN); 13C
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NMR 5C (100MHz; D20 )  166.6, 150.3, 148.4 (C), 146.1, 145.1, 142.9, 142.7, 139.9 
(CH), 134.0 (C), 128.8 (CH), 119.6, 118.0 (C), 100.1, 94.5, 87.4, 83.9, 77.8, 77.4,
71.1, 69.8 (CH), 65.2, 65.1, 60.8 and 19.7 (CH2); 31P NMR 5P (109 MHz; D20 )  -0.30  
and -11.03; m/z [FAB+] 795.1 (M+, 60 %) [found 795.0953 C24H3oN8Oi7P3+ requires
795.0942].
Nicotinamide adenine 3'-0-(3-hydroxy -1,1,3,3- 
tetraisopropyldisiloxane-1-yl) dinucleotide 2'-(2-cyanoethoxy) 
phosphate
TIPDSO O
Carbonyl diimidazole (107 mg, 0.60 mmol) and Et3N (34 pL, 0.24 mmol) were added 
to a solution of p-NMN 21 (75 mg, 0.22 mmol) in DMF (750 p.L). This was stirred at 
room temperature under a nitrogen atmosphere for three hours and monitored by 31P 
NMR (-9.5 ppm). Once complete a few drops of methanol were added and the 
solution stirred for a further five minutes. The solution was then evaporated to 
dryness and co-evaporated with DMF (3 x 100 pL). A solution of 5' phosphate 
adenosine 74 (140 mg, 0.17 mmol) in DMF (700 pL) was added to the residue and the 
reaction stirred at room temperature overnight. The reaction was evaporated to 
dryness under reduced pressure, suspended in H20  (5 mL), extracted with CH2C12 (3 
x 5 mL) and loaded onto Q sepharose fast flow resin. The compound was eluted 
using a linear gradient of 1 M aq. TEAB. Fractions were analysed by ion exchange 
HPLC (method A) and the appropriate fractions evaporated to dryness. The white 
powder was then re-suspended in CH3OH, repeatedly co-evaporated with CH3OH to
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remove excess Et3N and lyophilised from D2O to afford the pyrophosphate 
triethylammonium salt 85 as a white hygroscopic powder (129 mg, 63 %).
Rt  11 minutes (AG-MP1 water: 150 mM aq. TFA); *H NMR 6 H (400 MHz; CD3OD)
CH2CN) 1.33-0.95 (28H, m, (CH(CH3)2)4). H-3' occluded by HDO peak at 4.60; 13C
To a solution of 5' phosphate adenosine 74 (50 mg, 0.063 mmol) in THF (1 mL) at 
0°C buffered with AcOH (6  pL) was added 1 N TBAF in THF (120 pL). The 
solution was stirred under a nitrogen atmosphere for three hours, evaporated to 
dryness, re-suspended in water (10 mL) and extracted with CH2CI2 (3 x 10 mL). The 
aqueous phase was applied to a Q sepharose fast flow column and eluted with a 
gradient of water to 1 M aq. TEAB and analysed by ion exchange HPLC. Fractions 
eluting at 80% TEAB (Rt 14.9 min) were collected and evaporated to dryness under 
reduced pressure. The white powder was then re-suspended in CH3OH, repeatedly 
co-evaporated with CH3OH to remove excess Et3N and lyophilised from D20  to 
afford the cyclic phosphate 87 as a white hydroscopic powder (8  mg, 32%).
9 .3 2  (1 H , s, H -2nic) , 9 .1 2  (1 H , d, J  6 .6 , H - 6 nic) , 8 .6 3  (1 H , d, J  6 .6 , H -4niC) , 8 .2 7 ,  (1 H , s, 
H -2 'ad) , 7 .9 4  (1 H , t, J  6 .6 , H -5niC), 7 .8 6  (1 H , s, H - 8 'ad), 6 .0 0  (1 H , d, J  6 .2 ,  H-l'), 5 .8 1  
(1 H , d, J  5 .1 ,  H-l), 4 .9 8  (1 H , m , H -2 ') ,  4 .2 4  (1 H , t, J 5 .1 ,  H - 2 ) ,  4 .1 7 - 3 .9 7  (7 H , m , H -  
3 , H -4 , H -5 , H -4 ', H -5 ') ,  3 .5 5  (2 H , m , C H 2 C t f 2 0 ) ,  2 .2 2  (2 H , dd, 7 h h  1 0 .9 , Jm  6 .2 ,
NMR 8 C (100MHz; CD3OD) 163.9, 155.5, 152.2 (C), 149.8, 145.6, 142.9, 140.9,
140.5 (CH), 134.3 (C), 128.3 (CH), 118.8, 117.8 (C), 100.7, 88.3, 85.8, 85.6, 78.2,
77.4, 72.9, 71.3 (CH), 66.0, 65.0, 60.5, 19.0 (CH2), 17.14 (4 x CH3), 17.09 (2 x CH3),
17.0 (2 x CH3), 14.0, 13.9, 13.8 and 13.1 (CH); 31P NMR 8 P (109 MHz; D20 )  -0.82  





Rt 15 min (AG-MP1 water: 150 mM aq. TFA); ]H NMR 8 h (400 MHz; D2O) 8.23 
(1H, s, H-2), 8.08 (1H, s, H-8 ), 6.17 (1H, d, J  3.9, H-l'), 5.28 (1H, m, H-2'), 5.04 (1H, 
m, H-3'), 4.45 (1H, m, H-4') and 4.00-3.97 (2H, m, H-5'); 31P NMR 6 P (109 MHz; 
D20 )  20.7 and 1.2; m/z [FAB+] 408.1 (M+, 70 %).
Nicotinamide adenine dinucleotide 2'-(2-cyanoethoxy) phosphate
To a solution of purified pyrophosphate (TEA salt) 24 (73 mg, 0.063 mmol) in THF 
(700 pL) at 0°C were added AcOH (4  pL) and IN TBAF in THF (80 pL). The 
solution was stirred for three hours, then evaporated to dryness under reduced 
pressure, re-suspended in water (10 mL) and extracted with CH2CI2 (3 x 10 mL). The 
aqueous phase was loaded onto a column of AG-MP1 resin, eluted using a gradient of 
water: 150 mM aq. TFA and analysed by ion exchange HPLC. The desired fractions 
were then evaporated to dryness and lyophilised from D20  to afford desilylated 
pyrophosphate 23 as a white hydroscopic powder (37mg, 75 %).
R t  1 1 minutes (AG-MP1 water: 1 5 0  mM aq. TFA); *H NMR Sh  (4 0 0  MHz; D 20 )  9 .2 4  
(1 H , s, H -2nic), 9 .0 8  (1 H , d, J  6 .6 ,  H -6niC), 8 .7 6  (1 H , d, J 7 .8 ,  H A i c ) ,  8 .4 1 ,  (1 H , s, H -  
2'ad), 8 .2 7  (1 H , s, H -8'ad), 8 .1 0  (1 H , dd, J  7 .8 ,  6 .6 ,  H -5niC) , 6 .1 3  (1 H , d, J 5 .0 ,  H-l'),
5 .9 8  (1 H , d, J  5 .4 ,  H-l), 4 .9 6  (1 H , m, H -2 ') ,  4 .5 0  (1 H , m, H -3 ') ,  4 .4 1 - 4 .3 8  (2 H , m, H -  
2 , 3 ) ,  4 .3 0  (1 H , m , H -4 ') ,  4 .2 4 - 4 .0 4  (5 H , m , H -4 , H -5 ', H -5 ) ,  3 .8 1 -3 .7 3  (2 H , m , 
C H 2C t f 20 ) ,  2 .5 6 - 2 .5 3  (2 H , m, C H 2C N );  31P NMR 8P (1 0 9  MHz; D 20 )  - 0 . 2 5  and -  
1 0 .7 0 . m/z [FAB+] 7 9 5 .1  (M+, 6 0  %) [found 7 9 5 .0 9 5 3  C24H3oN8Oi7P3+ requires
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Method One
Af,G-Bw(trimethylsilyl)acetamide (232 pL, 0.94 mmol) and DBU (23 juL, 0.15 mmol) 
were added to a solution of 5' phosphate adenosine 74 (20 mg, 0.025 mmol) in 
pyridine (2.5 mL). It was stirred under a nitrogen atmosphere for ninety minutes, 
after which time the solvent was removed under reduced pressure, re-suspended in 
water (5 mL) and extracted with ether (3 x 10 mL). The aqueous phase was 
evaporated to dryness, co-evaporated with toluene and suspended in THF (500 pL). 1 
N TBAF in THF (50 pL) was added and the solution stirred for two hours at 0°C 
under a nitrogen atmosphere. This was evaporated to dryness under reduced pressure, 
re-suspended in water (5 mL), extracted with CH2CI2 ( 3 x 1 0  mL) and loaded onto a 
column of AG-MP1 resin. Fractions were analysed by ion exchange HPLC (method 
A) and the desired fractions were evaporated to dryness and lyophilised from D2O to 
afford 2',5'-ADP 87 as a white hydroscopic powder (4 mg, 36 %).
Method Two
A,0-Bw(trimethylsilyl)acetamide (185 pL, 0.75 mmol) and DBU (18 pL, 0.12 mmol) 
were added to a solution of purified pyrophosphate 85 (20 mg, 0.017 mmol) in 
pyridine (2.0 mL). It was stirred under a nitrogen atmosphere for ninety minutes, 
after which time the solvent was removed under reduced pressure, re-suspended in 
water (5 mL) and extracted with ether (3 x 10 mL). The aqueous phase was 
evaporated to dryness and co-evaporated with toluene and suspended in THF (500 
pL). 1 N TBAF in THF (50 pL) was added and the reaction stirred for two hours at 
0°C under a nitrogen atmosphere. This was evaporated to dryness under reduced 
pressure, re-suspended in water (5 mL), extracted with CH2CI2 (3 x 10 mL) and 
loaded onto a column of AG-MP1 resin. Fractions were analysed by ion exchange
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HPLC and the desired fractions were evaporated to dryness to afford 2',5'-ADP 87 as 
a clear glassy solid (3 mg, 42 %).
Rt 14 minutes (AG-MP1 water:150 mM aq. TFA); *H NMR 8h (400 MHz; D20 )  8.45 
(1H, s, H-2), 8.26 (1H, s, H-8 ), 6.16 (1H, d, 75.8, H-l'), 4.97 (1H, m, H-2'), 4.47 (1H, 
m, H-3'), 4.27 (1H, m, H-4') and 4.00-3.99 (2H, m, H-5'); 31P NMR 8 P (109 MHz; 
D20 )  1.1 and 0.6.




Rw(benzyloxy)diisopropylaminophosphine 52 (499 mg, 1.47 mmol) and imidazolium 
triflate 51 (856 mg, 3.98 mmol) were added to a solution of 3',5' protected adenosine 
65 (500 mg, 0.98 mmol) in CH2C12 (30 mL) under a nitrogen atmosphere and stirred 
overnight. TLC analysis showed quantitative conversion to the phosphite 
intermediate (CHCI3:acetone 1:1 Rp 0.6). The reaction was cooled to -78°C, mCPBA 
(508 mg, 2.95 mmol) was added and the oxidation monitored by 31P NMR (149 ppm 
to -0.77 ppm) and TLC (CHCI3:acetone 2:8 Rf 0.6). The reaction was quenched with 
10% Na2S2C>3 (50 mL) and warmed to room temperature. The mixture was washed 
with NaHCC>3 (3 x 20 mL), brine (3 x 20 mL), dried (Na2SC>4), filtered and evaporated 
to dryness. The product was then subject to flash chromatography on silica gel using 
CH2Cl2to CH2C12:CH3 0 H (95:5) as the eluent to afford the protected phosphate 93 as 
a white solid (591 mg, 78 %).
R f 0.4 (CH2Cl2:CH3OH 95:5); mp 160-162 °C (from CH2C12); ]H NMR 8 H (600 
MHz; CDCI3) 8.20 (1H, s, H-2ad), 7.82 (1H, s, H-8 ad), 7.33-7.30 (10H, m, H-Ar), 6.00 
(1H, s, H-l'), 5.73 (2H, s, NH2), 5.33 (1H, dd, 7hh 8.2, / PH 4.9, H-2'), 5.17-5.07 (5H, 
m, 2 x OCH2Ph, H-3'), 4.16 (1H, dd, J 13.2, 2.0, H-5'a), 4.06 (1H, dt, J  2.6, 2.0, H-4'),
4.00 (1H, dd, J  13.2, 2.6, H-5'b) and 1.10-1.00 (28H, m, 4 x CH(CH3)2)\ 13C NMR 8 C
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(150 MHz; CDCI3) 155.6 (C), 153.2 (CH), 149.3 (C), 139.6 (CH), 135.9, 135.7 (C), 
128.77, 128.76, 128.73, 128.71, 128.13, 128.08 (CH), 120.4 (C), 8 8 .8 , 81.5, 79.8 
(CH), 69.9, 69.8 (CH2), 6 8 .8  (CH), 60.1 (CH2), 17.6, 17.49, 17.48, 17.46, 17.2, 17.0
(CH3), 13.5, 13.2, 13.0 and 12.8 (CH), 4 aromatic CH and 2 silanol CH3 occluded; 31P 
NMR 5P (162 MHz; CDC13) -0.77 m/z [FAB4] 770.3 (M+, 100%) [found 770.3156 
C36H53N5 0 gPSi2+ requires 770.3170].
2'-(Dibenzyloxyphosphoryl)-3'-0(3-hydroxy-1,1,3,3- 
tetraisopropyldisiloxane-1 -yl) adenosine
Benzyl protected phosphate adenosine 93 (591 mg, 0.77 mmol) at 0 °C was dissolved 
in TFA-H20-THF (1:1:4; v/v/v, 60 mL, 0 °C) and stirred for four hours at 0 °C after 
which TLC analysis (CH2Cl2:CH3OH, 9:1; Rf 0.55) showed the reaction had gone to 
completion. It was neutralised with aq. saturated NaHC03 and the organic layer 
extracted with H20  (3 x 20 mL) and brine (3 x 20 mL). The organic phase was 
collected, dried (Na2SC>4), filtered and evaporated to dryness to afford the deprotected 
hydroxyl 94 as a white solid (456 mg, 76 %).
mp >210°C (decomposed); *H NMR 5H (400 MHz; CD3OD) 8.48 (1H, s, H-2ad), 8.17 
(1H, s, H-8 ad), 7.32-7.30 (6 H, m, Ar-H), 7.19-7.13 (4H, Ar-H), 6.32 (1H, d, /  6 .6 , H- 
10, 5.57 (1H, m, H-20, 4.95-4.81 (5H, m, 2 x OCH2Ph, H-30, 4.35 (1H, m, H-40,
3.89 (1H, dd, J  12.5, 2.7, H-5'a), 3.85 (1H, dd, J  12.5, 2.5, H-5'b) and 1.16-1.10 (28H, 
m, 4 x CH(CH3)2y, 13C NMR 8C (100 MHz; CD3OD) 153.2, 148.8 (C), 148.1 (CH),
141.9 (CH), 135.3 (2 x C), 128.6, 128.5, 127.79 127.75, 127.71, 127.69 (CH), 119.5 
(C), 87.9, 87.0, 78.6, 72.3 (CH), 70.1, 70.0, 61.5 (CH2), 17.0 (8  x CH3), 13.9 (2 x CH) 
and 13.6 (2 x CH); 31P NMR 8 P (109 MHz; CD3OD) -1.16. m/z [FAB4] 788.4 (M+, 









A solution of imidazole (69 mg, 1.01 mmol), PCI3 (142 juL, 1.62 mmol) and Et3N 
(300 pL, 2.16 mmol) in THF (8  mL) was stirred at 0°C for fifteen minutes after which 
time the 5' alcohol 94 (425 mg, 0.54 mmol) in THF (12 mL) was added in one 
portion. The reaction was warmed to room temperature and stirred for fifteen 
minutes, quenched using 1 M aq. triethylammonium bicarbonate (TEAB) (20 mL) 
and stirred for a further fifteen minutes before the addition of CH2CI2 (20 mL). The 
organic phase was washed with equal portions of 1 M aq. TEAB (1 x 20 mL), ice 
water (3 x 20 mL) and 1 M aq. TEAB (3 x 40 mL). The combined aqueous layers 
were extracted with CH2CI2 (5 x 20 mL). The combined organic layers were dried 
(MgSCU), filtered and evaporated to dryness. The oil was then subject to flash 
chromatography on silica gel eluting with a gradient of EtOAc to Et0 Ac:CH3 0 H:H2 0  
(10:2:1). The desired fractions were collected and evaporated to dryness to afford the 
ff-phosphonate salt 103 as a white foam (358 mg, 70 %).
lU NMR 8 h (270 MHz; CDC13) 8.69 (1H, s, H-2ad), 8.08 (1H, s, H-8 ad), 7.18-7.04 
(10H, m, H-Ar), 6.72 (1H, d, Jm  630, P-H), 6.33 (1H, d, J  5.7, H-l'), 5.45 (1H, m, H- 
2'), 4.83-4.74 (4H, m, CH2Ar), 4.73-4.62 (2H, m, H-3', H-4'), 3.96 (2H, m, H-5') and
1.04-0.89 (28H, m, 4 x (CH(CH3)2) l  13C NMR 6 C ( 1 0 0  MHz; CDC13) 155.4, 150.0 
(C), 149.8 (CH), 140.0 (CH), 135.1, 135.0 (C), 128.6, 127.7 (CH), 118.8 (C), 85.1,
79.1, 71.5 (CH) (one carbon under CHC13 peak), 69.9, 69.8, 29.9 (CH2), 17.53 (4 x 
CH3), 17.47 (3 x CH3), 17.39 (CH3), 13.8 (CH), 13.7 (2 x CH) and 13.5 (CH). 8 
aromatic CH occluded; 31P NMR 6 P (109 MHz; CDC13) 6.78 and -0.90; m/z [FAB*]








N, 0 -Bz5(trimethylsilyl)acetamide (500 pL, 2.0 mmol) was added to a solution of H- 
phosphonate 29 (160 mg, 0.17 mmol) in CDCI3 (2 mL) and allowed to react for one 
hour after which time 31P NMR showed the presence of a new peak at 6  116 ppm. 
(1 £)-(+)-10-(Camphorsulphonyl)oxaziridine 106 (135 mg, 0.59) was added and the 
oxidation monitored by 31P NMR (-17 ppm). After fifteen minutes the solution was 
evaporated to dryness and the white precipitate re-suspended in a 1:1  mixture of 
CH3 0 H:CHCl3 (1 mL) with two drops of D2O. The reaction was stirred for two hours 
and monitored by P NMR for the phosphate peak (1.5 ppm). It was then evaporated 
to dryness and subject to flash chromatography on silica gel eluting with a gradient of 
EtOAc to Et0 Ac:CH3 0 H:H2 0  (8:2:1). The desired fractions were collected and 
evaporated to dryness to afford the phosphate 104 as a white foam (73 mg, 50 %).
*H NMR §H (270 MHz; CH3OD) 8.70 (1H, s, H-2ad), 8.14 (1H, s, H-8 ad), 7.31-7.04 
(10H, m, H-Ar), 6.43 (1H, d, J  7.4, H-l'), 5.43 (1H, m, H-2'), 4.94-4.90 (4H, m, 
CH2Ar), 4.83-4.64 (2H, m, H-3', H-4'), 4.13 (2H, m, H-5') and 1.09-0.88 (28H, m, 4 x 
(CH(CH3)2)); 13C NMR 5C (67.5 MHz; CDC13) 157.0 (C), 153.6 (CH), 151.2 (C),
141.2 (CH), 136.4, 136.3 (C), 129.7 (4 x CH), 129.6 (4 x CH), 128.9 (2 x CH), 119.9 
(C), 87.6, 86.1, 80.2, 74.3 (CH), 71.1, 71.0, 65.9 (CH2), 18.1, 18.0 (CH3), 17.92 (2 x 
CH3), 17.89 (4 x CH3), 14.8 (2 x CH), 14.5, 14.0 (CH); 31P NMR 5P (109 MHz; 
CDCI3) 1.2 and -0.90. m/z [FAB ] 869.7 (M \ 65 %).
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7.6 Synthesis of NADP and NAADP
Nicotinamide adenine dinucleotide 2'-(b/sbenzyloxy) phosphate
109
Carbonyl diimidazole (43 mg, 0.26 mmol) and EtaN (14 pL, 0.096 mmol) were added 
to a solution of p-NMN 21 (30 mg, 0.088 mmol) in DMF (300 pL) and stirred at 
room temperature under a nitrogen atmosphere for three hours monitoring by 31P 
NMR (-9.5 ppm). A few drops of methanol were then added and the solution was 
stirred for a further five minutes. It was then evaporated to dryness and co-evaporated 
with DMF (3 x 100 pL). A solution of fcisphosphate adenosine 104 (69 mg, 0.08 
mmol) in DMF (500 pL) was added and the resulting mixture was stirred at room 
temperature for twenty-four hours. The reaction material was evaporated to dryness 
under reduced pressure, suspended in H2O (5 mL), extracted with CH2CI2 ( 3 x 5  mL) 
and the aqueous phase evaporated to dryness before being used crude in the following 
reaction.
Crude silylated pyrophosphate 108 (70mg) was suspended in THF (2.5 mL) and 
treated with a solution of 1 N TBAF in THF (300 pL) buffered with AcOH (15 pL). 
This reaction was stirred at 0°C for three hours after which complete conversion to a 
new peak was observed by ion exchange HPLC (Rt 11 minutes). The reaction was 
evaporated to dryness, re-suspended in water (10 mL), extracted three times with 
EtOAc (3 x 10 mL) and loaded onto a column of AG-MP1. The compound was then 
eluted using a gradient of water: 150 mM aq. TFA and the fractions were analysed by 
ion exchange HPLC (method A). The desired fractions were combined and
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lyophilised from D2O to afford monobenzyl NADP 109 as a white hygroscopic 
powder (11 mg, 14 % from starting adenosine 104).
Rt 11 minutes (AG-MP1 water:150 mM aq. TFA); *H NMR 8 H (400 MHz; D20 )  9.26 
(1H, s, H -2niC) , 9.10 (1H, d, J  6.3, H - 6 nic) , 8.76 (1H, d, J  8.2, H -4„iC), 8.37 (1H, s, H- 
2 'ad) , 8.12 (1H, dd, J  8.2, 6.3, H -5niC), 8.01 (1H, s, H -8 'ad) , 7.12-7.09 (3H, m, H-Ar), 
6.83-6.81 (2 H , m, H-Ar), 6.03 (1H, d, /  6 .6 , H-l), 5.99 (1H, d, J 5.4, H-l'), 5.11-5.05 
(1H, m, H -2 ') ,  4.73 (2 H , s, CH2Ar), 4.46-4.43 (2 H , m, H-4' and H -2 ) , 4.31 (1H, m, H- 
3) and 4.23-4.05 (5 H , m, H -4 , H -5 , H -5 ') .  H-3' under HDO peak; 13C NMR 5C (100 
MHz; D20 )  164.5, 149.3 148.7 (C), 146.2, 144.5, 142.9, 142.7, 140.0 (CH), 136.8,
134.0 (C), 128.84, 128.77, 128.44, 128.41, 127.9, 125.9 (CH), 118.3 (C), 100.1, 87.3,
86.4, 84.5, 77.7, 77.1, 74.0 (CH), 70.9 (CH2), 70.5 (CH), 66.7, and 65.6 (CH2); 31P 
NMR 5P (109 MHz; D20 )  -0.04 and -11 .6 .
Nicotinamide adenine dinucleotide phosphate (NADP)
7
Monobenzyl NADP 109 (1 lmg, 0.013 mmol) was suspended in a degassed mixture of 
H20 :CH3 0 H (3:1) (2 mL). Cyclohexadiene (100 pL, 1.04 mmol) and 10 % Pd/C (10 
mg) were added and the reaction was stirred for two hours at room temperature. The 
palladium was filtered through a membrane filter, washed with water, applied to a 
column of AG-MP1 and eluted using a gradient of water: 150 mM aq. TFA. Fractions 
were analysed by ion exchange HPLC and the appropriate fractions (R t 11 minutes) 
were combined and lyophilised from D20  to afford NADP 7as a white hygroscopic 
powder (3 mg, 31 %).
Rt 11 minutes (AG-MP1 water: 150 mM aq. TFA); !H NMR 8H (400 MHz; D20 )  9.30 
(1H, s, H-2„ic), 9.14 (1H, d, J. 5.4, H-6niC), 8.81 (1H, d, J  8.2, H-4nic), 8.46 (1H, s, H-
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2'ad), 8 .3 1  (1 H , s, H -8'ad), 8 .1 6  (1 H , m, H -5niC), 6 .1 6  (1 H , d, J  5 .4 ,  H-l), 6 .0 3  (1 H , d, J 
5 .5 ,  H-l'), 4 .9 9  (1 H , m, H -2 ') ,  4 .5 2  (1 H , m, H -3 ') ,  4 .4 6 - 4 .4 3  (2 H , m, H -4 ',  H - 2 ) ,  4 .3 5  
(1 H , m, H -3 ) , 4 .2 8 - 4 .1 2  (5 H , m, H - 4 , H -5 , H - 5 0 ;  13C  NMR 5 C ( 1 0 0  MHz; D 20 )
1 6 5 .4 , 1 5 1 .9  1 4 8 .5  (C ), 1 4 7 .9 , 1 4 5 .9 , 1 4 2 .5 , 1 4 1 .6 , 1 3 9 .8  (C H ), 1 3 3 .7  (C ) , 1 2 8 .6  
(C H ), 1 1 8 .2  (C ) , 9 9 .9 ,  8 7 .1 ,  8 6 .4 ,  8 3 .7 ,  7 7 .5 ,  7 6 .7 ,  7 0 .7 ,  6 9 .9  (C H ), 6 5 .3 ,  and 6 4 .9  
(C H 2); 31P  NMR 6P (1 0 9  MHz; D 20 )  0 .3 8  and - 1 0 .6 .
Nicotinic acid adenine dinucleotide phosphate (NAADP)





To a solution of NADP 7 (5.0 mg, 0.007 mmol) in a 100 mM AcOH-NaOH buffer 
(pH 4 ,  1.25 mL) was added nicotinic acid (15 mg, 0.12 mmol) and crude ADP ribosyl 
cyclase enzyme (7 pL). It was stirred at room temperature for six hours and 
monitored by ion exchange HPLC. Once complete the reaction was applied to an ion 
exchange column of AG-MP1 and purified using a water-150 mM aq. TFA gradient. 
The desired fractions were combined, evaporated to dryness, co-evaporated from D20  
and lyophilised from D20  to afford NAADP 3 as a white hygroscopic powder (3 mg, 
60 %).
R t 16  minutes (AG-MP1 water: 1 5 0  mM aq. TFA); ]H  NMR 6H ( 4 0 0  MHz; D zO ) 9 .3 2  
(1 H , s, H -2niC), 9 .1 8  (1 H , d, J 5 .9 ,  H -6n iC), 8 .8 7  (1 H , d, J 8 .1 ,  K-4^), 8 .4 5  (1 H , s, H -  
2'ad), 8 .2 8  (1 H , s, H -8 'ad), 8 .1 3  (1 H , m, H -5niC) , 6 .1 4  (1 H , d, J  5 .5 ,  H-l), 6 .0 3  (1 H , d, J
5 .1 ,  H - 1 0 ,  4 .9 8  (1 H , m, H -2 ') ,  4 .5 1  (1 H , m, H -3 ') ,  4 .4 4  (2 H , br s, H -4 ')  4 .4 1  (1 H , m, 
H -2 ) , 4 .3 2  (1 H , m, H -3 ) , 4 .2 7 - 4 .1 0  (5 H , m, H -4 , H -5 , H -5 ') ;  13C  NMR 5 C (1 0 5  MHz; 
D 20 )  1 6 5 .5  (C O O H ), 1 4 9 .8  (C A4 )  1 4 8 .3  (C A6 ) ,  1 4 7 .0  (C H A2 ) , 1 4 4 .6  (C H N6 ) , 1 4 2 .8  
(C H n4 ) ,  1 4 1 .8  (C H a 8 , C H n 2 ) , 1 3 3 .8  (C N3 ) , 1 2 8 .6  (C H N5 ) ,  1 1 8 .4  (C A5 ) ,  9 9 .8  
(C H n 1'), 8 6 .8  (C H a 4 ') ,  8 3 .9  (C H A1 ') , 7 7 .4  (C H N2 ') , 7 6 .8  (C H A2 ') ,  7 3 .9  (C H N4 ') ,  7 0 .5
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(CHn3'), 69.9 (CHa3'), 65.2, and 64.8 (CH2); 31P NMR 8P (109 MHz; D20 )  1.47 and 
-9.67; m/z [FAB4] 744.8 (M+, 50 %) [found 745.0658 C2iH28N6Oi8P3+ requires 
745.0673].





To a stirred solution of l-0-acetyl-2,3,5-tri-0-benzoyl-(3-D-ribofuranose 122 (5.0 g,
9.9 mmol) in CH2C12 under a nitrogen atmosphere (13 mL) was added TMSCN (2.7 
mL, 20.3 mmol). The reaction mixture was treated with one portion of tin (TV) 
chloride (1M in CH2C12) (11.9 mL, 10.2 mmol). The darkening solution was stirred 
for two minutes then poured into aq. saturated NaHCC>3 (100 mL) and stirred for five 
minutes. CH2C12 (125 mL) was added and the emulsion filtered through a celite pad. 
The CH2C12 layer was separated and the aqueous layer further extracted with CH2C12 
(3 x 20 mL). The combined organics were dried (Na2SC>4), filtered and evaporated to 
dryness to afford the nitrile 116 as a light orange syrup. A portion was removed and 
subject to flash chromatography on silica gel using a gradient of hexane-EtOAc as 
eluent. The required fractions were collected and evaporated to dryness to afford the 
nitrile 116 as a white foam.
Rf 0.41 (hexane:EtOAc 8:2); mp 59-60 °C (from hexane) (lit.78 58 °C); vmax (KBr)/cm‘ 
1 2956 (Ar-H), 1728 (C=0) and 1268 (C-O); *H NMR 8 H (400 MHz; CDC13) 8.04-
8.07 (2H, m, Ar-H), 7.85-7.91 (4H, m, Ar-H), 7.48-7.55 (3H, m, Ar-H), 7.29-7.42 
(6 H, m, Ar-H), 5.94 (1H, dd, J  5.4, 4.4, H-2), 5.79 (1H, t, J 5.4, H-3), 4.92 (1H, d, J 
4.4, H-l), 4.66 (1H, dd, J 10.2, 5.4, H-5a), 4.65 (1H, m, H-4) and 4.54 (1H, m, H-5b); 
13C NMR 8 C (100 MHz; CDC13) 166.2, 165.1, 164.9 (C=0), 134.2, 134.0, 133.6, 
130.02, 130.00, 129.9 (CH), 129.3 (C), 128.9, 128.8, 128.7 (CH), 128.5, 128.3 (C)
115.9 (C), 81.2, 74.7, 72.1, 69.7 (CH) and 63.5 (CH2), 6  aromatic CH and 1 aromatic 







Cysteine methyl ester (2.5 g, 14.8 mmol) and Et3N (2.1 mL, 14.8 mmol) were added 
to a solution of the crude nitrile 116 (5.0 g, 10.6 mmol) in CH3OH (200 mL) and 
stirred under nitrogen at room temperature. After three hours the solution was 
evaporated to dryness, dissolved in CH2CI2 (20 mL), washed twice with equal 
volumes of water (2 x 20 mL), 5% aq. NaHC03 (2 x 20 mL) and brine (2 x 20 mL). 
The organic layers were combined, dried (Na2SC>4), filtered and evaporated to dryness 
under reduced pressure to afford the thiazoline 123 as an equal mixture of 
diastereoisomers. A portion was removed and subject to flash chromatography on 
silica gel using a gradient of hexane-EtOAc as eluent. The required fractions were 
collected and evaporated to dryness to afford the nitrile as a white foam.
Rf 0.36 (hexane:EtOAc 7:3); mp 60-63 °C (from hexane); *H NMR 8h (400 MHz; 
CDCI3) 8.13-8.10 (4H, m, H-Ar), 8.00-7.90 (8H, m, H-Ar, H-Ar*), 7.59-7.52 (6 H, m, 
H-Ar, H-Ar*), 7.46-7.33 (12H, m, H-Ar, H-Ar*), 5.91 (1H, t, 7 5.1, H-2'), 5.89 (1H, t, 
J  5.1, H-2'*), 5.83 (1H, t, J  5.1, H-3'), 5.82 (1H, t, J  5.1, H-3'*), 5.23 (1H, m, H-l'), 
5.23 (1H, m, H-l'*), 5.18 (1H, t, J  9.4, H-4), 5.14 (1H, t, J 9.4, H-4*), 4.80 (1H, dd, J  
10.0, 3.5, H-5'a), 4.77 (1H, dd, J 10.0, 3.5, H-5'a*), 4.69 (2H, m, H-4', H-4'*), 4.61 
(1H, dd, J  10.0, 4.3, H-5'b), 4.58 (1H, dd, J  10.0, 4.3, H-5'b*), 3.79 (3H, s, CH3), 3.70 
(3H, s, CH3*), 3.59 (1H, dd, J  11.5, 9.3, H-5a), 3.57 (1H, dd, J 11.5, 9.3, H-5a*), 3.52 
(1H, dd, J  11.5, 9.3, H-5b) and 3.46 (1H, dd, J 11.5, 9.3, H-5b*); 13C NMR 8C (100 
MHz; CDCI3) 174.0, 173.9, 170.8, 170.6, 166.22, 166.18 (C, C*), 165.3 (C and C*), 
165.14, 165.09 (C, C*), 133.6 (CH and CH*), 133.5 (CH and CH*), 133.2 (CH and 
CH*), 129.9, 129.8 (6  x CH, 6 x CH*), 129.63, 129.59, 129.0, 128.9, 128.7 (3 x C, 3 x 
C*), 128.5 (6  x CH, 6  x CH*), 80.8, 80.6, 78.14, 78.10, 74.9, 74.8, 72.54, 72.47 (CH, 
CH*), 64.0, 63.9 (CH2, CH2*), 60.4 (CH and CH*), 52.83,52.76 (CH3, CH3*), 34.6 and 





B zo ' OBz 
121
To a solution of crude thiazoline 123 (4.7 g, 8.0 mmol) in CH2CI2 (250 mL) was 
added DBU (16 mmol, 2.4 mL). This was cooled to 0°C and B1CCI3 (0.95 mL, 9 
mmol) was added dropwise, stirred overnight and concentrated under vacuum. The 
solution was washed three times with aq. saturated NH4CI (3 x 20 mL) and the 
aqueous phase extracted twice with EtOAc (2 x 20 mL). The combined organics were 
dried (Na2SC>4), filtered and evaporated to dryness under vacuum. The residue was 
subject to flash chromatography on silica gel using a gradient of hexane-EtOAc (9:1 
to 7:3) as eluent. The required fractions were collected and evaporated to dryness to 
afford the thiazole 121 as a light yellow foam (3.6 g, 61 % over three steps).
Rf 0.48 (hexane:EtOAc, 6:4); mp 61 °C (from hexane); [oc]25d -43 (c 1 in CHCI3); 
vmax (KBrycm1 2962 (Ar-H), 1726 (C=0) and 1269 (C-O); *H NMR 5H (400 MHz; 
CDCI3) 8.15 (1H, s, H-5), 8.09-8.07 (2H, m, H-Ar), 8.00-7.97 (2H, m, H-Ar), 7.92-
7.89 (2H, m, H-Ar), 7.58-7.51 (3H, m, H-Ar), 7.45-7.3 (6 H, m, Ar-H), 5.91-5.88 (2H, 
m, H-2', H-3'), 5.75 (1H, d, 7 4.7, H-10, 4.89 (1H, dd, 7 12.1, 3.1, H-5'a), 4.78-4.75 
(1H, m, H-4') 4.61 (1H, dd, 7 12.1, 3.9, H-5'b) and 3.91 (3H, s, CH3); 13C NMR 5C 
(100 MHz; CDCI3) 169.6, 166.2, 165.3, 165.2, 161.6, 147.3 (C), 133.72, 133.68,
133.5, 130.1, 129.92, 129.90 (CH), 129.6, 129.0, 128.9 (C), 128.8, 128.7, 128.6, 80.9, 
80.8, 76.8, 72.5 (CH), 64.0 (CH2) and 52.8 (CH3), 7 aromatic CH occluded; m/z 




ho'  OH 
124
CH3 0 'Na+ (92 mg, 0.017 mmol) was added to a solution of thiazole 121 (100 mg,
0.17 mmol) in CH3OH (3 mL) and stirred overnight at room temperature then 
quenched with Dowex 50WX 4-100. The mixture was filtered, evaporated to dryness 
subject to flash chromatography on silica gel using a gradient CH2CI2 to 
CH2Cl2:CH3 0 H (100 to 97:3) as eluent to afford the methyl carboxylate 124 as a 
white solid (37 mg, 80 %).
Rf 0.46 (CH2Cl2:CH3OH, 9:1); mp 119-121 °C (from CH2C12); [a]25D -6  (c 1 in 
CH3OH); vmax (KBr diskycm ' 1 3369 (O-H), 1726 (C=0) and 1237 (C-O); *H NMR 5H 
(400 MHz; CD3OD) 8.20 (1H, s, H-5), 4.95 (1H, d, J  5.5, H-l'), 4.10 (1H, m, H-4'), 
3.98-3.94 (2H, m, H-2', H-3'), 3.72 (3H, s, CH3), 3.68 (1H, dd, J  12.5, 2.3 H-5'a) and 
3.56 (1H, dd, J  12.5, 4.6, H-5'b); 13C NMR 8  (100 MHz; CD3OD) 172.2, 163.1, 145.7 
(C), 129.8, 84.7, 81.8, 76.8, 71.2 (CH), 61.8 (CH2) and 53.0 (CH3); m/z [FAB+] 276.1 




ho'  OH 
111
To a stirred solution of freshly prepared saturated methanolic ammonia (5 mL) at 0°C 
was added the methyl carboxylate 121 (40 mg, 0.68 mmol). The reaction was stirred 
at room temperature overnight in a glass pressure tube, then evaporated to dryness, re- 
suspended in methanolic ammonia (5 mL), and stirred for a further twenty-four hours. 
The solvent was evaporated, the residue dissolved in water (10 mL) and washed with 
EtOAc (5 x 20 mL). The aqueous phase was concentrated under reduced pressure and
129
lyophilised from D2O to afford tiazofurin 111 as a yellowish waxy solid (152 mg, 8 6
%).
mp 145-147 °C (from D20 )  (lit.75, 143 °C); [a]25D-7.5 (c 1 in H20); vmax (film)/cm_1 
3390 (O-H) and 1667 (C=0); *H NMR 8 H (400 MHz; D20 )  8.02 (1H, s, H-5), 4.98 
(1H, d, J  5.1, H-l'), 4.16 (1H, dd, J  5.5, 3.9, H-4'), 4.03-3.99 (2H, m, H-2', H-3'), 
3.70 (1H, dd, J  12.5, 3.9, H-5'a) and 3.59 (1H, dd, J  12.5, 5.5, H-5'b); 13C NMR 8 C 
(100 MHz; D20 )  171.5, 165.4, 148.3 (C), 129.2, 84.9, 81.7, 76.7, 71.4 (CH) and 61.9 
(CH2); m/z [FAB+] 261.1 (M+, 100 %) [found 261.0543 C9Hi3N20 5S requires 
261.0545].
2-(p-D-Ribofuranosyl)thiazole-4-carboxylic acid
ho' oh  
113
To a stirred solution of methyl carboxylate 121 (10 mg, 0.17 mmol) in dioxane (3 
mL) was added 1 M NaOH (3 mL) and stirred overnight. The reaction was acidified 
using Dowex resin (50WX 4-100), filtered, washed with water and extracted three 
times with EtOAc ( 3 x 5  mL). The aqueous phase was concentrated under reduced 
pressure and lyophilised from D20  to afford the carboxylic acid 113 as a white 
hygroscopic solid (38 mg, 8 6  %).
[ c c ] 2 5 d  -10  (c 1 in H20); vmax (film)/cm_1 3390 (O-H) 1713 (C=0); ]H NMR 8 H  (400 
MHz; D20 )  8.02 (1H, s, H-5), 5.01 (1H, d, J  5.1, H-l'), 4.18 (1H, m, H-4'), 4.03-4.01 
(2H, m, H-2', H-3'), 3.72 (1H, dd, J  12.5, 3.1, H-5'a) and 3.61 (1H, dd, J  12.5, 5.1, H- 
5'b). 13C NMR 8 C (100 MHz; D20 )  172.1, 163.8, 146.1 (C), 129.9, 84.6, 81.9, 76.8,







POCI3 (20 jliL, 0.22 mmol) was added to a stirred solution of methyl carboxylate 124 
(50 mg, 0.18 mmol) in triethylphosphate (0.75 mL) under a nitrogen atmosphere at 
0°C. The reaction was monitored by using an ion exchange HPLC (method A) and 
after ninety minutes the reaction was quenched using H2O (5 mL) and stirred for 5 
minutes. The excess triethylphosphate was extracted five times with ethyl acetate (5 x 
15 mL) and the aqueous phase loaded onto ion exchange gradifac column (AG-MP1) 
eluted with a gradient of 150 mM aq. TFA. Fractions were analysed by ion exchange 
HPLC (method A), desired fractions collected, evaporated to dryness and lyophilised 
from D2O to afford the phosphate 127 as a light yellow hygroscopic gum (46 mg, 72
Rt  14 minutes (AG-MP1 water:150 mM aq. TFA); lH NMR 8 H (400 MHz; D20 )  8.13
(CH3); 31P NMR 8 P (162 MHz; D20 )  0.97.
2-(5'-Phosphoryl-p-D-ribofuranosyl)thiazole-4-carboxylic acid
POCI3 (70 pL, 0.75 mmol) was added to a stirred solution of methyl carboxylate 124 
(180 mg, 0.67 mmol) in triethylphosphate (3.0 mL) under a nitrogen atmosphere at 
0°C. The reaction was monitored by using an ion exchange HPLC (method A) and 
after 1.5 hours the reaction was quenched using H2O (5 mL) and stirred for 5 minutes. 
The excess triethylphosphate was extracted five times with ethyl acetate (5 x 15 mL)
%).
(1H, s, H-5), 4.88 (1H, d, J 5.1, H-l'), 4.06 (1H, t, J 5.1, H-4'), 4.01-3.98 (2H, m, H- 
2', H-3'), 3.93-3.80 (2H, m, H-5') and 3.63 (3H, s, CH3); 13C NMR 8 C (100 MHz; 
D20 )  172.4, 163.0, 145.4 (C), 130.0, 83.3, 82.0, 76.8, 71.3 (CH), 65.4 (CH2) and 53.0
OH
ho '  "oh 
128
131
and the pH of the aqueous phase adjusted to 10 with 1 M NaOH and stirred overnight 
then loaded onto ion exchange column (AG-MP1) and eluted using a gradient of TFA. 
Fractions were analysed by ion exchange HPLC (method A), desired fractions 
collected, evaporated to dryness and lyophilised from D2O to afford the phosphate 
128 as a light yellow hygroscopic solid (187 mg, 82 %).
R t 17 minutes (AG-MP1 water: 150 mM aq. TFA); *H NMR 5h (400 MHz; D2O) 8.14 
(1H, s, H-5), 4.92 (1H, d, J  5.1, H-l'), 4.09 (1H, t, J  4.9, H-4'), 4.07-4.01 (2H, m, H- 
2', H-3') and 4.01-3.88 (2H, m, H-5'); 13C NMR 8 C (100 MHz; D20 )  172.5, 163.7,
145.7 (C), 130.2, 82.9, 81.9, 76.7, 71.0 (CH) and 65.5 (CH2); 31P NMR 5P(162 MHz; 
D20 )  0.21.
2-Thiazole-4-carboxylate adenine dinucleotide phosphate
P-OH  ^ -A HO OH
OcSp-OH
114
Carbonyl diimidazole (8 8  mg, 0.6 mmol) and Et3N (31 pL, 0.22 mmol) were added to 
a solution of methyl carboxylate phosphate 127 (70 mg, 0.2 mmol) in DMF (500 pL) 
and stirred at room temperature under a nitrogen atmosphere for three hours (31P 
NMR S-lOppm). Two drops of CH3OH were added and the solution stirred for 
further 10 minutes. The reaction was evaporated to dryness, co-evaporated with DMF 
(3 x 100 pL), a solution of diphosphate adenosine 74 (151 mg, 0.19 mmol) in DMF 
(500 pL) added and the reaction stirred overnight. The solution was applied to a 
column of Q-Sepharose and eluted with a gradient of water- 2 M aq. TEAB. The 
desired fractions were analysed by ion exchange HPLC, collected and evaporated to 
dryness. The product was then used crude in the following reaction.
132
To a crude solution of protected pyrophosphate 131 (60 mg) in CH3OH (1.5 mL) was 
added 1 M NaOH (1.5 mL) and stirred overnight. 31P NMR showed a new peak at 4.2 
ppm corresponding to a free phosphate. The reaction was neutralised to pH 7, loaded 
onto a Q-Sepharose column and eluted with a gradient of water- aq. 2 M TEAB. The 
desired fractions were analysed by HPLC, collected and evaporated to dryness. The 
product was then used crude in the following reaction.
HF/pyridine (7:3 v/v) (25 |uL, 0.96 mmol) was added to a solution of crude silyl 
protected pyrophosphate 132 (23 mg) in pyridine (1 mL) and stirred for 20 minutes 
then neutralised with aq. saturated NaHCC>3. The solution was evaporated to dryness, 
re-suspended in H2O, applied to a column of AG-MP1 and eluted using a gradient of 
water: 150 mM aq. TFA. The desired fractions were analysed, collected, evaporated 
to dryness and lyophilised from D2O to afford TAADP 114 as a white hygroscopic 
powder (7 mg, 5 % over three steps from starting adenosine 74).
R t 20 minutes (AG-MP1 water:150 mM aq. TFA); *H NMR 8H (400 MHz; D20 )  8.39 
(1H, s, H-2'ad), 8.25 (1H, s, H-8 'ad), 8.09 (1H, s, H-5th), 6.12 (1H, d, 7 5.5, H-l'), 5.03 
(1H, m, H-2'), 4.91 (1H, d, J  5.1, H-l), 4.52 (1H, t, J  3.9, H-3'), 4.29 (1H, m, H-4'), 
4.14 (5H, m, H-2, H-3, H-4, H-5 ') and 4.00 (2H, m, H-5); 13C NMR 8 c (150 MHz; 
D20 )  172.9, 164.1, 150.0 (C), 148.6, (CH) 145.8 (C), 144.9, 143.2 (CH), 130.5, 118.7 
(C), 87.2, 84.3, 83.5, 82.0, 77.3, 77.1, 71.5, 70.3 (CH), 66.0 and 65.7 (CH2); 31P NMR 
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Abstract— Successful oxidation of a key thiazoline intermediate allows an efficient synthesis of tiazofurin in four steps from 
commercially available 1 '-acetoxy-2',3',5'-tri-0-benzoyl-P-D-ribofuranose. © 2002 Elsevier Science Ltd. All rights reserved.
Tiazofurin 4 1 is converted in vivo into the active 
m etabolite thiazole-4-carboxam ide adenine dinucleotide 
(T A D ), an analogue o f  N A D  that prevents de novo  
guanine nucleotide synthesis via inhibition o f  inosine 
m onophosphate dehydrogenase (IM PD H , EC 
1.1.1.205).2 The consequent decrease in cellular G TP  
and deoxyG T P concentrations interrupts D N A  and 
R N A  synthesis in rapidly-dividing tum our cells. T iazo­
furin proved effective in reducing the leukaemic cell 
burden in acute m yelogenous leukaemia patients, but 
was found to be too  toxic for general clinical applica­
tion .3-5 Subsequent discovery o f  tw o IM PD H  isoform s, 
o f  which type II is up-regulated in human leukaemia 
cell lines,6,7 has prompted studies to inform the design  
o f  isoform  selective inhibitors8 and has renewed interest 
in tiazofurin and its analogues.9,10
Several routes have been published toward this com ­
pound; o f  these the preparation reported by Ram asam y  
and co-w orkers11 provides tiazofurin, while avoiding  
the use o f  hydrogen sulfide gas. These authors reported 
unsuccessful oxidation o f  thiazoline 1 with M n 0 2, or a 
range o f  other conditions, observing elim ination o f  the
1 2
Scheme 1. Reagents and conditions:n (a) M n 0 2/benzene/ 
reflux.
2',3'-benzoate esters to afford thiazole-furan 2 in each 
case (Schem e 1).
Instead, isopropylidene 3 was converted into the target 
com pound 4 with good  reported yields, but the intro­
duction and removal o f  the isopropylidene protecting  
group introduced an extra three steps from l'-acetoxy- 
2',3',5'-tri-0-benzoyl-|3-D-ribofuranose 5 (Schem e 2).
W e now report the successful oxidation o f  thiazoline 1 
that removes the need for this detour and reduces the 
synthesis o f  tiazofurin to a simple four-step procedure.
Thiazoline 1 was prepared by reaction o f  l'-cyano- 
2',3',5'-tri-0-benzoyl-(}-D -ribofuranose12 with L-cysteine 
methyl ester in the presence o f  triethylam ine according 
to an established p rotocol.11 C om plete epim erisation o f  
the cysteine a-proton was observed by N M R , but 
this centre will becom e part o f  the arom atic thiazole. A 
number o f  oxidation conditions, including D D Q  in 
to luene,13 did not proceed to  our satisfaction, but we 
were pleased to observe clean conversion o f  the thiazo­
line 1 in the presence o f  brom otrichlorom ethane and 




Scheme 2. Reagents and conditions:n (a) cysteine ethyl 
ester-HCl/Et3N; (b) M n 0 2/benzene/refiux; (c) 90% TFA; (d) 
N H 3/MeOH.* Corresponding author. E-mail: j .d o w d e n f S ib a th .a c .u k
0040-4039/02/$ - see front matter © 2002 Elsevier Science Ltd. All rights reserved. 
PII: S0040-4039(02)01470-3











ho' ^ Q ' V  BzO ^ Q ^ S
HO OH
Scheme 3. Reagents and conditions', (a) TMSCN, SnCl4, 
CH2C12, rt, 2 min; (b) L-cysteine methyl ester hydrochloride, 
Et3N, CH2C12; (c) BrCCl3, DBU, CH2C12, 0°C, 61% over 
three steps; (d) N H 3/MeOH, rt, 20 h, 86%.
dally available 1 '-acetoxy-2', 3 ',5 '-tri- O -benzoyl- [ 3 - d -  
ribofuranose 5 in an unoptimised isolated yield of 61% 
over the three steps with just one chromatographic 
separation (Scheme 3).15
Ester aminolysis and global deprotection were effected 
by stirring 6 in methanolic ammonia.16 Dissolution of 
the concentrated crude reaction mixture into water and 
extraction of all contaminants into ethyl acetate proved 
sufficient to afford pure tiazofurin 4 in 86% yield.
In summary, selective dehydrogenation of a thiazoline 1 
in the presence of sensitive ribose 2',3',5'-tribenzoate 
ester protecting groups is described. The immediate 
benefit of this discovery is to improve the efficiency of 
tiazofurin synthesis in the absence of hydrogen sulfide 
affording a productive four-step protocol.
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15. Preparation of methyl 2-(2',3',5'-tri-0-benzoyl-p-D-ribo- 
furanosyl)thiazole-4-carboxylate 6 . 1,8-Diazabicyclo[5.4.0]- 
undec-7-ene (2.4 mL, 16 mmol, 2 equiv.) was added to a 
stirred solution o f methyl 1 '-(2',3',5'-tri-<9-benzoyl-P-D- 
ribofuranosyl)thiazoline-4'-carboxylate 1 (4.7 g, 8 mmol) 
in CH2C12 (250 mL). The solution was cooled to 0°C and 
BrCCl3 (1.9 g, 9 mmol, 1.0 mL) was added dropwise and 
the resulting mixture stirred overnight. The reaction mix­
ture was then concentrated, dissolved into ethyl acetate 
and the solution washed 3x with satd aq. N H 4C1. The 
organic layer was dried (Na2S 0 4), filtered, concentrated 
and subject to column chromatography on silica gel using 
a gradient o f hexane:ethyl acetate from 9:1 to 7:3 as 
eluent to afford 6 as a light yellow foam. Yield 3.6 g, 6.1 
mmol, 61% over three steps. [a]o -43.3 (c 1, CHC13); IR 
(KBr) 1726, 1269, 1095, 710 cm"1; lH  N M R  (400 MHz 
CDC13): S 8.15 (1H, s, SCH) 8.09-8.07 (2H, m, Ar-H) 
8.00-7.97 (2H, m, Ar-H) 7.92-7.87 (2H, m, Ar-H) 7.58- 
7.51 (3H, m, Ar-H) 7.45-7.33 (6H, m, Ar-H) 5.91-5.88 
(2H, m, H-2',3') 5.75 (1H, d, 7 = 4 .7 , H -l') 4.89 (1H, dd, 
7= 12 .1 , 3.1, H-5'a) 4.75-4.78 (1H, m, H-4') 4.61 (1H, dd, 
7= 12 .1 , 3.9, H-5'b) 3.91 (3H, s, COOCH3); ,3C NM R  
(100 MHz (DEPT) CDC13): S 169.6(0), 166.2(0), 165.3(0), 
165.2(0), 161.6(0), 147.3(0), 133.8(1), 133.7(1), 133.5(1), 
130.1(1), 129.92(1), 129.91(1), 129.6(0), 128.98(0),
128.92(0), 128.76(1), 128.7(1), 128.6(1), 80.9(1), 80.8(1), 
76.9(1), 72.5(1), 64.0(2), 52.8(3). MS (FAB+) m /z  (M+H)+ 
588 (100). MS (FAB+/HR) m /z  (M +H)+ calcd for 
C31H25N 0 9S: 588.1329. Found: 588.1341.
16. Srivastava, P. C.; Pickering, M. V.; Allen, L. B.; Streeter, 
D. G.; Campbell, M. T.; Whitowski, J. T.; Sidwell, R. 
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Modulation of intracellular calcium concentration creates 
signals that control a range of biological pathways. Orches­
tration of these signals by an array of small molecule second 
messengers provides the necessary complexity to complement 
multiple cellular responses, such as activation of the immune 
system or fertilization.1’1 The discovery that nicotinic acid 
adenine dinucleotide phosphate (NAADP, 1; Figure 1) 
potently induces intracellular calcium release in the eggs of 
sea urchins121 raised its status, from minor contaminant of 
nicotinamide adenine dinucleotide phosphate (NADP, 2), to 
an important novel second messenger.131 Recent studies attest 
to the higher potency of this molecule than the well-known 
messengers for calcium release [i.e., inositol trisphosphate 
and cyclic adenosine diphosphoribose (cADPR)] and many of 
these extend its actions to a wide range of mammalian cells,
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1 NAADP; R = OH
2 NADP, R = NH2
Figure i. Compounds 1 and 2.
including cardiac,14*1 skeletal,14b) T cells,14*1 smooth muscle,14dl 
pancreatic acinar14*1 and pancreatic beta cells.13a,4f,4El
Compound 1 also appears to play an important role in 
calcium signaling by triggering and coordinating calcium 
signals evoked by other calcium-mobilizing messengers. 
Sensitive radio-receptor assays for tissue measurements of 
this dinucleotide have been developed,151 but it is clear that 
further understanding of its biology will draw heavily on the 
development of selective molecules to probe this novel 
signaling pathway and characterize its protein components. 
A chemo-enzymatic route has so far generated 1 and a small 
number of analogues from 2 by enzyme-mediated exchange 
of nicotinamide for nicotinic acid. Clearly, the chemistry that 
can be performed on this sensitive molecule and compatibility 
with the enzyme limits the range of available analogues. A 
synthetic route would provide a wider range of tailored 
derivatives, such as non-hydrolysable analogues, that could 
not be achieved by established methods.
We are currently exploring a range of strategies to 
generate chemical tools with which to interrogate this bio­
logical system, including the total synthesis of both dinucleo­
tides. Whitesides and co-workers developed a semisynthetic 
route to p-nicotinamide adenine dinucleotide (NAD) by 
using NAD pyrophosphorylase immobilized on polyacryla­
mide gel, but this relied on a battery of enzymes and reagents 
to generate stoichiometric quantities of adenosine triphos­
phate (ATP).16*1 More recently, Lee et al.l6b) reported a 
practical total chemical synthesis of nicotinamide adenine 
dinucleotide (NAD) that built upon a much earlier synthesis 
by Todd and co-workers.171 Indeed, a number of researchers 
have developed chemical approaches to NAD derivatives, not 
least for the preparation of cyclic adenosine 5'-diphosphate 
ribose.181 However, the presence of a sensitive 2'-phosphate on 
a ribose makes the synthesis of 1 or 2 significantly more 
complex. During early studies Todd and co-workers reported 
an apparent preparation of 2 inferred from biological 
evaluation of the complex product mixture but did not 
successfully isolate the desired coenzyme from the mixture.17b] 
Given that this dinucleotide is readily available from com­
mercial sources, it is perhaps not surprising that further 
developments toward its chemical synthesis are not apparent
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in the general literature. To the best of our knowledge 
therefore, we describe the first chemical synthesis of 2 as a 
single isomer, its enzymatic conversion to the potent second 
messenger 1, and both chemical characterization and bio­
logical proof of the integrity of the latter dinucleotide.
The potentially fragile nature of 2 and its intermediates 
encouraged a conservative approach that involves the late 
construction of the pyrophosphate bond by activation of 0- 
nicotinamide mononucleotide ((3-NMN, 4; Scheme 1) and 
reaction with a suitably decorated adenosine building block. 
It is known that the 2'-phosphate motif is critical for the 
activity of I 1®1 and may be involved in its degradation.1101 
Structural modifications are likely to be informative and 
thus we designed a synthesis that was both robust and 
sufficiently flexible to accommodate future modifications at 
any position on the NAADP framework.
Compound 4 was generated from tetra-0-acetyl-(3-D- 
ribose.16,111 Reaction between adenosine and 1,3-dichloro- 
1,1,3,3,-tetraisopropyl disiloxane in pyridine proceeded with­
out complication and lead to simultaneous tethering of the 3'- 
and 5'-hydroxyls of adenosine, thus permitting unambiguous 
phosphorylation of the 2'-alcohol. Subsequent elaboration of 
the 2'-alcohol 5 could be achieved with a range of phosphor- 
amidites, including 6ri(benzyloxy)-A^JV-diisopropylamino- 
phosphane 6 (Scheme 1), to afford the respective phosphate 
7 in high yield after oxidation of the intermediate phosphite 
with m-chloroperoxybenzoic acid (mCPBA). Imidazolium 
triflate1121 was used instead of tetrazole to produce a less
reactive phosphytilating intermediate that does not react with 
the purinyl amine, thus saving two steps. Carefully controlled 
acidic conditions, as previously reported by Scott and co­
workers afforded exclusive protodesilylation at the less 
hindered 5'-position in quantitative yield.1131
Generally, phosphoramidite chemistry did not proceed in 
acceptable yields at the 5'-hydroxyl of the precursor, presum­
ably because this position is somewhat crowded. Resorting to 
the reactive tetrazole-activated phosphoramidites required 
amine protection and actually led to incorporation of an 
unwelcome silanol phosphate. It was frustrating that a 
multitude of protection strategies failed due to unexpected 
incompatibility with the desired route. Although this chemis­
try might be optimized to provide acceptable yields of the 
desired compound, we found that //-phosphonate chemistry 
offered a very effective alternative. Selective 5'-protodesilyl- 
ation of bis(benzyloxy)phosphate 7, then treatment of the 
product with trisimidazolylphosphane, generated in situ from 
PC13 and imidazole, rapidly furnished 8 in quantitative yield 
(Scheme 1). Oxidation was best achieved by using conditions 
reported by Sekine and co-workers1141 in a process monitored 
by 31PNM R spectroscopy, such that the //-phosphonate 
triethylammonium salt (<5(31P) =  5.5 ppm) was treated with 
iV,0-bis(trimethylsilyl)acetamide (BSA) to afford the bis(tri- 
methysilylphosphonate) (<5(31P) =  116ppm) after approxi­
mately 1 h; the oxidant (l/?)-(+)-(10-camphorsulfonyl)oxa- 
ziridine (CSO) was added to this to generate 6w(trimethylsi- 
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Scheme 1. a) Nicotinamide, CH3CN, then TMSOTf, RT; 1.5 h, then MeOH, RT; 1 h; b) POClj, PO(OMe)3, 0°C, 4 h; c) 6, CH2CI2l RT; 3 h, then 
mCPBA, - 7 8 °C, 0.5 h, 98%; d) TFA/H20/TH F 1:1:4, 0°C, 3 h, 98%; e) PCl3, imidazole, Et3N, THF, 0°C, 15 mins, then 1 m TEAB aq. pH 7, RT, 
15 mins, quant.; f) BSA, CHCl3, RT, 1 h, then CSO, RT, 0.5 h, then MeOH/D20 ,  RT, 15 mins, 72%; g) fl-NMN, carbonyl diimidazole, Et3N, DMF, 
RT, 3 h, then 9, DMF, RT, 16 h; h) 1 m TBAF/THF, AcOH, 0°C, 1.5 h, 22% i) 10% Pd/C, cydohexadiene, MeOH/H2Ot RT, 2 h, 77%; j) Nicotinic 
acid, Aplysia ADP-ribosyl cyclase, 1 m NaOAc aq. pH 4, RT, 5 h, 63%.
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slowly hydrolyzed to give the phosphate 9 (<S(31P) =  1 ppm) 
upon addition of D20.
Successful repetition of the approach to NAD reported by 
Lee and co-workersl6bl encouraged initial exploration of 
morpholidate activation of the precursor 8, but attempted 
conversions were not productive. Production and reaction of 
the (3-NMN imidazolide could be monitored by using 
31P NMR spectroscopy (d(31P) =  -10.6 ppm).
Contrary to other reports,161 we found that bisbenzylphos- 
phate precursor 9 appeared to react with good conversion 
when monitored by 3IP NMR spectroscopy and offered an 
attractive protecting-group strategy (Scheme 1). Both benzyl 
groups remained intact during this reaction and the resulting 
product could not be purified by using our preferred ion- 
exchange chromatography method. Instead, the crude mate­
rial was treated with 1 m  TBAF in THF/AcOH to effect 
simultaneous cleavage of the silanol ether and one of the 
benzyl protecting groups to yield monobenzyl NADP 10 after 
ion-exchange chromatography. Although there was no evi­
dence of migration of the 2'-phosphate, the overall yield of 
around 22 % for these two steps is modest, but is comparable 
to many literature reports as pyrophosphate bond formation 
and isolation of the resulting product is generally difficult and 
yields are highly variable. An alternative route that employs a 
bis(2-cyanoethyl) protected precursor related to 9 gave yields 
in the range of 60-80 % for the pyrophosphate coupling and 
we are currently exploring improvements of this route to 
achieve useful conversion. Nonetheless, transfer hydrogena­
tion of 10 yielded material that was identical to commercial 
preparations of (3-NADP 2 in satisfactory (77%) yield.
With a wider objective in mind we chose to convert 
synthetic NADP 2 into the target NAADP 1 to test its 
behavior in a relevant biological system. Base exchange to 
replace nicotinamide with nicotinic acid was achieved by 
using an excess of the latter and crude Aplysia ADP-ribosyl 
cyclase [enzyme commission number E.C.3.2.2.5] prepared 
from Aplysia ovotestis1151 to provide NAADP 1 in 63 % yield.
The ability of 1 to induce release of Ca2+ ions was tested 
by using a cell-free system derived from the eggs of sea 
urchins. Aliquots of homogenates of sea-urchin eggs comprise 
vesicles derived from the intracellular stores that sequester 
calcium when supplemented with an ATP-regenerating 
system. Concentration-dependent calcium release is observed 
when this mixture is challenged with second messengers, such 
as 1, which can be measured by using cuvette-based fluorim- 
etry and the calcium reporter dye fluo-3.1161 Synthetic 
NAADP, carefully quantified by using total phosphate assay 
prior to evaluation,1171 potently induced calcium release in an 
identical manner to “authentic” NAADP prepared from 
commercial NADP (Figure 2). Both preparations display an 
important characteristic of this signaling pathway that occurs 
at subthreshold concentrations of NAADP in homogenate of 
sea-urchin eggs. They both potently deactivate the calcium 
store in a time dependent manner, so that further challenge 
with NAADP does not lead to significant calcium release 
(Figure 3). This property allows competition binding experi­
ments that measure the extent that nonlabeled NAADP 
displaces subthreshold concentrations of [32P]NAADP 
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Figure 2. Ca2+-ion release from homogenate of sea-urchin eggs by 
100 nM authentic NAADP (dotted arrows) or 100 nM synthetic 
NAADP, 1 (solid arrows): Samples diluted to 2.5% in GlulM in the 
presence of regenerating system and kept at 17°C with agitation for 
3 h to facilitate Ca2+-ion uptake into stores. Ca2+-ion release deter­
mined by an increase of Fluo-3 fluorescence at 526 nm; data 
expressed as released [Ca2+], determined by fluorescence in arbritrary 





Figure 3. Inhibition of NAADP-induced Ca2+-ion release by authentic 
NAADP (squares) or synthetic NAADP 1 (triangles) in the homogenate 
of sea-urchin eggs: Samples diluted to 2.5% in GlulM in the presence 
of a regenerating system and kept at 17°C with agitation for 3 h to 
facilitate Ca2+-ion uptake into stores. Ca2+-ion release determined by 
an increase of Fiuo-3 fluorescence at 526 nm; data expressed as 
pmoles of Ca2+-ions released; n = > 3 for each point.
In summary, the strategy of using 1,1,3,3-tetraisopropyl 
disiloxane protecting groups offers a robust (70%, five steps 
from adenosine) route to 2',5'-adenosine diphosphate pre­
cursors and the potential to incorporate a range of function­
ality at these positions. Pyrophosphate formation requires 
some further development, but affords benzyl protected 
precursor 10 that, after transfer hydrogenation, leads to the 
first total chemical synthesis of 2. This flexible route to 2'- 
phosphate furnished dinucleotides will allow the develop­
ment of new chemical tools that probe biological systems at 
the molecular level. Analogues of 1 are of immediate 
importance for dissecting this novel and important second
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Figure 4. Competitive displacement of [32P]NAADP (0.2 dm) with 
authentic NAADP (squares) or synthetic NAADP 1 (triangles) from 
sea-urchin homogenate: Samples diluted in GlulM, then 0.2 nM  
[32P]NAADP in the presence of increasing NAADP added and incu­
bated at room temperature for 20 mins. Samples filtered through 
Whatman GF/B filters to separate bound and free [32P]NAADP ligand. 
Nonspecific binding is defined by incubation of the homogenate in the 
presence of 10p.M NAADP; n =  3 ±S E M ; data expressed as specific 
cpm.
messenger pathway. Enzymatic conversion into 1 is confirmed 
both by identical behavior when evaluated for Ca2+-release 
properties against sea-urchin-egg homogenate and spectro­
scopic characterization. Expansion of the route to include 
suitably protected beta-nicotinic acid mononucleotide (P- 
NAMN) towards the first total chemical synthesis of 1 and 
improved isolated yields of pyrophosphate will be reported in 
due course.
Experimental Section
2: Benzyl NADP 9 (15 mg, 0.018 mmol), 10% Pd/C (15 mg) and 
cyclohexadiene (100 pL) in a degassed mixture of H20:MeOH (3:1, v/ 
v, 2 mL) were stirred at room temperature under an argon atmos­
phere for 3 h, after which the palladium was filtered and the resulting 
filtrate subject to ion-exchange chromatography (AG MP-1) by using 
a 150 mM aqueous TFA gradient. Fractions were combined and 
lyophilized to yield 2 as a white powder (10 mg, 77%): ’HNMR  
(400 MHz, DjO): <3 =  9.29 (s, 1H; HN2), 9.11 (d,7 =  6.3 Hz, 1H; HN6), 
8.78 (d, 7= 8 .2  Hz, 1 H; H ^ ), 8.41 (s, 1H; HA8), 8.23 (s, 1H; HA2), 
8.13 (m, 1H; HN5), 6.11 (d, 7 =  5.9 Hz, 1H; HA1'), 6.01 (d, 7 =  5.1 Hz, 
1H; Hn1'), 4.96 (m, 1H; HA2'), 4.49 (m, 1H; HA3'), 4.44 (br s, 1H; 
Hn4'), 4.40 (m, 1H; HN2'), 4.31 (m, 1H; HN3'), 4.27 (m, 1H; HA4'), 
4.26 (m, 1H; HA5'a), 4.12 ppm (m, 3H; HA5'„, HN5'); 31PNMR  
(162 MHz, DjO): 6 =  -0.73 and -11.42 to -11.84 ppm (br m); MS 
[FAB +  ]: mlz (%): 744.0 (50) [M+-H ]; found 744.0842 [M+-H] 
C aH ^ O n P ., requires 744.0833.
1: NADP 2 (4 mg 5 mM) and 100 mM nicotinic acid (12 mg) in a 
100 mM aqueous AcOH/NaOH (pH 4, 1 mL) were incubated with 
5 pL of ADP-ribosyl cyclase at room temperature. After 5 h, HPLC 
analysis (AG MP-1, aqueous TFA) showed complete consumption of 
NADP and formation of NAADP (RT=  16.8 mins). The crude 
mixture was purified on an ion-exchange resin (AG MP-1) by using 
an aqueous TFA gradient (150 mM), the product eluted at 15 % TFA. 
Combined fractions were evaporated under vacuum at room temper­
ature and lyophilized overnight to afford 1 as a white powder (2.5 mg, 
63%): 'HNMR (400MHz, D:0): 6 =  9.32 (s, 1H; HN2), 9.17 (d,7 =  
5.9 Hz, 1H; HN6), 8.87 (d, 7 =  8.1 Hz, 1 H; Hn4), 8.45 (s, 1H; HA8), 
8.28 (s, 1H ; HA2), 8.14 (m, 1H; HN5), 6.14 (d, 7 =  5.5 Hz. 1H; HA1'), 
6.03 (d, 7 =  5.1 Hz, 1H ; HN1'), 4.97 (m, 1H ; HA2'), 4.50 (m, 1H ; HA3'), 
4.44 (br, 1H; H ^ '), 4.41 (m, 1H; HN2), 4.30 (m, 1H; HN3'), 427-4.22 
(m, 2H; HA4' and HA5'„), 4.12-4.10ppm (m, 3H; HA5'h, HN5'); 
13CNMR (100 MHz, D ,0): 6=165.4 (CO.H), 149.8 (CA4), 148.3
(Ca6), 147.0 (CHa2), 144.6 (CHN6), 142.7 (CHN4), 142.5(CHA8) 141.8 
(CHn2), 133.8 (Cn3), 128.6 (CHN5), 118.4 (CA5), 99.7 (CHNT), 86.8 
(CHa4'), 83.9 (CHa1'), 77.4 (CHN2'), 76.8 (CHA2'), 73.8 (CHN4'), 70.3 
(CHn3'), 69.9 (CHa3'), 65.1 and 64.8 ppm (2xC H 2); 31P NMR 
(162 MHz, DjO): 6 =  1.47 and -9.40 to -9.80 ppm (br m); MS 
[FAB+] 744.8 [Af+-H ]; found 745.0658 [A/+-H Q jH^NtO hP, 
requires 745.0673.
Received: March 19, 2004
Keywords: b io lo g ica l activity • ca lc iu m  • in tracellu lar s ig n a lin g  
n u c le o tid e s  • to ta l sy n th e s is
[1] M. J. Berridge, M. D. Bootman, H. L. Roderick, Nat. Rev. Mol. 
Cell Biol. 2003, 4, 517 -  529.
[2] H. C. Lee, Curr. Biol. 2003,13, R186-R188.
[3] a) R. Masgrau, G. C. Churchill, A. J. Morgan, S. J. H. Ashcroft, 
A. Galione, Curr. Biol. 2003. 13, 247 -  251; b) G. C. Churchill, 
J. S. O’Neill, R. Masgrau, S. Patel, J. M. Thomas, A. A. 
Genazzani, A. Galione, Curr. Biol. 2003. 13 ,125-128.
[4] a) J. Bak, R. A. Billington, G. Ttmar, A. C. Dutton, A. A. 
Genazzani, Curr. Biol. 2001,11, 987 -  990; b) M. Hohenegger. J. 
Suko, R. Gscheidlinger, H. Drobny, A. Zidar, Biochem. 7. 2002, 
367,423-431; c) A. H. Guse, Cyclic A DP-Ribose NAADP  2002. 
301 -318; d) F. X. Boittin, A. Galione, A. M. Evans, Circ. Res 
2002, 97, 1168-1175; e) J. M. Cancela, G. C. Churchill, A. 
Galione, Nature 1999, 398, 74-76; f) J. D. Johnson, S. Misler, 
Proc. Natl. Acad. Sci. USA 2002, 99, 14566-14571; g) K. J. 
Mitchell, F. A. Lai, G. A. Rutter, 7. Biol. Chem. 2003, 278. 
11057-11064.
[5] A. Galione, J. M. Cancela, G. C. Churchill, A. A. Genazzani, C. 
Lad, J. M. Thomas, H. L. Wilson, D. A. Terrar in Methods in 
Calcium Signalling (Ed.: J. W. J. Putney), CRC, Boca Raton, FL, 
2000, pp. 249-296.
[6] a) D. R. Walt, M. A. Findeis, V. M. Rios-Mercadillo, J. Auge, 
G. M. Whitesides, 7. Am. Chem. Soc. 1984, 106, 234 -  239; b) J. 
Lee, H. Churchil, W. B. Choi, J. E. Lynch, F. E. Roberts, R. P. 
Volante, P. J. Reider, Chem. Commun. 1999, 729 -  730.
[7] a) L. J. Haynes, N. A. Hughes, G. W. Kenner, A. Todd, 7. Chem. 
Soc. 1957, 3727 -  3732; b) N. A. Hughes, G. W. Kenner, A. Todd. 
7. Chem. Soc. 1957, 3733 -  3738.
[8] V. C. Bailey, J. K. Sethi, S. M. Fortt, A. Galione, B. V. L. Potter. 
Chem. Biol. 1997, 4, 51-61.
[9] H. C. Lee, R. Aarhus, 7. Biol. Chem. 1997, 272, 20378 -  20383.
[10] G. Berridge, R. Cramer, A. Galione, S. Patel, Biochem. J. 2002 
365, 295 -  301.
[11] S. Tanimori, T. Ohta, M. Kirihata, Bioorg. Med. Chem. Lett. 
2002, 72, 1135-1137.
[12] Y. Hayakawa, M. Kataoka, 7. Am. Chem. Soc. 1998.120,12395 -  
12401.
[13] X. F. Zhu, H. J. Williams, A. I. Scott, Tetrahedron Lett. 2000,41. 
9541-9545.
[14] T. Wada, A. Mochizuki, Y. Sato, M. Sekine, Tetrahedron Lett. 
1998. 39, 7123 -  7126.
[15] M. E. Migaud, R. L. Pederick, V. C. Bailey, B. V. L. Potter. 
Biochemistry 1999,38, 9105 -  9114.
[16] A.Minta, J. P. Y. Kao, R. Y. Tsien, J. Biol. Chem. 1989, 264. 
8171-8178
[17] D. Lampe, C. S. Liu, B. V. L. Potter, 7. Med. Chem. 1994,37,907 -  
912.
4 6 4 0  ©  2004 Wiley-VCH Verlag Gm bH & Co. KGaA, Weinheim www.angewandte.org Angew. Chem. Int. Ed. 2004, 43, 4637-4640
